Pharmaceutical composition

ABSTRACT

The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. 
     According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional patent application of U.S. Ser. No.13/056,593, filed on Jan. 28, 2011 and published as US 2011-0124687 A1on May 26, 2011. U.S. Ser. No. 13/056,593 is a National StageApplication of PCT/JP2009/063708, filed on Jul. 27, 2009, which claimspriority to Japanese Patent Application No. 2008-194219, filed on Jul.28, 2008. The entire contents of the above-mentioned applications areincorporated herein by reference.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to a stabilized pharmaceutical compositioncomprising a nonpeptidic pharmaceutically active ingredient having aprimary or secondary amino group, an excipient and an acidic compound,and a stabilizing method thereof.

Furthermore, the present invention relates to a solid preparationimproved in the stability during light irradiation, which comprises apharmaceutically active ingredient, titanium oxide, a plasticizer and achain organic acid, and a stabilizing method thereof.

BACKGROUND OF THE INVENTION

The “nonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group” is widely used as a pharmaceutically activeingredient for various diseases. For example, patent document 1describes a compound represented by the following formula and a saltthereof as agents for the treatment or prophylaxis of peptic ulcer,gastritis, erosive esophagitis and the like.

wherein r₁ is a monocyclic nitrogen-containing heterocyclic groupoptionally condensed with a benzene ring or a heterocycle, themonocyclic nitrogen-containing heterocyclic group optionally condensedwith a benzene ring or a heterocycle optionally has substituent(s), r₂is an optionally substituted C₆₋₁₄ aryl group, an optionally substitutedthienyl group or an optionally substituted pyridyl group, r₃ and r₄ areeach a hydrogen atom, or one of r₃ and r₄ is a hydrogen atom, and theother is an optionally substituted lower alkyl group, an acyl group, ahalogen atom, a cyano group or a nitro group, and r₅ is an alkyl group.

Patent document 2 describes a proton pump inhibitor (PPI) comprising acompound represented by the following formula or a salt thereof, or aprodrug thereof as an agent for the treatment or prophylaxis of pepticulcer, gastritis, erosive esophagitis and the like.

wherein Z and W are the same or different and each is a bond or a spacerhaving 1 to 20 atoms in the main chain, r₆ is an optionally substitutedhydrocarbon group or an optionally substituted heterocyclic group, r₇,r₈ and r₉ are the same or different and each is a hydrogen atom, anoptionally substituted hydrocarbon group, an optionally substitutedthienyl group, an optionally substituted benzo[b]thienyl group, anoptionally substituted furyl group, an optionally substituted pyridylgroup, an optionally substituted pyrazolyl group, an optionallysubstituted pyrimidinyl group, an acyl group, a halogen atom, a cyanogroup or a nitro group, and r₁₀ and r₁₁ are the same or different andeach is a hydrogen atom or an optionally substituted hydrocarbon group.

Patent document 3 describesN-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide(the following formula) or a pharmacologically acceptable salt thereofas an active ingredient of a stabilized pharmaceutical compositioncontaining an indoline compound.

Patent document 4 describes, as an improved preparation for oral use ofa compound, a pharmaceutical composition for oral administration, whichcomprises at least a) ethyl3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzoimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionaterepresented by the following formula or one of the pharmaceuticallyacceptable salts thereof and b) one or more pharmaceutically acceptableorganic acids having water-solubility higher than 1 g/250 ml at 20° C.

On the other hand, regarding a stabilizer of a pharmaceutically activeingredient in a pharmaceutical composition, patent document 5 disclosesan aqueous pharmaceutical solution comprising an aqueous solutioncontaining an organic acid salt of a polymyxin antibiotic and carboxylicacid (organic acid, as a stabilizer).

In addition, non-patent document 1 describes, for stabilization ofpeptide (P66) in a nonaqueous solvent, acidification of peptide byaddition of HCl, TFA, H₃PO₄ and the like.

Beside the above, patent document 6 describes a pharmaceuticalcomposition comprising a proton pump antagonist (acid pump antagonist,APA) and one or more basic excipients to stabilize APA, and patentdocument 7 describes a sustained-release pharmaceutical compositioncomprising reversible PPI, wherein APA is stabilized with one or morebasic excipients (carbonate, magnesium salt etc.).

Patent document 8 discloses a stabilized pharmaceutical preparationcoated with a coating agent containing a) a light shielding agentcapable of generating free radical by UV light, and b) a free radicalscavenger. In addition, as the light shielding agent capable ofgenerating free radical by UV light, metal oxides such as titanium oxideand the like are described, and as the free radical scavenger, forexample, organic acids such as benzoic acid and the like are described.

In addition, non-patent document 2 describes the principles ofphotocatalytic reaction of titanium oxide, and explains the HondaFujiyama effect that various substances adsorbed to a photocatalyticsurface are oxidized and reduced when titanium oxide, which is one kindof the photocatalysts, is exposed to a light having a wavelength of 380nm or below.

CITATION LIST Patent Literature

-   patent document 1: WO 2007/026916-   patent document 2: WO 2006/036024-   patent document 3: JP-A-2005-263788-   patent document 4: JP-A-2007-056018-   patent document 5: JP-A-3-44333 (JP-B-2844351)-   patent document 6: WO 2004/089342-   patent document 7: WO 2006/037766-   patent document 8: JP-A-11-147819

Non Patent Literature

-   non-patent document 1: International Journal of Pharmaceutics    (Volume 351, Issues 1-2, 3 Mar. 2008, Pages 1-7), “Stabilization of    a polypeptide in non-aqueous solvents”-   non-patent document 2: titanium oxide (property and applied    technique): Manabu Kiyono, GIHODO SHUPPAN Co., Ltd.

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

An object of the present invention is to provide a stabilizedpharmaceutical composition for use of a nonpeptidic pharmaceuticallyactive ingredient having a primary or secondary amino group as an activeingredient of a pharmaceutical composition and a stabilizing methodthereof.

A further object of the present invention is to provide a solidpreparation improved in the stability of a pharmaceutically activeingredient during light irradiation, for use of a pharmaceuticallyactive ingredient as a solid active ingredient of a pharmaceuticalcomposition, and a stabilizing method thereof.

Means of Solving the Problems

The present inventors have conducted intensive studies of stabilizationof a pharmaceutical composition and found that the stability of apharmaceutical composition (pharmaceutically active ingredient) can befurther increased by adding an acidic compound (e.g., particular organicacid) to a pharmaceutical composition comprising a nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup, which resulted in the completion of a first invention of thepresent invention. In addition, they have conducted intensive studies ofphotostabilization of a pharmaceutical composition and found that thestability of a pharmaceutically active ingredient during lightirradiation can be improved by adding titanium oxide and a chain organicacid to a solid preparation comprising the pharmaceutically activeingredient, which resulted in the completion of a second invention.

Accordingly, the first invention of the present invention relates to

[1] a stabilized pharmaceutical composition comprising a nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup, an excipient and an acidic compound,[2] the pharmaceutical composition of the above-mentioned [1], whereinthe acidic compound is an organic acid or a salt thereof,[3] the pharmaceutical composition of the above-mentioned [2], whereinthe nonpeptidic pharmaceutically active ingredient has a pKa valuehigher than that of the organic acid or a salt thereof,[4] the pharmaceutical composition of the above-mentioned [1], whereinthe nonpeptidic pharmaceutically active ingredient is an organic acidsalt,[5] the pharmaceutical composition of the above-mentioned [1], whereinthe excipient has pH 4.5 or above when dissolved or dispersed in water,[6] the pharmaceutical composition of the above-mentioned [1], whereinthe excipient is any one kind or more selected from the group consistingof mannitol, croscarmellose sodium, hydroxypropylcellulose,hydroxypropylmethylcellulose, polyethylene glycol, polyvinylpyrrolidone,crystalline cellulose, lactose, sucrose, starch, cornstarch, titaniumoxide (TiO₂) and light anhydrous silicic acid,[7] the pharmaceutical composition of the above-mentioned [1], whereinthe nonpeptidic pharmaceutically active ingredient is a salt with anunsaturated carboxylic acid,[8] the pharmaceutical composition of the above-mentioned [2], whereinthe organic acid is any one kind or more selected from the groupconsisting of adipic acid, ascorbic acid, benzoic acid, oleic acid,succinic acid, acetic acid, tartaric acid, sorbic acid, fumaric acid,lactic acid, maleic acid, malonic acid, citric acid and malic acid,[9] the pharmaceutical composition of the above-mentioned [1], whereinthe nonpeptidic pharmaceutically active ingredient is a compoundrepresented by the formula

wherein R^(a) is an organic residue, R^(b) is a hydrogen atom or ahydrocarbon group optionally having substituent(s), or a salt thereof,[10] the pharmaceutical composition of the above-mentioned [1], whereinthe nonpeptidic pharmaceutically active ingredient is a compoundrepresented by the formula

wherein X and Y are the same or different and each is a bond or a spacerhaving 1 to 20 atoms in the main chain, R¹ is an optionally substitutedhydrocarbon group or an optionally substituted heterocyclic group, R²,R³ and R⁴ are the same or different and each is a hydrogen atom, anoptionally substituted hydrocarbon group, an optionally substitutedthienyl group, an optionally substituted benzo[b]thienyl group, anoptionally substituted furyl group, an optionally substituted pyridylgroup, an optionally substituted pyrazolyl group, an optionallysubstituted pyrimidinyl group, an acyl group, a halogen atom, a cyanogroup or a nitro group, and R⁵ is a hydrogen atom or an optionallysubstituted hydrocarbon group, or a salt thereof,[11] the pharmaceutical composition of the above-mentioned [1], whereinthe nonpeptidic pharmaceutically active ingredient is1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamineor a salt thereof,1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamineor a salt thereof,1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamineor a salt thereof, or1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,[12] the pharmaceutical composition of the above-mentioned [1], which isa solid preparation, and[13] a method of stabilizing a pharmaceutical composition comprising anonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group and an excipient, comprising adding an acidiccompound to the pharmaceutical composition.

In addition, the second invention of the present invention relates to

[14] a solid preparation improved in the stability during lightirradiation, comprising a pharmaceutically active ingredient, titaniumoxide, a plasticizer and a chain organic acid,[15] the solid preparation of the above-mentioned [14], wherein theplasticizer is represented by the formula

HOCH₂(CH₂OCH₂)_(n)CH₂OH

(n=an integer of 2-870),[16] the solid preparation of the above-mentioned [14], wherein theplasticizer is polyethylene glycol (PEG),[17] the solid preparation of the above-mentioned [14], wherein thechain organic acid has pH 6.0 or below when dissolved or dispersed inwater,[18] the solid preparation of the above-mentioned [14], wherein thechain organic acid has an acid dissociation constant (pKa) of a protoncomplex of 4.0 or below when dissolved or dispersed in water,[19] the solid preparation of the above-mentioned [14], wherein thechain organic acid is any one kind or more selected from the groupconsisting of adipic acid, oleic acid, succinic acid, acetic acid,tartaric acid, sorbic acid, fumaric acid, lactic acid, maleic acid,malonic acid, citric acid and malic acid,[20] the solid preparation of the above-mentioned [14], wherein thecontent (%) of the chain organic acid is 0.01-50 wt %,[21] the solid preparation of the above-mentioned [14], wherein thepharmaceutically active ingredient is a compound represented by theformula

wherein X and Y are the same or different and each is a bond or a spacerhaving 1 to 20 atoms in the main chain, R¹ is an optionally substitutedhydrocarbon group or an optionally substituted heterocyclic group, R²,R³ and R⁴ are the same or different and each is a hydrogen atom, anoptionally substituted hydrocarbon group, an optionally substitutedthienyl group, an optionally substituted benzo[b]thienyl group, anoptionally substituted furyl group, an optionally substituted pyridylgroup, an optionally substituted pyrazolyl group, an optionallysubstituted pyrimidinyl group, an acyl group, a halogen atom, a cyanogroup or a nitro group, and R⁵ is a hydrogen atom or an optionallysubstituted hydrocarbon group, or a salt thereof,[22] the solid preparation of the above-mentioned [14], wherein thepharmaceutically active ingredient is1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamineor a salt thereof,1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamineor a salt thereof,1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamineor a salt thereof, or1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof, and[23] a method of stabilizing a solid preparation comprising apharmaceutically active ingredient, titanium oxide and a plasticizerduring light irradiation, comprising adding a chain organic acid to thesolid preparation.

Effect of the Invention

According to the first invention of the present invention, a stabilizedpharmaceutical composition comprising a nonpeptidic pharmaceuticallyactive ingredient having a primary or secondary amino group is provided.To be specific, since development of a decomposed product of thepharmaceutically active ingredient (nonpeptidic one having a primary orsecondary amino group) in the pharmaceutical composition is suppressed,a more stable pharmaceutical composition is provided. According to thepresent invention, moreover, since development of a decomposed productof the pharmaceutically active ingredient is suppressed regardless ofbeing in a closed bottle/open bottle, a pharmaceutical composition alsosuperior in the preservation stability can be provided.

In addition, according to the second invention of the present invention,a solid preparation improved in the stability of a pharmaceuticallyactive ingredient to light irradiation is provided. To be specific, asolid preparation stable to light irradiation can be provided by, whenthe pharmaceutically active ingredient contained in the solidpreparation is exposed to light, shielding the light and suppressing anincrease in a decomposed product.

DETAILED DESCRIPTION OF THE INVENTION

Firstly, the first invention of the present invention is explained indetail by referring to specific embodiments.

The pharmaceutical composition relating to the first invention of thepresent invention is characterized by addition of an acidic compound(third component) to a pharmaceutical composition containing anonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group (first component) and an excipient (secondcomponent). That is, the composition contains at least a nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup, an excipient and an acidic compound.

[1. Nonpeptidic Pharmaceutically Active Ingredient Having a Primary orSecondary Amino Group (First Component)]

Examples of the first component, “nonpeptidic pharmaceutically activeingredient having a primary or secondary amino group”, in thepharmaceutical composition of the present invention include a compoundrepresented by the following formula or a salt thereof. The compoundrepresented by the formula (A1) and a salt thereof do not include acompound having an amide group and a salt thereof.

wherein R^(a) is an organic residue, and R^(b) is a hydrogen atom or ahydrocarbon group optionally having substituent(s).

In the formula (A1), the “organic residue” for R^(a) is a monovalentgroup having 1 to 700 carbon atoms, and may contain, besides a carbonatom, a hydrogen atom, a nitrogen atom, an oxygen atom, a sulfur atom, ahalogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodineatom etc.) and the like. The “organic residue” is a hydrocarbon groupoptionally having substituent(s). Here, examples of the “hydrocarbongroup optionally having substituent(s)” include those similar to the“optionally substituted hydrocarbon group” for the below-mentioned R⁴⁰.When the hydrocarbon group has two or more substituents, they may form aring.

Examples of the “hydrocarbon group optionally having substituent(s)” forR^(b) in the formula (A1) include those similar to the “optionallysubstituted hydrocarbon group” for R⁵ in a compound represented by thefollowing (A2) to be described in detail in the following.

In the nonpeptidic pharmaceutically active ingredient having a primaryor secondary amino group, which is represented by the formula (A1), themore preferred are, for example, a compound represented by the followingformula (A1′) and a salt thereof.

wherein R^(C) is an organic residue, and Y is a bond or a spacer having1 to 20 atoms in the main chain.

In the above-mentioned formula (A1′), the “organic residue” for R^(c) isas defined above.

In the above-mentioned formula (A1′), examples of the “spacer having 1to 20 atoms in the main chain” for Y include those similar to Y in acompound represented by the following (A2).

Preferable examples of the above-mentioned nonpeptidic pharmaceuticallyactive ingredients having a primary or secondary amino group include acompound disclosed in WO 2006/036024 represented by the followingformula (A2) and a salt thereof.

wherein X and Y are the same or different and each is a bond or a spacerhaving 1 to 20 atoms in the main chain, R¹ is an optionally substitutedhydrocarbon group or an optionally substituted heterocyclic group, R²,R³ and R⁴ are the same or different and each is a hydrogen atom, anoptionally substituted hydrocarbon group, an optionally substitutedthienyl group, an optionally substituted benzo[b]thienyl group, anoptionally substituted furyl group, an optionally substituted pyridylgroup, an optionally substituted pyrazolyl group, an optionallysubstituted pyrimidinyl group, an acyl group, a halogen atom, a cyanogroup or a nitro group, and R⁵ is a hydrogen atom or an optionallysubstituted hydrocarbon group.

In the formula (A2), the “spacer having 1 to 20 atoms in the main chain”for X or Y means a divalent group having 1 to 20 contiguous atoms in themain chain. Here, the “number of atoms in the main chain” is countedsuch that the number of atoms in the main chain becomes minimum.

As the “spacer having 1 to 20 atoms in the main chain”, for example, adivalent group that can be formed with 1 to 5 (preferably 1 to 3)contiguous groups selected from

—O—; —S—; —CO—; —SO—; —SO₂—;

—NR⁴⁰— (wherein R⁴⁰ is a hydrogen atom, an optionally substitutedhydrocarbon group, an optionally substituted (e.g., halogenated) C₁₋₆alkyl-carbonyl, or an optionally substituted (e.g., halogenated) C₁₋₆alkylsulfonyl); anda divalent C₁₋₆ aliphatic hydrocarbon group optionally havingsubstituent(s)and the like can be mentioned.

As the “hydrocarbon group” of the “optionally substituted hydrocarbongroup” for R⁴⁰, for example, a chain or cyclic hydrocarbon group (e.g.,alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl etc.) can bementioned. Of these, a chain or cyclic hydrocarbon group having 1 to 16carbon atoms and the like are preferable.

As the “alkyl”, for example, C₂₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)and the like can be mentioned.

As the “alkenyl”, for example, C₂₋₆ alkenyl (e.g., vinyl, allyl,isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl,1-methyl-2-propenyl, 2-methyl-1-propenyl etc.) and the like can bementioned.

As the “alkynyl”, for example, C₂₋₆ alkynyl (e.g., ethynyl, propargyl,1-butynyl, 2-butynyl, 3-butynyl, 1-hexynyl etc.) and the like can bementioned.

As the “cycloalkyl”, for example, C₃₋₇ cycloalkyl (e.g., cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc.) and the like canbe mentioned.

As the “aryl”, for example, C₆₋₁₄ aryl (e.g., phenyl, 1-naphthyl,2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.)and the like can be mentioned.

As the “aralkyl”, for example, C₇₋₂₆ aralkyl (e.g., phenyl-C₁₋₆ alkyl,naphthyl-C₁₋₆ alkyl or diphenyl-C₁₋₄ alkyl etc. such as benzyl,phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl,2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl and thelike) and the like can be mentioned.

When the above-mentioned hydrocarbon group is an alkyl, an alkenyl or analkynyl, the hydrocarbon group is optionally substituted by 1 to 3substituents selected from (1) a halogen atom (e.g., a fluorine atom, achlorine atom, a bromine atom, an iodine atom etc.), (2) nitro, (3)cyano, (4) hydroxy, (5) C₁₋₆ alkoxy optionally having 1 to 3 halogenatoms (e.g., a fluorine atom, a chlorine atom, a bromine atom, an iodineatom) (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy,sec-butoxy, pentyloxy, hexyloxy, fluoromethoxy etc.), (6) C₆₋₁₄ aryloxy(e.g., phenyloxy, naphthyloxy etc.), (7) C₇₋₁₆ aralkyloxy (e.g.,benzyloxy, phenethyloxy, diphenylmethyloxy, 1-naphthylmethyloxy,2-naphthylmethyloxy, 2,2-diphenylethyloxy, 3-phenylpropyloxy,4-phenylbutyloxy, 5-phenylpentyloxy etc.), (8) mercapto, (9) C₁₋₆alkylthio optionally having 1 to 3 halogen atoms (e.g., a fluorine atom,a chlorine atom, a bromine atom, an iodine atom) (e.g., methylthio,difluoromethylthio, trifluoromethylthio, ethylthio, propylthio,isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio,hexylthio etc.), (10) C₆₋₁₄ arylthio (e.g., phenylthio, naphthylthioetc.), (11) C₇₋₁₆ aralkylthio (e.g., benzylthio, phenethylthio,diphenylmethylthio, 1-naphthylmethylthio, 2-naphthylmethylthio,2,2-diphenylethylthio, 3-phenylpropylthio, 4-phenylbutylthio,5-phenylpentylthio etc.), (12) amino, (13) mono-C₁₋₆ alkylamino (e.g.,methylamino, ethylamino etc.), (14) mono-C₆₋₁₄ arylamino (e.g.,phenylamino, 1-naphthylamino, 2-naphthylamino etc.), (15) mono-C₇₋₁₆aralkylamino (e.g., benzylamino etc.), (16) di-C₁₋₆ alkylamino (e.g.,dimethylamino, diethylamino etc.), (17) di-C₆₋₁₄ arylamino (e.g.,diphenylamino etc.), (18) di-C₇₋₁₆ aralkylamino (e.g., dibenzylaminoetc.), (19) formyl, (20) C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyletc.), (21) C₆₋₁₄ aryl-carbonyl (e.g., benzoyl, 1-naphthoyl, 2-naphthoyletc.), (22) carboxyl, (23) C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl etc.), (24) C₆₋₁₄aryloxy-carbonyl (e.g., phenoxycarbonyl etc.), (25) carbamoyl, (26)thiocarbamoyl, (27) mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl,ethylcarbamoyl etc.), (28) di-C₁₋₆ alkyl-carbamoyl (e.g.,dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl etc.), (29)C₆₋₁₄ aryl-carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl,2-naphthylcarbamoyl etc.), (30) C₁₋₆ alkylsulfonyl (e.g.,methylsulfonyl, ethylsulfonyl etc.), (31) C₆₋₁₄ arylsulfonyl (e.g.,phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl etc.), (32) C₁₋₆alkylsulfinyl (e.g., methylsulfinyl, ethylsulfinyl etc.), (33) C₆₋₁₄arylsulfinyl (e.g., phenylsulfinyl, 1-naphthylsulfinyl,2-naphthylsulfinyl etc.), (34) formylamino, (35) C₁₋₆alkyl-carbonylamino (e.g., acetylamino etc.), (36) C₆₋₁₄aryl-carbonylamino (e.g., benzoylamino, naphthoylamino etc.), (37) C₁₋₆alkoxy-carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino,propoxycarbonylamino, butoxycarbonylamino etc.), (38) C₁₋₆alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino etc.),(39) C₆₋₁₄ arylsulfonylamino (e.g., phenylsulfonylamino,2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.), (40) C₁₋₆alkyl-carbonyloxy (e.g., acetoxy, propionyloxy etc.), (41) C₆₋₁₄aryl-carbonyloxy (e.g., benzoyloxy, naphthylcarbonyloxy etc.), (42) C₁₋₆alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy,propoxycarbonyloxy, butoxycarbonyloxy etc.), (43) mono-C₁₋₆alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy etc.),(44) di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy,diethylcarbamoyloxy etc.), (45) C₆₋₁₄ aryl-carbamoyloxy (e.g.,phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), (46) a 5- to 7-memberedsaturated cyclic amino optionally containing, besides one nitrogen atomand carbon atom, 1 or 2 kinds of 1 to 4 hetero atoms selected from anitrogen atom, a sulfur atom and an oxygen atom (e.g., pyrrolidin-1-yl,piperidino, piperazin-1-yl, morpholino, thiomorpholino,hexahydroazepin-1-yl etc.), (47) a 5- to 10-membered aromaticheterocyclic group containing, besides carbon atom, 1 or 2 kinds of 1 to4 hetero atoms selected from a nitrogen atom, a sulfur atom and anoxygen atom (e.g., 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl,4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl,1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl,2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl,3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), (48) C₁₋₃alkylenedioxy (e.g., methylenedioxy, ethylenedioxy etc.), and (49) C₃₋₇cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl etc.) (hereinafter to be referred to as substituent group A)and the like. The substituent may have 1 to 4 substituents atsubstitutable position. Examples of such substituent include thosesimilar to substituents in substituent group A.

When the above-mentioned hydrocarbon group is a cycloalkyl, an aryl oran aralkyl, the hydrocarbon group is optionally substituted by 1 to 5(preferably 1 to 3) substituents selected from (1) a halogen atom (e.g.,a fluorine atom, a chlorine atom, a bromine atom, an iodine atom etc.),(2) nitro, (3) cyano, (4) hydroxy, (5) C₁₋₆ alkoxy optionally having 1to 3 halogen atoms (e.g., a fluorine atom, a chlorine atom, a bromineatom, an iodine atom) (e.g., methoxy, ethoxy, propoxy, isopropoxy,butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, fluoromethoxy etc.),(6) C₆₋₁₄ aryloxy (e.g., phenyloxy, naphthyloxy etc.), (7) C₇₋₁₆aralkyloxy (e.g., benzyloxy, phenethyloxy, diphenylmethyloxy,1-naphthylmethyloxy, 2-naphthylmethyloxy, 2,2-diphenylethyloxy,3-phenylpropyloxy, 4-phenylbutyloxy, 5-phenylpentyloxy etc.), (8)mercapto, (9) C₁₋₆ alkylthio optionally having 1 to 3 halogen atoms(e.g., a fluorine atom, a chlorine atom, a bromine atom, an iodine atom)(e.g., methylthio, difluoromethylthio, trifluoromethylthio, ethylthio,propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio,pentylthio, hexylthio etc.), (10) C₆₋₁₄ arylthio (e.g., phenylthio,naphthylthio etc.), (11) C₇₋₁₆ aralkylthio (e.g., benzylthio,phenethylthio, diphenylmethylthio, 1-naphthylmethylthio,2-naphthylmethylthio, 2,2-diphenylethylthio, 3-phenylpropylthio,4-phenylbutylthio, 5-phenylpentylthio etc.), (12) amino, (13) mono-C₁₋₆alkylamino (e.g., methylamino, ethylamino etc.), (14) mono-C₆₋₁₄arylamino (e.g., phenylamino, 1-naphthylamino, 2-naphthylamino etc.),(15) mono-C₇₋₁₆ aralkylamino (e.g., benzylamino etc.), (16) di-C₁₋₆alkylamino (e.g., dimethylamino, diethylamino etc.), (17) di-C₆₋₁₄arylamino (e.g., diphenylamino etc.), (18) di-C₇₋₁₆ aralkylamino (e.g.,dibenzylamino etc.), (19) formyl, (20) C₁₋₆ alkyl-carbonyl (e.g.,acetyl, propionyl etc.), (21) C₆₋₁₄ aryl-carbonyl (e.g., benzoyl,1-naphthoyl, 2-naphthoyl etc.), (22) carboxyl, (23) C₁₋₆ alkoxy-carbonyl(e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,tert-butoxycarbonyl etc.), (24) C₆₋₁₄ aryloxy-carbonyl (e.g.,phenoxycarbonyl etc.), (25) carbamoyl, (26) thiocarbamoyl, (27)mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl etc.),(28) di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl,ethylmethylcarbamoyl etc.), (29) C₆₋₁₄ aryl-carbamoyl (e.g.,phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), (30)C₁₋₆ alkylsulfonyl optionally having 1 to 3 halogen atoms (e.g., afluorine atom, a chlorine atom, a bromine atom, an iodine atom) (e.g.,methylsulfonyl, ethylsulfonyl, trifluoromethylsulfonyl etc.), (31) C₆₋₁₄arylsulfonyl (e.g., phenylsulfonyl, 1-naphthylsulfonyl,2-naphthylsulfonyl etc.), (32) C₁₋₆ alkylsulfinyl (e.g., methylsulfinyl,ethylsulfinyl etc.), (33) C₆₋₁₄ arylsulfinyl (e.g., phenylsulfinyl,1-naphthylsulfinyl, 2-naphthylsulfinyl etc.), (34) formylamino, (35)C₁₋₆ alkyl-carbonylamino (e.g., acetylamino etc.), (36) C₆₋₁₄aryl-carbonylamino (e.g., benzoylamino, naphthoylamino etc.), (37) C₁₋₆alkoxy-carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino,propoxycarbonylamino, butoxycarbonylamino etc.), (38) C₁₋₆alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino etc.),(39) C₆₋₁₄ arylsulfonylamino (e.g., phenylsulfonylamino,2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.), (40) C₁₋₆alkyl-carbonyloxy (e.g., acetoxy, propionyloxy etc.), (41) C₆₋₁₄aryl-carbonyloxy (e.g., benzoyloxy, naphthylcarbonyloxy etc.), (42) C₁₋₆alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy,propoxycarbonyloxy, butoxycarbonyloxy etc.), (43) mono-C₁₋₆alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy etc.),(44) di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy,diethylcarbamoyloxy etc.), (45) C₆₋₁₄ aryl-carbamoyloxy (e.g.,phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), (46) a 5- to 7-memberedsaturated cyclic amino optionally containing, besides one nitrogen atomand carbon atom, 1 or 2 kinds of 1 to 4 hetero atoms selected from anitrogen atom, a sulfur atom and an oxygen atom (e.g., pyrrolidin-1-yl,piperidino, piperazin-1-yl, morpholino, thiomorpholino,hexahydroazepin-1-yl etc.), (47) a 5- to 10-membered aromaticheterocyclic group containing, besides carbon atom, 1 or 2 kinds of 1 to4 hetero atoms selected from a nitrogen atom, a sulfur atom and anoxygen atom (e.g., 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl,4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl,1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl,2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl,3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), (48) C₁₋₃alkylenedioxy (e.g., methylenedioxy, ethylenedioxy etc.), (49) C₃₋₇cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl etc.), (50) C₁₋₆ alkyl group (e.g., methyl, ethyl, n-propyl,isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,sec-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl etc.) optionallyhaving 1 to 3 halogen atoms (e.g., a fluorine atom, a chlorine atom, abromine atom, an iodine atom) or hydroxy groups, (51) a C₂₋₆ alkenylgroup (e.g., allyl, isopropenyl, isobutenyl, 1-methylallyl, 2-pentenyl,2-hexenyl etc.) optionally having 1 to 3 halogen atoms (e.g., a fluorineatom, a chlorine atom, a bromine atom, an iodine atom), (52) a C₂₋₆alkynyl group (e.g., propargyl, 2-butynyl, 3-butynyl, 3-pentynyl,3-hexynyl etc.), (53) mono-C₃₋₇ cycloalkyl-carbamoyl (e.g.,cyclopropylcarbamoyl, cyclobutylcarbamoyl etc.), and (54) a 5 to10-membered heterocyclyl-carbonyl containing, besides carbon atom, oneor two kinds of 1 to 4 hetero atoms selected from a nitrogen atom, asulfur atom and an oxygen atom (e.g., 4-morpholinocarbonyl etc.)(hereinafter to be referred to as substituent group B) and the like.

In the present specification, the substituent of the “optionallysubstituted hydrocarbon group” does not include an oxo group.

As the “optionally halogenated C₁₋₆ alkyl-carbonyl” for R⁴⁰, forexample, C₁₋₆ alkyl-carbonyl optionally having 1 to 5, preferably 1 to 3halogen atoms (e.g., a fluorine atom, a chlorine atom, a bromine atom,an iodine atom and the like) at substitutable positions and the like canbe mentioned. Specific examples include, for example, acetyl,monochloroacetyl, trifluoroacetyl, trichloroacetyl, propanoyl, butanoyl,pentanoyl, hexanoyl and the like.

As the “optionally halogenated C₁₋₆ alkylsulfonyl” for R⁴⁰, for example,C₁₋₆ alkylsulfonyl optionally having 1 to 5, preferably 1 to 3 halogenatoms (e.g., a fluorine atom, a chlorine atom, a bromine atom, an iodineatom and the like) at substitutable positions and the like can bementioned. Specific examples include, for example, methylsulfonyl,difluoromethylsulfonyl, trifluoromethylsulfonyl, ethylsulfonyl,propylsulfonyl, isopropylsulfonyl, butylsulfonyl,4,4,4-trifluorobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl,pentylsulfonyl, hexylsulfonyl and the like.

As the “divalent C₁₋₆ aliphatic hydrocarbon group” of the aforementioned“divalent C₁₋₆ aliphatic hydrocarbon group optionally havingsubstituent(s)”, an alkylene group, an alkenylene group, an alkynylenegroup can be mentioned, for example,

(1) a C₁₋₆ alkylene (e.g., —CH₂—, —(CH₂)₂—, —(CH₂)₃—, —(CH₂)₄—,—(CH₂)₅—, —(CH₂)₆—, —CH(CH₃)—, —C(CH₃)₂—, —(CH(CH₃))₂—, —(CH₂)₂C(CH₃)₂—,—(CH₂)₃C(CH₃)₂— and the like);(2) a C₂₋₆ alkenylene (e.g., —CH═CH—, —CH₂—CH═CH—, —CH═CH—CH₂—,—CH═CH—CH₂—CH₂—, —C(CH₃)₂—CH═CH—, —CH₂—CH═CH—CH₂—, —CH₂—CH₂—CH═CH—,—CH═CH—CH═CH—, —CH═CH—CH₂—CH₂—CH₂— and the like);(3) a C₂₋₆ alkynylene (e.g., —C≡C—, —CH₂—C≡C—, —CH₂—C≡C—CH₂—CH₂— and thelike) and the like can be mentioned.

As the “substituent” of the “divalent C₁₋₆ aliphatic hydrocarbon groupoptionally having substituent(s)”, for example, those similar to thesubstituents of the alkyl, alkenyl or alkynyl exemplified as theaforementioned “optionally substituted hydrocarbon group” for R⁴⁰, canbe mentioned, particularly, halogen atom (e.g., a fluorine atom, achlorine atom, a bromine atom, an iodine atom), hydroxy and the like arepreferable. The number of the substituents is, for example, 1 to 5,preferably 1 to 3.

As preferable examples of the “spacer having 1 to 20 atoms in the mainchain”

(1) an optionally substituted alkylene group: specifically, a C₁₋₂₀alkylene (e.g., —CH₂—, —(CH₂)₂—, —(CH₂)₃—, —CH(OH)—(CH₂)₂—, —(CH₂)₄—,—(CH₂)₅—, —(CH₂)₆—, —CHCH₃—, —C(CH₃)₂—, —CH(CF₃)—, —(CH(CH₃))₂—,—(CF₂)₂—, —(CH₂)₂C(CH₃)₂—, —(CH₂)₃C(CH₃)₂—, —(CH₂)₇—, —(CH₂)₈—,—(CH₂)₉—, —(CH₂)₁₀—, —(CH₂)₁₁—, —(CH₂)₁₂—, —(CH₂)₁₃—, —(CH₂)₁₄—,—(CH₂)₁₅—, —(CH₂)₁₆—, —(CH₂)₁₇—, —(CH₂)₁₈—, —(CH₂)₁₉—, —(CH₂)₂₀— and thelike) optionally having 1 to 3 substituents (preferably, halogen atom,hydroxy and the like); (2) an optionally substituted alkenylene group:specifically, a C₂₋₂₀ alkenylene (e.g., —CH═CH—, —CH₂—CH═CH—,—CH═CH—CH₂—, —CH═CH—CH₂—CH₂—, —CH₂—CF═CH—, —C(CH₃)₂—CH═CH—,—CH₂—CH═CH—CH₂—, —CH₂—CH₂—CH═CH—, —CH═CH—CH═CH—, —CH═CH—CH₂—CH₂—CH₂— andthe like) optionally having 1 to 3 substituents (preferably, halogenatom, hydroxy and the like); (3) an optionally substituted alkynylenegroup:specifically, a C₂₋₂₀ alkynylene (e.g., —C≡C—, —CH₂—C≡C—,—CH₂—C≡C—CH₂—CH₂— and the like) optionally having 1 to 3 substituents(preferably, halogen atom, hydroxy and the like); (4)—(CH₂)_(w1a)O(CH₂)_(w2a)—, —(CH₂)_(w1a)S(CH₂)_(w2a)—,—(CH₂)_(w1a)CO(CH₂)_(w2a)—, —(CH₂)_(w1a)SO(CH₂)_(w2a)—,—(CH₂)_(w1a)SO₂(CH₂)_(w2a)—, —(CH₂)_(w1a)NR⁴⁰(CH₂)_(w2a)—; (5)—(CH₂)_(w3a)CO—, —(CH₂)_(w3a)CONR⁴⁰(CH₂)_(w4a)—,—(CH₂)_(w3a)NR⁴⁰CO(CH₂)_(w4a)—, —(CH₂)_(w3a)SO₂NR⁴⁰(CH₂)_(w4a)—,—(CH₂)_(w3a)NR⁴⁰SO₂(CH₂)_(w4a)—, —(CH₂)_(w3a)COO(CH₂)_(w4a)—; (6)—(CH₂)_(w5a)NR⁴⁰CONR^(40b)(CH₂)_(w6a)—;wherein R⁴⁰ is as defined above; R^(40b) is as defined as R⁴⁰; w1a andw2a are each an integer of 0 to 19, and w1a+w2a is 0 to 19; w3a and w4aare each an integer of 0 to 18, and w3a+w4a is 0 to 18; w5a and w6a areeach an integer of 0 to 17, and w5a+w6a is 0 to 17,and the like can be mentioned.

As the aforementioned “spacer having 1 to 20 atoms in the main chain”,the following “spacer having 1 to 8 atoms in the main chain” ispreferable.

(1) a C₁₋₈ alkylene optionally having 1 to 3 substituents (preferably,halogen atom, hydroxy and the like) (e.g., —CH₂—, —(CH₂)₂—, —(CH₂)₃—,—CH(OH)—(CH₂)₂—, —(CH₂)₄—, —(CH₂)₅—, —(CH₂)₆—, —CHCH₃—, —C(CH₃)₂—,—CH(CF₃)—, —(CH(CH₃))₂—, —(CF₂)₂—, —(CH₂)₂C(CH₃)₂—, —(CH₂)₃C(CH₃)₂— andthe like); (2) a C₂₋₈ alkenylene optionally having 1 to 3 substituents(preferably, halogen atom, hydroxy and the like) (e.g., —CH═CH—,—CH₂—CH═CH—, —CH═CH—CH₂—, —CH═CH—CH₂—CH₂—, —CH₂—CF═CH—, —C(CH₃)₂—CH═CH—,—CH₂—CH═CH—CH₂—, —CH₂—CH₂—CH═CH—, —CH═CH—CH═CH—, —CH═CH—CH₂—CH₂—CH₂— andthe like); (3) a C₂₋₈ alkynylene (e.g., —C≡C—, —CH₂—C≡C—,—CH₂—C≡C—CH₂—CH₂— and the like) optionally having 1 to 3 substituents(preferably, halogen atom, hydroxy and the like); (4)—(CH₂)_(w1)O(CH₂)_(w2)—, —(CH₂)_(w1)S(CH₂)_(w2)—,—(CH₂)_(w1)CO(CH₂)_(w2)—, —(CH₂)_(w1)SO(CH₂)_(w2)—,—(CH₂)_(w1)SO₂(CH₂)_(w2)—, —(CH₂)_(w1)NR⁴⁰(CH₂)_(w2)—; (5)—(CH₂)_(w3)CO—, —(CH₂)_(w3)CONR⁴⁰(CH₂)_(w4)—,—(CH₂)_(w3)NR⁴⁰CO(CH₂)_(w4)—, —(CH₂)_(w3)SO₂NR⁴⁰(CH₂)_(w4)—,—(CH₂)_(w3)NR⁴⁰SO₂CH₂)_(w4)—, —(CH₂)_(w3)COO(CH₂)_(w4)—; (6)—(CH₂)_(w5)NR⁴⁰CONR^(40b)(CH₂)_(w6)—;wherein R⁴⁰ is as defined above; R^(40b) is as defined as R⁴⁰; w1 and w2are each an integer of 0 to 5, and w1+w2 is 0 to 7; w3 and w4 are eachan integer of 0 to 4, and w3+w4 is 0 to 6; w5 and w6 are each an integerof 0 to 3, and w5+w6 is 0 to 5, and the like can be mentioned.

The “spacer having 1 to 20 atoms in the main chain” is preferably thefollowing (1) to (6).

(1) —SO₂—; (2) —SO₂—N(R⁷)— wherein R⁷ is a hydrogen atom or anoptionally substituted hydrocarbon group, and as the “optionallysubstituted hydrocarbon group” for R⁷, those similar to theaforementioned “optionally substituted hydrocarbon group” for R⁴⁰ can bementioned; (3) —N(R⁸)—SO₂— wherein R⁸ is a hydrogen atom or anoptionally substituted hydrocarbon group, and as the “optionallysubstituted hydrocarbon group” for R⁸, those similar to theaforementioned “optionally substituted hydrocarbon group” for R⁴⁰ can bementioned; (4) —N(R⁹)— wherein R⁹ is a hydrogen atom or an optionallysubstituted hydrocarbon group, and as the “optionally substitutedhydrocarbon group” for R⁹, those similar to the aforementioned“optionally substituted hydrocarbon group” for R⁴⁰ can be mentioned; (5)—O—; (6) an optionally substituted alkylene group, preferably a C₁₋₈alkylene optionally having 1 to 3 substituents (preferably, halogenatom, hydroxy and the like) (e.g., —CH₂—, —(CH₂)₂—, —(CH₂)₃—,—CH(OH)—(CH₂)₂—, —(CH₂)₄—, —(CH₂)₅—, —(CH₂)₆—, —CHCH₃—, —C(CH₃)₂—,—CH(CF₃)—, —(CH(CH₃))₂—, —(CF₂)₂—, —(CH₂)₂C(CH₃)₂—, —(CH₂)₃C(CH₃)₂— andthe like).

In the formula (A2), X is preferably —SO₂—, —SO₂—N(R⁷)— (wherein R⁷ isas defined above), —N(R⁸)—SO₂— (wherein R⁸ is as defined above), —N(R⁹)—(wherein R⁹ is as defined above) or —O—, particularly preferably —SO₂—.

Y is preferably a bond or a C₁₋₈ alkylene (e.g., —CH₂—, —(CH₂)₂—,—(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅—, —(CH₂)₆—, —CHCH₃—, —C(CH₃)₂—,—(CH(CH₃))₂—, —(CH₂)₂C(CH₃)₂—, —(CH₂)₃C(CH₃)₂— and the like).

In the aforementioned formula (A2), R¹ is an optionally substitutedhydrocarbon group or an optionally substituted heterocyclic group.

As the “optionally substituted hydrocarbon group”, those similar to theaforementioned “optionally substituted hydrocarbon group” for R⁴⁰ can bementioned.

As the “heterocyclic group” of the “optionally substituted heterocyclicgroup”, for example, a 3 to 8-membered heterocyclic group (preferably 5-or 6-membered heterocyclic group) containing 1 to 4 hetero atomsselected from a nitrogen atom (optionally oxidized), an oxygen atom, asulfur atom (optionally mono- or di-oxidized) and the like; or a groupformed by condensing a 3 to 8-membered heterocyclic group (preferably 5-or 6-membered heterocyclic group) containing 1 to 4 hetero atomsselected from a nitrogen atom (optionally oxidized), an oxygen atom, asulfur atom (optionally mono- or di-oxidized) and the like, and abenzene ring or a 3 to 8-membered heterocyclic group (preferably 5- or6-membered heterocyclic group) containing 1 to 4 hetero atoms selectedfrom a nitrogen atom (optionally oxidized), an oxygen atom, a sulfuratom (optionally mono- or di-oxidized) and the like, preferably a groupformed by condensing the 5- or 6-membered heterocyclic group and a 5- or6-membered ring containing 1 to 4 hetero atoms selected from a nitrogenatom (optionally oxidized), an oxygen atom, a sulfur atom (optionallymono- or di-oxidized) and the like, can be mentioned.

To be specific, aziridinyl (e.g., 1- or 2-aziridinyl), azirinyl (e.g.,1- or 2-azirinyl), azetyl (e.g., 2-, 3- or 4-azetyl), azetidinyl (e.g.,1-, 2- or 3-azetidinyl), perhydroazepinyl (e.g., 1-, 2-, 3- or4-perhydroazepinyl), perhydroazocinyl (e.g., 1-, 2-, 3-, 4- or5-perhydroazocinyl), pyrrolyl (e.g., 1-, 2- or 3-pyrrolyl), pyrazolyl(e.g., 1-, 3-, 4- or 5-pyrazolyl), imidazolyl (e.g., 1-, 2-, 4- or5-imidazolyl), triazolyl (e.g., 1,2,3-triazol-1-, 4- or -5-yl,1,2,4-triazol-1-, 3-, 4- or 5-yl), tetrazolyl (e.g., tetrazol-1-, 2- or5-yl), furyl (e.g., 2- or 3-furyl), thienyl (e.g., 2- or 3-thienyl),thienyl wherein the sulfur atom is oxidized (e.g., 2- or3-thienyl-1,1-dioxide), oxazolyl (e.g., 2-, 4- or 5-oxazolyl),isoxazolyl (e.g., 3-, 4- or 5-isoxazolyl), oxadiazolyl (e.g.,1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl,1,2,5-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl), thiazolyl (e.g., 2-, 4- or5-thiazolyl), isothiazolyl (e.g., 3-, 4- or 5-isothiazolyl),thiadiazolyl (e.g., 1,2,3-thiadiazol-4- or 5-yl, 1,2,4-thiadiazol-3- or5-yl, 1,2,5-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl), pyrrolidinyl (e.g.,1-, 2- or 3-pyrrolidinyl), pyridyl (e.g., 2-, 3- or 4-pyridyl), pyridylwherein the nitrogen atom is oxidized (e.g., 2-, 3- or4-pyridyl-N-oxide), pyridazinyl (e.g., 3- or 4-pyridazinyl), pyridazinylwherein one or both of the nitrogen atom is oxidized (e.g., 3-, 4-, 5-or 6-pyridazinyl-N-oxide), pyrimidinyl (e.g., 2-, 4- or 5-pyrimidinyl),pyrimidinyl wherein one or both of the nitrogen atoms is(are) oxidized(e.g., 2-, 4-, 5- or 6-pyrimidinyl-N-oxide), pyrazinyl, piperidinyl(e.g., 1-, 2-, 3- or 4-piperidinyl), piperazinyl (e.g., 1- or2-piperazinyl), indolyl (e.g., 3H-indol-2-, 3-, 4-, 5-, 6- or 7-yl),pyranyl (e.g., 2-, 3- or 4-pyranyl), thiopyranyl (e.g., 2-, 3- or4-thiopyranyl), thiopyranyl wherein the sulfur atom is oxidized (e.g.,2-, 3- or 4-thiopyranyl-1,1-dioxide), morpholinyl (e.g., 2-, 3- or4-morpholinyl), thiomorpholinyl, quinolyl (e.g., 2-, 3-, 4-, 5-, 6-, 7-or 8-quinolyl), isoquinolyl, pyrido[2,3-d]pyrimidinyl (e.g.,pyrido[2,3-d]pyrimidin-2-yl), naphthyridinyl such as 1,5-, 1,6-, 1,7-,1,8-, 2,6- or 2,7-naphthyridinyl and the like (e.g., 1,5-naphthyridin-2-or 3-yl), thieno[2,3-d]pyridyl (e.g., thieno[2,3-d]pyridin-3-yl),pyrazinoquinolyl (e.g., pyrazino[2,3-d]quinolin-2-yl), chromenyl (e.g.,2H-chromen-2- or 3-yl), 2-benzo[b]thienyl, 3-benzo[b]thienyl,2-benzo[b]furanyl, 3-benzo[b]furanyl, 2,3-dihydro-1-benzofuranyl,2,1,3-benzothiadiazolyl, 2,3-dihydro-1,4-benzodioxin-5- or -6-yl,1,3-benzothiazol-6-yl, 1,1-dioxido-2,3-dihydro-1-benzothien-6-yl,1-benzothienyl and the like can be used.

Examples of the “substituent” of the heterocyclic group include thosesimilar to the substituents selected from the above-mentionedsubstituent group B. The number of the substituents is, for example, 1to 5, preferably 1 to 3.

R¹ is preferably an optionally substituted alkyl group, an optionallysubstituted aryl group, an optionally substituted aralkyl group, anoptionally substituted thienyl group or an optionally substitutedpyridyl group, more preferably an optionally substituted alkyl group, anoptionally substituted aryl group, an optionally substituted aralkylgroup or an optionally substituted pyridyl group, particularlypreferably an optionally substituted aryl group or an optionallysubstituted pyridyl group.

To be specific, R¹ is preferably [1] C₁₋₆ alkyl (e.g., methyl, ethyl,propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyletc.), [2] a C₆₋₁₄ aryl group (e.g., phenyl etc.) optionally substitutedby 1 to 5 (preferably 1 to 3) substituents selected from (i) halogen(e.g., fluorine, chlorine, bromine, iodine), (ii) hydroxy, (iii) cyano,(iv) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl,isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine,chlorine, bromine, iodine), (v) C₁₋₆ alkoxy (e.g., methoxy, ethoxy,propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxyetc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens(e.g., fluorine, chlorine, bromine, iodine) and (vi) phenyl, or [3] an(unsubstituted) thienyl group or [4] an (unsubstituted) pyridyl group,

particularly preferably a C₆₋₁₄ aryl group (e.g., phenyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) substituentsselected from halogen, hydroxy and C₁₋₆ alkyl or an (unsubstituted)pyridyl group.

In the aforementioned formula (A2), R², R³ and R⁴ are the same ordifferent and each is a hydrogen atom or an optionally substitutedhydrocarbon group, an optionally substituted thienyl group, anoptionally substituted benzo[b]thienyl group, an optionally substitutedfuryl group, an optionally substituted pyridyl group, an optionallysubstituted pyrazolyl group, an optionally substituted pyrimidinylgroup, an acyl group, a halogen atom, a cyano group or a nitro group,preferably, a hydrogen atom or an optionally substituted hydrocarbongroup, an optionally substituted thienyl group, an optionallysubstituted benzo[b]thienyl group, an optionally substituted furylgroup, an optionally substituted pyridyl group, an acyl group, a halogenatom, a cyano group or a nitro group.

As the “optionally substituted hydrocarbon group” for R², R³ or R⁴,those similar to the aforementioned “optionally substituted hydrocarbongroup” for R⁴⁰ can be mentioned.

As the “thienyl group” of the “optionally substituted thienyl group” forR², R³ or R⁴, 2- or 3-thienyl can be mentioned.

Examples of the “substituent” of the thienyl group include those similarto the substituents selected from the above-mentioned substituent groupB. The number of the substituents is 1 to 3.

As the “benzo[b]thienyl group” of the “optionally substitutedbenzo[b]thienyl group” for R², R³ or R⁴, 2- or 3-benzo[b]thienyl can bementioned.

Examples of the “substituent” of the benzo[b]thienyl group include thosesimilar to the substituents selected from the above-mentionedsubstituent group B. The number of the substituents is, for example, 1to 5, preferably 1 to 3.

As the “furyl group” of the “optionally substituted furyl group” for R²,R³ or R⁴, 2- or 3-furyl can be mentioned.

Examples of the “substituent” of the furyl group include those similarto the substituents selected from the above-mentioned substituent groupB. The number of the substituents is 1 to 3.

As the “pyridyl group” of the “optionally substituted pyridyl group” forR², R³ or R⁴, 2-, 3- or 4-pyridyl can be mentioned.

Examples of the “substituent” of the pyridyl group include those similarto the substituents selected from the above-mentioned substituent groupB. The number of the substituents is 1 to 3.

As the “pyrazolyl group” of the “optionally substituted pyrazolyl group”for R², R³ or R⁴, 3- or 4-pyrazolyl can be mentioned.

Examples of the “substituent” of the pyrazolyl group include thosesimilar to the substituents selected from the above-mentionedsubstituent group B. The number of the substituents is 1 to 3.

As the “pyrimidinyl group” of the “optionally substituted pyrimidinylgroup” for R², R³ or R⁴, 2-, 4- or 5-pyrimidinyl can be mentioned.

Examples of the “substituent” of the pyrimidinyl group include thosesimilar to the substituents selected from the above-mentionedsubstituent group B. The number of the substituents is 1 to 3.

As the “acyl group” for R², R³ or R⁴, an acyl group having 1 to 20carbon atoms, which is derived from an organic carboxylic acid can bementioned. For example, C₁₋₇ alkanoyl groups (e.g., formyl; C₁₋₆alkyl-carbonyl such as acetyl, propionyl, butyryl, isobutyryl,pentanoyl, hexanoyl, heptanoyl and the like; etc.), C₆₋₁₄ aryl-carbonylgroups (e.g., benzoyl, naphthalenecarbonyl etc.), C₁₋₆ alkoxy-carbonylgroups (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl,sec-butoxycarbonyl, tert-butoxycarbonyl etc.), C₆₋₁₄ aryloxy-carbonylgroups (e.g., phenoxycarbonyl group), C₇₋₁₉ aralkyl-carbonyl groups(e.g., phenyl-C₁₋₄ alkylcarbonyl such as benzylcarbonyl,phenethylcarbonyl, phenylpropylcarbonyl and the like, naphthyl-C₁₋₄alkylcarbonyl such as benzhydrylcarbonyl, naphthylethylcarbonyl and thelike, etc.), C₇₋₁₉ aralkyloxy-carbonyl groups (e.g., phenyl-C₁₋₄alkyloxycarbonyl such as benzyloxycarbonyl and the like, etc.), 5- or6-membered heterocyclyl-carbonyl group or condensedheterocyclyl-carbonyl groups thereof (e.g., pyrrolylcarbonyl such as 2-or 3-pyrrolylcarbonyl and the like; pyrazolylcarbonyl such as 3-, 4- or5-pyrazolylcarbonyl and the like; imidazolylcarbonyl such as 2-, 4- or5-imidazolylcarbonyl and the like; triazolylcarbonyl such as1,2,3-triazol-4-ylcarbonyl, 1,2,4-triazol-3-ylcarbonyl and the like;tetrazolylcarbonyl such as 1H- or 2H-tetrazol-5-ylcarbonyl and the like;furylcarbonyl such as 2- or 3-furylcarbonyl and the like;thienylcarbonyl such as 2- or 3-thienylcarbonyl and the like;oxazolylcarbonyl such as 2-, 4- or 5-oxazolylcarbonyl and the like;isoxazolylcarbonyl such as 3-, 4- or 5-isoxazolylcarbonyl and the like;oxadiazolylcarbonyl such as 1,2,3-oxadiazol-4- or 5-ylcarbonyl,1,2,4-oxadiazol-3- or 5-ylcarbonyl, 1,2,5-oxadiazol-3- or 4-ylcarbonyl,1,3,4-oxadiazol-2-ylcarbonyl and the like; thiazolylcarbonyl such as 2-,4- or 5-thiazolylcarbonyl and the like; isothiazolylcarbonyl such as 3-,4- or 5-isothiazolylcarbonyl and the like; thiadiazolylcarbonyl such as1,2,3-thiadiazol-4- or 5-ylcarbonyl, 1,2,4-thiadiazol-3- or5-ylcarbonyl, 1,2,5-thiadiazol-3- or 4-ylcarbonyl,1,3,4-thiadiazol-2-ylcarbonyl and the like; pyrrolidinylcarbonyl such as2- or 3-pyrrolidinylcarbonyl and the like; pyridylcarbonyl such as 2-,3- or 4-pyridylcarbonyl and the like; pyridylcarbonyl wherein nitrogenatom is oxidized such as 2-, 3- or 4-pyridyl-N-oxidocarbonyl and thelike; pyridazinylcarbonyl such as 3- or 4-pyridazinylcarbonyl and thelike; pyridazinylcarbonyl wherein one or both nitrogen atoms areoxidized, such as 3-, 4-, 5- or 6-pyridazinyl-N-oxidocarbonyl and thelike; pyrimidinylcarbonyl such as 2-, 4- or 5-pyrimidinylcarbonyl andthe like; pyrimidinylcarbonyl wherein one or both nitrogen atoms areoxidized, such as 2-, 4-, 5- or 6-pyrimidinyl-N-oxidocarbonyl and thelike; pyrazinylcarbonyl; piperidinylcarbonyl such as 2-, 3- or4-piperidinylcarbonyl and the like; piperazinylcarbonyl; indolylcarbonylsuch as 3H-indol-2- or 3-ylcarbonyl and the like; pyranylcarbonyl suchas 2-, 3- or 4-pyranylcarbonyl and the like; thiopyranylcarbonyl such as2-, 3- or 4-thiopyranylcarbonyl and the like; quinolylcarbonyl such as3-, 4-, 5-, 6-, 7- or 8-quinolylcarbonyl and the like;isoquinolylcarbonyl; pyrido[2,3-d]pyrimidinylcarbonyl (e.g.,pyrido[2,3-d]pyrimidin-2-ylcarbonyl); naphthyridinylcarbonyl (e.g.,1,5-naphthyridin-2- or 3-ylcarbonyl) such as 1,5-, 1,6-, 1,7-, 1,8-,2,6- or 2,7-naphthyridinylcarbonyl and the like;thieno[2,3-d]pyridylcarbonyl (e.g., thieno[2,3-d]pyridin-3-ylcarbonyl);pyrazinoquinolylcarbonyl (e.g., pyrazino[2,3-b]quinolin-2-ylcarbonyl); a5- or 6-membered heterocyclyl-carbonyl group (e.g., 5- or 6-memberedheterocyclyl-carbonyl group containing 1 to 4 hetero atoms such asnitrogen atom (optionally oxidized), oxygen atom, sulfur atom(optionally mono or dioxidized) and the like, such as chromenylcarbonyl(e.g., 2H-chromen-2- or 3-ylcarbonyl etc.) and the like), a 5- or6-membered heterocyclyl-acetyl group (e.g., 5- or 6-memberedheterocyclyl-acetyl group containing 1 to 4 hetero atoms such asnitrogen atom (optionally oxidized), oxygen atom, sulfur atom(optionally mono or dioxidized) and the like, such as 2-pyrrolylacetyl,3-imidazolylacetyl, 5-isoxazolylacetyl and the like, and the like) canbe used.

As regards the substituent of acyl group, for example, when theabove-mentioned acyl group is an alkanoyl group or alkoxy-carbonylgroup, the acyl group is optionally substituted by 1 to 3 selected fromalkylthio groups (e.g., C₁₋₄ alkylthio such as methylthio, ethylthio,n-propylthio, isopropylthio and the like, and the like), halogen (e.g.,fluorine, chlorine, bromine, iodine), alkoxy groups (e.g., C₁₋₆ alkoxysuch as methoxy, ethoxy, n-propoxy, tert-butoxy, n-hexyloxy and thelike, and the like), a nitro group, alkoxy-carbonyl groups (e.g., C₁₋₆alkoxy-carbonyl such as methoxycarbonyl, ethoxycarbonyl,n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl,isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl and the like,and the like), alkylamino group (e.g., mono- or di-C₁₋₆ alkylamino suchas methylamino, ethylamino, n-propylamino, n-butylamino,tert-butylamino, n-pentylamino, n-hexylamino, dimethylamino,diethylamino, methylethylamino, di-(n-propyl)amino, di-(n-butyl)aminoand the like, and the like), alkoxyimino groups (e.g., C₁₋₆ alkoxyiminosuch as methoxyimino, ethoxyimino, n-propoxyimino, tert-butoxyimino,n-hexyloxy-imino and the like, and the like) and hydroxyimino.

When the above-mentioned acyl group is an aryl-carbonyl group, anaryloxy-carbonyl group, an aralkyl-carbonyl group, an aralkyloxycarbonylgroup, a 5- or 6-membered heterocyclyl-carbonyl group or a 5- or6-membered heterocyclyl-acetyl group, the acyl group is optionallysubstituted by 1 to 5 (preferably 1 to 3) selected from alkyl groups(e.g., C₁₋₆ alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl,isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, isopentyl,neopentyl, n-hexyl, isohexyl and the like, C₃₋₆ cycloalkyl such ascyclohexyl and the like, and the like), alkenyl groups (e.g., C₂₋₆alkenyl such as allyl, isopropenyl, isobutenyl, 1-methylallyl,2-pentenyl, 2-hexenyl and the like, and the like), alkynyl groups (e.g.,C₂₋₆ alkynyl such as propargyl, 2-butynyl, 3-butynyl, 3-pentynyl,3-hexynyl and the like, and the like), alkoxy groups (e.g., C₁₋₆ alkoxysuch as methoxy, ethoxy, n-propoxy, tert-butoxy, n-hexyloxy and thelike, and the like), acyl groups [e.g., C₁₋₇ alkanoyl such as formyl,acetyl, propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl, heptanoyland the like; C₆₋₁₄ aryl-carbonyl such as benzoyl, naphthalenecarbonyland the like; C₁₋₆ alkoxy-carbonyl such as methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl,isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl and the like;C₆₋₁₄ aryloxy-carbonyl such as phenoxycarbonyl and the like; C₇₋₁₉aralkyl-carbonyl such as phenyl-C₁₋₄ alkyl-carbonyl (e.g.,benzylcarbonyl, phenethylcarbonyl, phenylpropylcarbonyl and the like)and the like; C₇₋₁₉ aralkyloxy-carbonyl such as phenyl-C₁₋₄alkyloxy-carbonyl (e.g., benzyloxycarbonyl and the like) and the like,and the like], nitro, amino, hydroxy, cyano, sulfamoyl, mercapto,halogen (e.g., fluorine, chlorine, bromine, iodine), and alkylthiogroups (C₁₋₄ alkylthio such as methylthio, ethylthio, n-propylthio,isobutylthio and the like, and the like).

As the “halogen atom” for R², R³ or R⁴, fluorine atom, chlorine atom,bromine atom and iodine atom can be mentioned.

R² is preferably a hydrogen atom, an optionally substituted hydrocarbongroup, an optionally substituted thienyl group, an optionallysubstituted benzo[b]thienyl group, an optionally substituted furylgroup, an optionally substituted pyridyl group, an optionallysubstituted pyrazolyl group or an optionally substituted pyrimidinylgroup, more preferably a hydrogen atom, an optionally substitutedhydrocarbon group, an optionally substituted thienyl group, anoptionally substituted benzo[b]thienyl group, an optionally substitutedfuryl group or an optionally substituted pyridyl group, further morepreferably a hydrogen atom, an optionally substituted hydrocarbon groupor an optionally substituted pyridyl group, particularly preferably ahydrogen atom, an optionally substituted aryl group or an optionallysubstituted pyridyl group.

To be specific, R² is preferably

[1] a hydrogen atom, [2] C₆₋₁₄ aryl group (e.g., phenyl group)optionally substituted by 1 to 5 (preferably 1 to 3) substituentsselected from (i) a halogen atom (e.g., a fluorine atom, a chlorineatom, a bromine atom, an iodine atom), (ii) cyano, (iii) aminooptionally substituted by 1 or 2 selected from C₁₋₆ alkyl (e.g., methyl,ethyl etc.) and acetyl, (iv) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g.,fluorine, chlorine, bromine, iodine), (v) C₁₋₆ alkoxy (e.g., methoxy,ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy,hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogens (e.g., fluorine, chlorine, bromine, iodine), (vi) phenoxy,(vii) C₁₋₆ alkylthio (e.g., methylthio, ethylthio etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine,chlorine, bromine, iodine), (viii) acetyl and (ix) aminocarbonyl, or [3]thienyl group, benzo[b]thienyl group, furyl group, pyridyl group,pyrazolyl group or pyrimidinyl group, each of which is optionallysubstituted by 1 to 3 substituents selected from halogen (e.g.,fluorine, chlorine, bromine, iodine), C₁₋₆ alkoxy (e.g., methoxy, ethoxyetc.) and C₁₋₆ alkyl (e.g., methyl, ethyl, n-propyl, isobutyl etc.)(preferably 1 to 3 C₁₋₆ alkoxy) [preferably thienyl group,benzo[b]thienyl group, furyl group or pyridyl group, each of which isoptionally substituted by 1 to 3 C₁₋₆ alkoxy],particularly preferably [1] (i) a hydrogen atom or (ii) a C₆₋₁₄ arylgroup (e.g., phenyl group) optionally substituted by 1 to 5 (preferably1 to 3) halogens atoms (e.g., a fluorine atom, a chlorine atom, abromine atom, an iodine atom) or [2] a pyridyl group optionallysubstituted by 1 to 3 halogen atoms (e.g., a fluorine atom, a chlorineatom, a bromine atom, an iodine atom).

R³ and R⁴ are preferably the same or different and each is a hydrogenatom or an optionally substituted hydrocarbon group, an acyl group, ahalogen atom, a cyano group or a nitro group.

Of these, a hydrogen atom, a C₁₋₆ alkyl group (e.g., methyl, ethyl,n-propyl, isobutyl etc.), a C₆₋₁₄ aryl group (e.g., phenyl etc.), a C₁₋₆alkyl-carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl,pentanoyl, hexanoyl, heptanoyl etc.), a halogen atom (e.g., a fluorineatom, a chlorine atom, a bromine atom, an iodine atom), a cyano groupand a nitro group are preferable, particularly, a hydrogen atom, a C₁₋₆alkyl group (e.g., methyl, ethyl, n-propyl, isobutyl etc.), a C₁₋₆alkyl-carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl,pentanoyl, hexanoyl, heptanoyl etc.), a halogen atom (e.g., a fluorineatom, a chlorine atom, a bromine atom, an iodine atom), a cyano groupand a nitro group are preferable.

In the aforementioned formula (A2), R⁵ is a hydrogen atom or anoptionally substituted hydrocarbon group.

Examples of the “optionally substituted hydrocarbon group” for R⁵include those similar to the “optionally substituted hydrocarbon group”for the aforementioned R⁴⁰.

As R⁵, particularly, a C₁₋₆ alkyl group (e.g., methyl, ethyl, n-propyl,isobutyl etc.) is preferable.

When the compound represented by the above-mentioned formula (A2) hasisomers such as optical isomer, stereoisomer, positional isomer,rotational isomer and the like, and any isomers and mixtures areencompassed in the compound (A2). For example, when compound (A2) has anoptical isomer, an optical isomer separated from a racemate is alsoencompassed in the compound (A2). These isomers can be obtained asindependent products by a synthesis means or a separation means (e.g.,concentration, solvent extraction, column chromatography,recrystallization and the like), and the like known per se.

The compound (A2) may be a crystal, and both a single crystal andcrystal mixtures are encompassed in the compound (A2). Crystals can beproduced by crystallization according to crystallization methods knownper se.

The compound (A2) may be a solvate (e.g., hydrate etc.) or anon-solvate, both of which are encompassed in the compound (A2).

A compound labeled with an isotope (e.g., ³H, ¹⁴C, ³⁵S, ¹²⁵I and thelike) is also encompassed in the compound (A2).

A compound represented by the above-mentioned formula (A2) can beproduced, for example, according to the method described in WO2006/036024.

In addition, preferable examples of the nonpeptidic pharmaceuticallyactive ingredient having a primary or secondary amino group include thecompound disclosed in WO 2007/026916, which is represented by thefollowing formula (A3), and a salt thereof.

wherein R^(1a) is a nitrogen-containing monocyclic heterocyclic groupoptionally condensed with a benzene ring or a heterocycle, thenitrogen-containing monocyclic heterocyclic group optionally condensedwith a benzene ring or a heterocycle optionally has substituent(s),R^(2a) is an optionally substituted C₆₋₁₄ aryl group, an optionallysubstituted thienyl group or an optionally substituted pyridyl group,R^(3a) and R^(4a) are each a hydrogen atom, or one of R^(3a) and R^(4a)is a hydrogen atom, and the other is an optionally substituted loweralkyl group, an acyl group, a halogen atom, a cyano group or a nitrogroup, and R^(5a) is an alkyl group.

In the formula (A3), as the “nitrogen-containing monocyclic heterocyclicgroup optionally condensed with a benzene ring or a heterocycle” forR^(1a),

(1) a nitrogen-containing monocyclic heterocyclic group, and(2) a fused ring group represented by the formula:

wherein ring A is a nitrogen-containing monocyclic heterocyclic group,ring B is a benzene ring or a heterocycle, a and b are each a bridgeheadring-constituting atom (e.g., a carbon atom, a nitrogen atom and thelike), and

shows a single bond or a double bond, provided that a bond to an —SO₂—group in the formula (A3) is present in a ring A-constituting atom (ringatom) other than the bridgehead ring-constituting atoms a and b, can bementioned.

As used herein, ring A needs only to contain, as a ring A-constitutingatom (ring atom), at least one (preferably 1 to 4, more preferably 1 or2) nitrogen atom, and one or both of the bridgehead ring-constitutingatoms a and b may be nitrogen atoms.

The “nitrogen-containing monocyclic heterocyclic group optionallycondensed with a benzene ring or a heterocycle” optionally hassubstituent(s), and the substituent(s) may be present in any of ring Aand ring B.

As the “nitrogen-containing monocyclic heterocyclic group” of the“nitrogen-containing monocyclic heterocyclic group optionally condensedwith a benzene ring or a heterocycle” and the above-mentioned ring A,for example, an aromatic nitrogen-containing monocyclic heterocyclicgroup, a saturated or unsaturated non-aromatic nitrogen-containingmonocyclic heterocyclic group (aliphatic nitrogen-containing monocyclicheterocyclic group) and the like containing, as a ring-constituting atom(ring atom), at least one (preferably 1 to 4, more preferably 1 or 2)nitrogen atom can be mentioned.

As the “aromatic nitrogen-containing monocyclic heterocyclic group”, forexample, aromatic nitrogen-containing monocyclic heterocyclic groupssuch as pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,imidazolyl (1H-imidazol-1-yl, 1H-imidazol-4-yl etc.), pyrazolyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl,1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl,1,2,3-triazolyl, 1,2,4-triazolyl (1,2,4-triazol-1-yl, 1,2,4-triazol-4-yletc.), tetrazolyl, pyridyl (2-, 3- or 4-pyridyl etc.), pyridazinyl,pyrimidinyl, pyrazinyl, triazinyl and the like, and N-oxide formsthereof and the like can be mentioned. Of these, a 5- or 6-memberedaromatic nitrogen-containing monocyclic heterocyclic group ispreferable, and thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyland pyridazinyl are preferable, and pyridyl is particularly preferable.

As the “saturated or unsaturated non-aromatic nitrogen-containingmonocyclic heterocyclic group”, partially reduced forms (e.g.,imidazolinyl, tetrahydropyrimidinyl and the like) of the above-mentioned“aromatic nitrogen-containing monocyclic heterocyclic group” and, forexample, azetidinyl, pyrrolidinyl, piperidyl (2-, 3- or 4-piperidyl),morpholinyl, thiomorpholinyl, piperazinyl (1-piperazinyl etc.),homopiperazinyl and the like can be mentioned. Of these, a 5- or6-membered non-aromatic nitrogen-containing monocyclic heterocyclicgroup is preferable.

As the “heterocycle” optionally condensed with a nitrogen-containingmonocyclic heterocyclic group, for example, an aromatic heterocycle ornon-aromatic heterocycle can be mentioned.

As the “aromatic heterocycle”, for example, 5- or 6-membered aromaticheteromonocyclic rings such as a furan ring, a thiophene ring, a pyrrolering, an oxazole ring, an isoxazole ring, a thiazole ring, anisothiazole ring, an imidazole ring, a pyrazole ring, a 1,2,3-oxadiazolering, a 1,2,4-oxadiazole ring, a 1,3,4-oxadiazole ring, a furazan ring,a 1,2,3-thiadiazole ring, a 1,2,4-thiadiazole ring, a 1,3,4-thiadiazolering, a 1,2,3-triazole ring, a 1,2,4-triazole ring, tetrazole ring,pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, triazinering and the like and, for example, 8- to 12-membered aromatic fusedheterocycles such as a benzofuran ring, an isobenzofuran ring, abenzo[b]thiophene ring, an indole ring, an isoindole ring, a 1H-indazolering, a benzindazole ring, a benzoxazole ring, a 1,2-benzoisoxazolering, a benzothiazole ring, a benzopyran ring, a 1,2-benzoisothiazolering, a 1H-benzotriazole ring, a quinoline ring, an isoquinoline ring, acinnoline ring, a quinazoline ring, a quinoxaline ring, a phthalazinering, a naphthyridine ring, a purine ring, a pteridine ring, a carbazolering, an α-carboline ring, a β-carboline ring, a γ-carboline ring, anacridine ring, a phenoxathiine ring, a phenothiazine ring, a phenazinering, a phenoxathiine ring, a thianthrene ring, a phenanthridine ring, aphenanthrone ring, an indolizine ring, a pyrrolo[1,2-b]pyridazine ring,a pyrazolo[1,5-a]pyridine ring, an imidazo[1,2-a]pyridine ring, animidazo[1,5-a]pyridine ring, an imidazo[1,2-b]pyridazine ring, animidazo[1,2-a]pyrimidine ring, a 1,2,4-triazolo[4,3-a]pyridine ring, a1,2,4-triazolo[4,3-b]pyridazine ring and the like (preferably, aheterocycle wherein the aforementioned 5- or 6-membered aromaticheteromonocyclic ring is condensed with a benzene ring or a heterocyclewherein the same or different two heterocycles of the aforementioned 5-or 6-membered aromatic heteromonocyclic ring are condensed, morepreferably a heterocycle wherein the aforementioned 5- or 6-memberedaromatic monocyclic heterocyclic group is condensed with a benzene ring,preferably imidazopyrimidinyl etc.) and the like can be mentioned.

As the “non-aromatic heterocycle”, for example, 3- to 8-memberedsaturated or unsaturated non-aromatic heterocycles such as an oxiranering, an azetidine ring, an oxetane ring, a thietane ring, a pyrrolidinering, a tetrahydrofuran ring, a thioran ring, a piperidine ring, atetrahydropyran ring, a morpholine ring, a thiomorpholine ring, apiperazine ring, a 3-hexahydrocyclopenta[c]pyrrole ring, ahomopiperidine ring, a homopiperazine ring and the like, or non-aromaticheterocycles wherein the double bonds of the aforementioned aromaticheteromonocyclic ring or aromatic fused heterocycle are partly orentirely saturated such as a dihydropyridine ring, a dihydropyrimidinering, a 1,2,3,4-tetrahydroquinoline ring, a1,2,3,4-tetrahydroisoquinoline ring and the like, and the like can bementioned.

As preferable nitrogen-containing monocyclic heterocyclic groupcondensed with a benzene ring or a heterocycle, for example,nitrogen-containing aromatic fused heterocyclic groups such as 8- to16-membered (preferably 8- to 12-membered) nitrogen-containing aromaticbicyclic fused heterocyclic groups such as 2- or 3-indolyl, 1- or3-isoindolyl, 1H-indazol-3-yl, 2-benzimidazolyl, 2-benzoxazolyl,3-benzoisoxazolyl, 2-benzothiazolyl, 3-benzoisothiazolyl, 2-, 3- or4-quinolyl, 1-, 3- or 4-isoquinolyl, 3- or 4-cinnolinyl, 2- or4-quinazolinyl, 2- or 3-quinoxalinyl, 1- or 4-phthalazinyl,naphthyridinyl, purinyl, pteridinyl, 1,7-phenanthrolin-2-, 3- or 4-yl,1-, 2- or 3-indolizinyl, pyrrolo[1,2-b]pyridazinyl,pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,2-b]pyrazolyl,imidazo[1,5-a]pyridyl, imidazo[4,5-c]pyridyl,pyrazolo[1,5-a]pyrimidinyl, pyrazolo[1,5-c]pyrimidinyl,pyrazolo[3,4-d]pyrimidinyl, imidazo[1,2-b]pyridazinyl,imidazo[1,5-b]pyridazinyl, pyrazolo[3,4-b]pyridyl,imidazo[1,2-a]pyrimidinyl, 1,2,4-triazolo[4,3-a]pyridyl,1,2,4-triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,2-a]pyridazinyl,[1,2,3]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-c]pyrimidinyl,[1,2,4]triazolo[1,5-a]pyridyl, [1,2,4]triazolo[4,3-a]pyridyl,pyrazolo[5,1-b]thiazolyl, pyrrolo[2,1-f][1,2,4]triazinyl,pyrrolo[1,2-b]pyridazinyl, pyrrolo[2,3-d]pyrimidinyl,pyrrolo[2,3-b]pyridyl, thieno[3,2-b]pyrimidinyl, thieno[2,3-b]pyridyl,thieno[2,3-c]pyridyl, thieno[3,2-b]pyridyl, thieno[3,2-c]pyridyl,pyrido[2,3-b]pyrazyl, pyrido[3,4-b]pyrazyl, pyrido[2,3-d]pyrimidinyl,pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl and the like, and thelike, and the like can be mentioned. As the nitrogen-containing aromaticfused heterocycle, fused pyridine wherein a pyridine ring is condensedwith one or two (preferably one) of the aforementioned 5- or 6-memberednitrogen-containing aromatic monocyclic heterocycles or one or two(preferably one) benzene rings (when condensed with a benzene ring, thepyridine ring has a bond), fused pyrimidine wherein a pyrimidine ring iscondensed with one or two (preferably one) of the aforementioned 5- or6-membered nitrogen-containing aromatic monocyclic heterocycles, or oneor two (preferably one) benzene rings (when condensed with a benzenering, the pyrimidine ring has a bond) and the like are preferable.

As the “non-aromatic nitrogen-containing heterocycle”, for example, 3-to 8-membered (preferably 5- or 6-membered) nitrogen-containingsaturated or unsaturated (preferably saturated) non-aromatic heterocycle(aliphatic nitrogen-containing heterocycle) such as azetidine,pyrrolidine, imidazolidine, thiazolidine, oxazolidine, piperidine,morpholine, thiomorpholine, piperazine and the like, ornitrogen-containing non-aromatic heterocycle wherein the double bonds ofthe aforementioned nitrogen-containing aromatic monocyclic heterocycleor nitrogen-containing aromatic fused heterocycle are partly or entirelysaturated, such as 1,2,3,4-tetrahydroquinoline,1,2,3,4-tetrahydroisoquinoline and the like, and the like can bementioned.

As the “nitrogen-containing monocyclic heterocyclic group optionallycondensed with a benzene ring or a heterocycle”, a 5- or 6-memberedaromatic nitrogen-containing monocyclic heterocyclic group is preferablefrom among those mentioned above. Of them, a 6-membered aromaticnitrogen-containing heterocyclic group such as pyridyl (e.g., 2-, 3- or4-pyridyl etc.), pyrimidinyl (e.g., 2-, 4- or 5-pyrimidinyl etc.),pyridazinyl (e.g., 3- or 4-pyridazinyl etc.) and the like is preferable,and pyridyl is particularly preferable.

As the substituent that the “nitrogen-containing monocyclic heterocyclicgroup optionally condensed with a benzene ring or a heterocycle” mayhave, the substituents of the above-mentioned substituent group A and(50) a C₁₋₆ alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl,n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl,isopentyl, neopentyl, n-hexyl, isohexyl etc.) optionally having 1 to 3halogen atoms (e.g., fluorine, chlorine, bromine, iodine), (51) a C₂₋₆alkenyl group (e.g., allyl, isopropenyl, isobutenyl, 1-methylallyl,2-pentenyl, 2-hexenyl etc.) optionally having 1 to 3 halogen atoms(e.g., fluorine, chlorine, bromine, iodine), (52) a C₂₋₆ alkynyl group(e.g., propargyl, 2-butynyl, 3-butynyl, 3-pentynyl, 3-hexynyl etc.),(53) a C₁₋₆ alkyl group substituted by 1 to 3 hydroxy (e.g.,hydroxymethyl, hydroxyethyl etc.) and the like can be mentioned.

The substituent may be present at a substitutable position, and thenumber of the substituents is 1 to 5, preferably 1 to 3.

As the “C₆₋₁₄ aryl group” of the “optionally substituted C₆₋₁₄ arylgroup” for R^(2a), for example, phenyl, 1-naphthyl, 2-naphthyl,2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl and the like can bementioned.

As the substituent that the “C₆₋₁₄ aryl group” optionally has, groupssimilar to the substituents that the “nitrogen-containing monocyclicheterocyclic group optionally condensed with a benzene ring or aheterocycle” for the aforementioned R^(1a) optionally has can bementioned.

The number of the substituents is 1 to 5, preferably 1 to 3. As the“thienyl group” of the “optionally substituted thienyl group” forR^(2a), 2- or 3-thienyl can be mentioned.

As the substituent that the “thienyl group” optionally has, groupssimilar to the substituents that the “nitrogen-containing monocyclicheterocyclic group optionally condensed with a benzene ring or aheterocycle” for the aforementioned R^(1a) optionally has can bementioned.

The number of the substituents is 1 to 4, preferably 1 to 3.

As the “pyridyl group” of the “optionally substituted pyridyl group” forR^(2a), 2-, 3- or 4-pyridyl, or bipyridyl (e.g., 2,3′-bipyridin-5-yl)can be mentioned.

As the substituent that the “pyridyl group” optionally has, groupssimilar to the substituents that the “nitrogen-containing monocyclicheterocyclic group optionally condensed with a benzene ring or aheterocycle” for the aforementioned R^(1a) optionally has can bementioned.

The number of the substituents is 1 to 4, preferably 1 to 3.

As the “lower alkyl group” of the “optionally substituted lower alkylgroup” for R^(3a) or R^(4a), for example, C₁₋₄ alkyl groups such asmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyland the like, and the like can be mentioned.

As the substituent that the “lower alkyl group” optionally has, thesubstituents of the above-mentioned substituent group A and the like canbe mentioned.

The number of the substituents is 1 to 3.

Examples of the “acyl group” for R^(3a) or R^(4a) include acyl groupssimilar to those exemplified as the “acyl group” for R², R³ or R⁴ of theabove-mentioned formula (A2).

As the “halogen atom” for R^(3a) or R^(4a), a fluorine atom, a chlorineatom, a bromine atom and an iodine atom can be mentioned.

As the “alkyl group” for R^(5a), for example, C₁₋₆ alkyl (e.g., methyl,ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,pentyl, hexyl etc.) and the like can be mentioned.

As R^(1a), a “nitrogen-containing monocyclic heterocyclic groupoptionally condensed with a benzene ring or a heterocycle” (e.g., 5 or6-membered aromatic nitrogen-containing monocyclic heterocyclic groupssuch as thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl,pyridazinyl, pyrazinyl and the like, and the like) optionallysubstituted by 1 to 3 substituents selected from (i) halogen (e.g.,fluorine, chlorine, bromine, iodine), (ii) hydroxy, (iii) cyano, (iv)C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1to 5 (preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine,iodine), (v) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy,butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine), (vi) amino group optionally substituted byC₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl etc.), (vii) oxo and (viii) C₁₋₆alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,tert-butoxycarbonyl etc.) is preferable.

As R^(1a), especially, a “nitrogen-containing monocyclic heterocyclicgroup optionally condensed with a benzene ring or a heterocycle” (e.g.,a 5 or 6-membered aromatic nitrogen-containing monocyclic heterocyclicgroup such as thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl,pyridazinyl, pyrazinyl and the like, and the like), which is optionallysubstituted by 1 to 3 substituents selected from (i) halogen (e.g.,fluorine, chlorine, bromine, iodine), (ii) hydroxy, (iii) cyano, (iv)C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1to 5 (preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine,iodine), (v) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy,butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine), (vi) an amino group optionally substitutedby C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl etc.) and (vii) oxo, is preferable.

As R^(1a), particularly, a 6-membered nitrogen-containing aromaticheterocyclic group (e.g., pyridyl groups (e.g., 2-, 3- or 4-pyridyletc.), pyrimidinyl groups (e.g., 2-, 4- or 5-pyrimidinyl etc.),pyridazinyl groups (e.g., 3- or 4-pyridazinyl etc.) etc.) optionallysubstituted by 1 to 3 substituents selected from (i) halogen (e.g.,fluorine, chlorine, bromine, iodine), (ii) hydroxy, (iii) cyano, (iv)C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1to 5 (preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine,iodine), (v) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy,butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine) and (vi) an amino group optionallysubstituted by C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) ispreferable, and a pyridyl group optionally substituted by 1 to 3substituents selected from (i) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) halogen (e.g.,fluorine, chlorine, bromine, iodine) and (ii) C₁₋₆ alkoxy (e.g.,methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy,pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1to 3) halogen (e.g., fluorine, chlorine, bromine, iodine) isparticularly preferable.

As R^(2a), [1] a C₆₋₁₄ aryl group (e.g., phenyl group) optionallysubstituted by 1 to 5 (preferably 1 to 3) substituents selected from (i)a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano,(iii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl,isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine), (iv) C₁₋₆ alkoxy (e.g., methoxy, ethoxy,propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxyetc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogen(e.g., fluorine, chlorine, bromine, iodine), (v) acetyl, (vi) C₃₋₇cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl etc.), (vii) C₁₋₆ alkylsulfonyl (e.g., methylsulfonyl,ethylsulfonyl etc.), (viii) a C₁₋₆ alkyl group substituted by 1 to 3hydroxy (e.g., hydroxymethyl, hydroxyethyl etc.), (ix) C₁₋₆ alkylthio(e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio,isobutylthio, sec-butylthio, pentylthio, hexylthio etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen atoms (e.g., fluorine,chlorine, bromine, iodine) and (x) C₁₋₆ alkylsulfinyl (e.g.,methylsulfinyl, ethylsulfinyl etc.),

[2] a thienyl group optionally substituted by 1 to 3 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) halogen (e.g.,fluorine, chlorine, bromine, iodine), (iv) C₁₋₆ alkoxy (e.g., methoxy,ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy,hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen (e.g., fluorine, chlorine, bromine, iodine) and (v) acetyl, or[3] a pyridyl group optionally substituted by 1 to 4 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) lower (specifically C₁₋₆) alkyl (e.g.,methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5(preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine, iodine),(iv) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy,isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substitutedby 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine, chlorine,bromine, iodine), (v) acyl (e.g., acetyl), (vi) nitro and (vii) amino ispreferable.

Of these, as R^(2a), [1] a C₆₋₁₄ aryl group (e.g., phenyl group)optionally substituted by 1 to 5 (preferably 1 to 3) substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) halogen (e.g.,fluorine, chlorine, bromine, iodine), (iv) C₁₋₆ alkoxy (e.g., methoxy,ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy,hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen (e.g., fluorine, chlorine, bromine, iodine) and (v) acetyl,

[2] a thienyl group optionally substituted by 1 to 3 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) halogen (e.g.,fluorine, chlorine, bromine, iodine), (iv) C₁₋₆ alkoxy (e.g., methoxy,ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy,hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen (e.g., fluorine, chlorine, bromine, iodine) and (v) acetyl, or[3] a pyridyl group optionally substituted by 1 to 4 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) lower (specifically C₁₋₆) alkyl (e.g.,methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5(preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine, iodine),(iv) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy,isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substitutedby 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine, chlorine,bromine, iodine), (v) acyl (e.g., acetyl), (vi) nitro and (vii) amino ispreferable.

Particularly, as R^(2a), [1] a phenyl group optionally substituted by 1to 5 (preferably 1 to 3) substituents selected from (i) a halogen atom(e.g., fluorine, chlorine, bromine, iodine) and (ii) C₁₋₆ alkyl (e.g.,methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5(preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine, iodine),

[2] a thienyl group optionally substituted by 1 to 3 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine) and (ii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl tc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine), or[3] a pyridyl group optionally substituted by 1 to 4 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine) and (ii) lower (specifically C₁₋₆) alkyl (e.g., methyl, ethyl,propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyletc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogen(e.g., fluorine, chlorine, bromine, iodine) is preferable.

Of those mentioned above, a preferable embodiment of R^(2a) include [1]a phenyl group optionally substituted by 1 to 5 substituents selectedfrom (i) a halogen atom and (ii) C₁₋₆ alkyl optionally substituted by 1to 5 halogen atoms, [2] a pyridyl group optionally substituted by 1 to 4substituents selected from lower (C₁₋₆) alkyl, a halogen atom, alkoxy(C₁₋₆ alkoxy), cyano, acyl (e.g., acetyl), nitro and amino, and thelike.

As R^(2a), a phenyl group, a 2-fluorophenyl group, a 2-methylphenylgroup, a 2-fluoropyridin-3-yl group, a 3-fluoropyridin-4-yl group, a2-chloropyridin-3-yl group, a 6-chloropyridin-3-yl group, a4-methylpyridin-3-yl group, a 2-methylpyridin-3-yl group, a3-methylpyridin-2-yl group, a 2-trifluoromethylpyridin-3-yl group and a6′-chloro-2,3′-bipyridin-5-yl group are particularly preferable.

Preferably R^(3a) and R^(4a) are each a hydrogen atom, or one of R^(3a)and R^(4a) is a hydrogen atom and the other is a C₁₋₆ alkyl group (e.g.,methyl, ethyl, n-propyl, isobutyl etc.), a C₁₋₆ alkyl-carbonyl group(e.g., acetyl, propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl,heptanoyl etc.), a halogen atom (e.g., fluorine, chlorine, bromine,iodine), a cyano group or a nitro group. A compound wherein both R³ andR⁴ are hydrogen atoms is particularly preferable.

As the “alkyl” for R^(5a), methyl or ethyl is preferable, and methyl isparticularly preferable.

The above-mentioned preferable embodiments of the substituents forR^(1a) to R^(5a) may be optionally combined to achieve a preferableembodiment of compound (A3).

Of compounds (A3), a compound wherein R^(1a) is a 5- or 6-memberedaromatic nitrogen-containing monocyclic heterocyclic group (e.g.,thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl,pyrazinyl and the like) or an imidazo[1,2-a]pyrimidinyl group, which areoptionally substituted by 1 to 3 substituents selected from (i) halogen(e.g., fluorine, chlorine, bromine, iodine), (ii) hydroxy, (iii) cyano,(iv) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl,isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine), (v) C₁₋₆ alkoxy (e.g., methoxy, ethoxy,propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxyetc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogen(e.g., fluorine, chlorine, bromine, iodine), (vi) amino group optionallysubstituted by C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) and (vii)C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl,propoxycarbonyl, tert-butoxycarbonyl etc.); R^(2a) is [1] a C₆₋₁₄ arylgroup (e.g., phenyl group) optionally substituted by 1 to 5 (preferably1 to 3) substituents selected from (i) a halogen atom (e.g., fluorine,chlorine, bromine, iodine), (ii) cyano, (iii) C₁₋₆ alkyl (e.g., methyl,ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen (e.g., fluorine, chlorine, bromine, iodine), (iv) C₁₋₆ alkoxy(e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy,sec-butoxy, pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5(preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine, iodine),(v) acetyl, (vi) C₃₋₇ cycloalkyl (e.g., cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl etc.), (vii) C₁₋₆ alkylsulfonyl(e.g., methylsulfonyl, ethylsulfonyl etc.), (viii) a C₁₋₆ alkyl groupsubstituted by 1 to 3 hydroxy (e.g., hydroxymethyl, hydroxyethyl etc.),(ix) C₁₋₆ alkylthio (e.g., methylthio, ethylthio, propylthio,isopropylthio, butylthio, isobutylthio, sec-butylthio, pentylthio,hexylthio etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen atoms (e.g., fluorine, chlorine, bromine, iodine) and (x) C₁₋₆alkylsulfinyl (e.g., methylsulfinyl, ethylsulfinyl etc.),

[2] a thienyl group optionally substituted by 1 to 3 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)optionally substituted by 1 to 5 (preferably 1 to 3) halogen (e.g.,fluorine, chlorine, bromine, iodine), (iv) C₁₋₆ alkoxy (e.g., methoxy,ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy,hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen (e.g., fluorine, chlorine, bromine, iodine) and (v) acetyl,[3] a pyridyl group optionally substituted by 1 to 4 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine), (ii) cyano, (iii) lower (specifically C₁₋₆) alkyl (e.g.,methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5(preferably 1 to 3) halogen (e.g., fluorine, chlorine, bromine, iodine),(iv) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy,isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substitutedby 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine, chlorine,bromine, iodine), (v) acyl (e.g., acetyl), (vi) nitro and (vii) amino,or[4] a bipyridyl group optionally substituted by 1 to 3 halogen atoms(e.g., fluorine, chlorine, bromine, iodine); R^(3a) and R^(4a) are eacha hydrogen atom, or one of R^(3a) and R^(4a) is a hydrogen atom and theother is a C₁₋₆ alkyl group (e.g., methyl, ethyl, n-propyl, isobutyletc.), a C₁₋₆ alkyl-carbonyl group (e.g., acetyl, propionyl, butyryl,isobutyryl, pentanoyl, hexanoyl, heptanoyl etc.), a halogen atom (e.g.,fluorine, chlorine, bromine, iodine), a cyano group or a nitro group;R^(5a) is methyl or ethyl is preferable, a compound wherein, forexample,R^(1a) is a pyridyl group optionally substituted by 1 to 3 substituentsselected from (i) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine) and (ii) C₁₋₆ alkoxy (e.g., methoxy, ethoxy,propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxyetc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogen(e.g., fluorine, chlorine, bromine, iodine),R^(2a) is [1] a phenyl group optionally substituted by 1 to 5(preferably 1 to 3) substituents selected from (i) a halogen atom (e.g.,fluorine, chlorine, bromine, iodine) and (ii) C₁₋₆ alkyl (e.g., methyl,ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3)halogen (e.g., fluorine, chlorine, bromine, iodine),[2] a thienyl group optionally substituted by 1 to 3 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine) and (ii) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionallysubstituted by 1 to 5 (preferably 1 to 3) halogen (e.g., fluorine,chlorine, bromine, iodine), or[3] a pyridyl group optionally substituted by 1 to 4 substituentsselected from (i) a halogen atom (e.g., fluorine, chlorine, bromine,iodine) and (ii) lower (specifically C₁₋₆) alkyl (e.g., methyl, ethyl,propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyletc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogen(e.g., fluorine, chlorine, bromine, iodine),R^(3a) and R^(4a) are each a hydrogen atom, and R^(5a) is methyl isparticularly preferable.

When the compound represented by the above-mentioned formula (A3) hasisomers such as optical isomer, stereoisomer, positional isomer,rotational isomer and the like, any isomers and mixtures are encompassedin the compound (A3). For example, when compound (A3) has an opticalisomer, an optical isomer separated from a racemate is also encompassedin the compound (A3). These isomers can be obtained as independentproducts by a synthesis means or a separation means (e.g.,concentration, solvent extraction, column chromatography,recrystallization and the like), and the like known per se.

The compound (A3) may be a crystal, and both a single crystal andcrystal mixtures are encompassed in the compound (A3). Crystals can beproduced by crystallization according to crystallization methods knownper se.

The compound (A3) may be a solvate (e.g., hydrate etc.) or anon-solvate, both of which are encompassed in the compound (A3).

A compound labeled with an isotope (e.g., ³H, ¹⁴C, ³⁵S, ¹²⁵I and thelike) is also encompassed in the compound (A3).

The compound represented by the above-mentioned formula (A3) can beproduced, for example, according to the method described in WO2007/026916.

In addition, preferable examples of the nonpeptidic pharmaceuticallyactive ingredient having a primary or secondary amino group also includethe compound and a salt thereof disclosed in WO 2008/108380, which isrepresented by the following formula (A4).

wherein R^(1b) is an optionally substituted cyclic group, R^(2b) is asubstituent, R^(3b) is an optionally substituted alkyl group, an acylgroup, an optionally substituted hydroxy group, an optionallysubstituted amino group, a halogen atom, a cyano group or a nitro group,R^(4b) and R^(5b) are each a hydrogen atom, an optionally substitutedalkyl group, an acyl group, an optionally substituted hydroxy group, anoptionally substituted amino group, a halogen atom, a cyano group or anitro group, R^(6b) and R^(6b′) are each a hydrogen atom or an alkylgroup, and n is an integer of 0-3.

Examples of the “optionally substituted cyclic group” for R^(1b) in theformula (A4) include an aryl group, an alicyclic hydrocarbon group and aheterocyclic group, each of which is optionally substituted.

Examples of the aryl group in the “optionally substituted aryl group”for R^(ib) include a C₆₋₁₄ aryl group such as phenyl, 1-naphthyl,2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl and thelike.

Examples of the substituent of the aryl group include (1) a halogen atom(e.g., fluorine atom, chlorine atom, bromine atom, iodine atom etc.),(2) nitro, (3) cyano, (4) hydroxy, (5) C₁₋₆ alkoxy optionally having 1to 5 (preferably 1 to 3) halogen atoms (e.g., fluorine, chlorine,bromine, iodine) (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy,isobutoxy, sec-butoxy, pentyloxy, hexyloxy, fluoromethoxy etc.), (6)C₆₋₁₄ aryloxy (e.g., phenyloxy, naphthyloxy etc.), (7) C₇₋₁₆ aralkyloxy(e.g., benzyloxy, phenethyloxy, diphenylmethyloxy, 1-naphthylmethyloxy,2-naphthylmethyloxy, 2,2-diphenylethyloxy, 3-phenylpropyloxy,4-phenylbutyloxy, 5-phenylpentyloxy etc.), (8) mercapto, (9) C₁₋₆alkylthio optionally having 1 to 5 (preferably 1 to 3) halogen atoms(e.g., fluorine, chlorine, bromine, iodine) (e.g., methylthio,difluoromethylthio, trifluoromethylthio, ethylthio, propylthio,isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio,hexylthio etc.), (10) C₆₋₁₄ arylthio (e.g., phenylthio, naphthylthioetc.), (11) C₇₋₁₆ aralkylthio (e.g., benzylthio, phenethylthio,diphenylmethylthio, 1-naphthylmethylthio, 2-naphthylmethylthio,2,2-diphenylethylthio, 3-phenylpropylthio, 4-phenylbutylthio,5-phenylpentylthio etc.), (12) amino, (13) mono-C₁₋₆ alkylamino (e.g.,methylamino, ethylamino etc.), (14) mono-C₆₋₁₄ arylamino (e.g.,phenylamino, 1-naphthylamino, 2-naphthylamino etc.), (15) mono-C₇₋₁₆aralkylamino (e.g., benzylamino etc.), (16) di-C₁₋₆ alkylamino (e.g.,dimethylamino, diethylamino etc.), (17) di-C₆₋₁₄ arylamino (e.g.,diphenylamino etc.), (18) di-C₇₋₁₆ aralkylamino (e.g., dibenzylaminoetc.), (19) formyl, (20) C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyletc.), (21) C₆₋₁₄ aryl-carbonyl (e.g., benzoyl, 1-naphthoyl, 2-naphthoyletc.), (22) carboxyl, (23) C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl etc.), (24) C₆₋₁₄aryloxy-carbonyl (e.g., phenoxycarbonyl etc.), (25) carbamoyl, (26)thiocarbamoyl, (27) mono-C₁₋₆ alkyl-carbamoyl optionally substituted byhydroxyl (e.g., methylcarbamoyl, ethylcarbamoyl, 2-hydroxyethylcarbamoyletc., preferably mono-C₁₋₆ alkyl-carbamoyl), (28) di-C₁₋₆alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl,ethylmethylcarbamoyl etc.), (29) C₆₋₁₄ aryl-carbamoyl (e.g.,phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), (30)C₁₋₆ alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl etc.), (31)C₆₋₁₄ arylsulfonyl (e.g., phenylsulfonyl, 1-naphthylsulfonyl,2-naphthylsulfonyl etc.), (32) C₁₋₆ alkylsulfinyl (e.g. methylsulfinyl,ethylsulfinyl etc.), (33) C₆₋₁₄ arylsulfinyl (e.g., phenylsulfinyl,1-naphthylsulfinyl, 2-naphthylsulfinyl etc.), (34) formylamino, (35)C₁₋₆ alkyl-carbonylamino (e.g., acetylamino etc.), (36) C₆₋₁₄aryl-carbonylamino (e.g., benzoylamino, naphthoylamino etc.), (37) C₁₋₆alkoxy-carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino,propoxycarbonylamino, butoxycarbonylamino etc.), (38) C₁₋₆alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino etc.),(39) C₆₋₁₄ arylsulfonylamino (e.g., phenylsulfonylamino,2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.), (40) C₁₋₆alkyl-carbonyloxy (e.g., acetoxy, propionyloxy etc.), (41) C₆₋₁₄aryl-carbonyloxy (e.g., benzoyloxy, naphthylcarbonyloxy etc.), (42) C₁₋₆alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy,propoxycarbonyloxy, butoxycarbonyloxy etc.), (43) mono-C₁₋₆alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy etc.),(44) di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy,diethylcarbamoyloxy etc.), (45) C₆₋₁₄ aryl-carbamoyloxy (e.g.,phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), (46) a 5- to 7-memberedsaturated cyclic amino optionally containing, besides one nitrogen atomand carbon atom, 1 or 2 kinds of 1 to 4 hetero atoms selected from anitrogen atom, a sulfur atom and an oxygen atom (e.g., pyrrolidin-1-yl,piperidino, piperazin-1-yl, morpholino, thiomorpholino,hexahydroazepin-1-yl etc.), (47) a 5- to 10-membered aromaticheterocyclic group containing, besides carbon atom, 1 or 2 kinds of 1 to4 hetero atoms selected from a nitrogen atom, a sulfur atom and anoxygen atom (e.g., 2-thienyl, 3-thienyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 2-pyridyl,3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl,8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl,1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl,3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), which isoptionally substituted by 1 to 3 C₂₋₆ alkyl groups (e.g., methyl, ethyl,n-propyl, isopropyl etc.), (48) C₂₋₃ alkylenedioxy (e.g.,methylenedioxy, ethylenedioxy etc.), (49) C₃₋₇ cycloalkyl (e.g.,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc.),(50) a C₂₋₆ alkyl group optionally having 1 to 5 (preferably 1 to 3)halogen atoms (e.g., fluorine, chlorine, bromine, iodine) or hydroxy(e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,tert-butyl, n-pentyl, sec-pentyl, isopentyl, neopentyl, n-hexyl,isohexyl, hydroxymethyl etc., preferably a C₂₋₆ alkyl group optionallyhaving 1 to 5 (preferably 1 to 3) halogen atoms), (51) a C₂₋₆ alkenylgroup (e.g., allyl, isopropenyl, isobutenyl, 1-methylallyl, 2-pentenyl,2-hexenyl etc.) optionally having 1 to 5 (preferably 1 to 3) halogenatoms (e.g., fluorine, chlorine, bromine, iodine), (52) a C₂₋₆ alkynylgroup (e.g., propargyl, 2-butynyl, 3-butynyl, 3-pentynyl, 3-hexynyletc.), (53) a C₆₋₂₄ aryl group (e.g., phenyl etc.) optionally having 1to 5 (preferably 1 to 3) halogen atoms (e.g., fluorine, chlorine,bromine, iodine), (54) C₇₋₁₆ aralkyl (e.g., benzyl, phenethyl etc.)optionally having 1 to 5 (preferably 1 to 3) halogen atoms (e.g.,fluorine, chlorine, bromine, iodine), (55) oxo (hereinafter to bereferred to as substituent group C), and the like.

The substituent may be present at a substitutable position, and thenumber of the substituents is 1 to 5, preferably 1 to 3.

Examples of the alicyclic hydrocarbon group in the “optionallysubstituted alicyclic hydrocarbon group” for R^(1b) include a C₃₋₁₄cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, perhydronaphthyl, perhydroanthranyl, bicyclo[2,2,1]heptyland the like (preferably a C₃₋₇ cycloalkyl group), a C₃₋₁₄ cycloalkenylgroup such as cyclopropenyl, cyclobuten-1- or 3-yl, cyclopenten-1-, 3-or 4-yl, cyclohexen-1- or 3-yl and the like (preferably a C₃₋₇cycloalkenyl group) and the like.

Examples of the substituent of the alicyclic hydrocarbon group includethose similar to the substituents selected from the above-mentionedsubstituent group C. The substituent may be present at a substitutableposition, and the number of the substituents is 1 to 5, preferably 1 to3.

Examples of the heterocyclic group in the “optionally substitutedheterocyclic group” for R^(1b) include a 4- to 7-membered non-aromaticheterocyclic group (preferably, a 4- to 6-membered non-aromaticheterocyclic group) containing 1 to 3 hetero atom selected from nitrogenatom, oxygen atom, sulfur atom and the like, such as oxiranyl,azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl,thiolanyl, piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl,piperazinyl, homomorpholinyl, homopiperazinyl and the like, and aheteroaryl group (preferably, a 5- or 6-membered aromatic heterocyclicgroup or a fused ring group thereof) such as pyrrolyl (e.g., 1-, 2- or3-pyrrolyl), pyrazolyl (e.g., 1-, 3-, 4- or 5-pyrazolyl), imidazolyl(e.g., 1-, 2-, 4- or 5-imidazolyl), triazolyl (e.g., 1,2,3-triazol-4-yl,1,2,3-triazol-1-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-1-yl,1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl, 1,2,4-triazol-5-yl), tetrazolyl(e.g., tetrazol-1-, 2- or 5-yl), furyl (e.g., 2- or 3-furyl), thienyl(e.g., 2- or 3-thienyl), oxazolyl (e.g., 2-, 4- or 5-oxazolyl),isoxazolyl (e.g., 3-, 4- or 5-isoxazolyl), oxadiazolyl (e.g.,1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl,1,2,5-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl), thiazolyl (e.g., 2-, 4- or5-thiazolyl), isothiazolyl (e.g., 3-, 4- or 5-isothiazolyl),thiadiazolyl (e.g., 1,2,3-thiadiazol-4- or 5-yl, 1,2,4-thiadiazol-3- or5-yl, 1,2,5-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl), pyridyl (e.g., 1-,2-, 3- or 4-pyridyl), pyridazinyl (e.g., 1-, 3- or 4-pyridazinyl),pyrimidinyl (e.g., 1-, 2-, 4- or 5-pyrimidinyl), pyrazinyl (e.g., 1- or2-pyrazinyl), benzofuryl (e.g., 2- or 3-benzofuryl), benzothienyl (e.g.,2- or 3-benzothienyl), isoindolyl (e.g., 1- or 3-isoindolyl),benzimidazolyl (e.g., 2-benzimidazolyl), benzoxazolyl (e.g.,2-benzoxazolyl), benzisoxazolyl (e.g., 3-benzisoxazolyl), benzothiazolyl(e.g., 2-benzothiazolyl), benzisothiazolyl (e.g., 3-benzisothiazolyl),cinnolinyl (e.g., 3- or 4-cinnolinyl), quinazolinyl (e.g., 2- or4-quinazolinyl), quinoxalinyl (e.g., 2- or 3-quinoxalinyl), phthalazinyl(e.g., 1- or 4-phthalazinyl), pteridinyl, indolyl (e.g., 3H-indol-2-,3-, 4-, 5-, 6- or 7-yl), quinolyl (e.g., 3-, 4-, 5-, 6-, 7- or8-quinolyl), isoquinolyl (e.g., 1-, 3- or 4-isoquinolyl),pyrido[2,3-d]pyrimidinyl (e.g., pyrido[2,3-d]pyrimidin-2-yl),naphthyridinyl such as 1,5-, 1,6-, 1,7-, 1,8-, 2,6- or2,7-naphthyridinyl and the like (e.g., 1,5-naphthyridin-2- or 3-yl),thieno[2,3-d]pyridyl (e.g., thieno[2,3-d]pyridin-3-yl), pyrazinoquinolyl(e.g., pyrazino[2,3-d]quinolin-2-yl), imidazo[1,2-a]pyridyl,imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyrimidinyl,imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]imidazolyl,imidazo[2,1-b](1.3.4)thiadiazolyl, pyrazolo[1,5-a]pyrimidinyl,pyrazolo[5,1-b]thiazolyl or pyrazolo[1,5-a]pyridyl and the like.

Examples of the substituent of the heterocyclic group include thosesimilar to the substituents selected from the above-mentionedsubstituent group C. The substituent may be present at a substitutableposition, and the number of the substituents is 1 to 5, preferably 1 to3.

R^(1b) is preferably an “optionally substituted aryl group or aheteroaryl group”.

Examples of the “substituent” for R^(2b) include an electron withdrawinggroup and an electron donating group, particularly preferably anelectron withdrawing group.

Examples of the electron withdrawing group include a halogen atom (e.g.,fluorine, chlorine, bromine, iodine), a cyano group, an acyl group, ahalogenoalkyl group (e.g., a halogeno(C₁₋₃)alkyl group such asfluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl,trifluoromethyl and the like etc.) and the like.

Examples of the aforementioned “acyl group” include an acyl groupderived from an optionally substituted carboxylic acid, an optionallysubstituted oxycarboxylic acid, an optionally substituted sulfonic acid,an optionally substituted sulfinic acid and the like, and the like, forexample, a group represented by the formula —S(O)_(p)—R^(7b) wherein pis 1 or 2, and R^(7b) is a hydroxyl group, a hydrocarbon groupoptionally having substituent(s) or a heterocyclic group optionallyhaving substituent(s), a group represented by the formula —COOR^(8b)wherein R^(8b) is a hydrogen atom, a hydrocarbon group optionally havingsubstituent(s) or a heterocyclic group optionally having substituent(s),a group represented by the formula —CONR^(9b)R^(10b) wherein R^(9b) andR^(10b) are the same or different and each is a hydrogen atom, ahydrocarbon group optionally having substituent(s) or a heterocyclicgroup optionally having substituent(s), a group represented by theformula —SO₂NH—R^(11b) wherein R^(11b) is a hydrogen atom, a hydrocarbongroup optionally having substituent(s) or a heterocyclic groupoptionally having substituent(s), a group represented by the formula—CO—R^(12b) wherein R^(12b) is a hydrogen atom, a hydrocarbon groupoptionally having substituent(s) or a heterocyclic group optionallyhaving substituent(s), and the like.

Examples of the “hydrocarbon group” of the “hydrocarbon group optionallyhaving substituent(s)” for R^(7b), R^(8b), R^(9b), R^(10b), R^(11b) orR^(12b) include a chain or cyclic hydrocarbon group (e.g., alkyl,alkenyl, alkynyl, cycloalkyl, aryl, aralkyl etc.). Of these, a chain orcyclic hydrocarbon group having 1 to 16 carbon atoms and the like arepreferable.

Examples of the “alkyl” include C₁₋₆ alkyl (e.g., methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.)and the like.

Examples of the “alkenyl” include C₂₋₆ alkenyl (e.g., vinyl, allyl,isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl,1-methyl-2-propenyl, 2-methyl-1-propenyl etc.) and the like.

Examples of the “alkynyl” include C₂₋₆ alkynyl (e.g., ethynyl,propargyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-hexynyl etc.) and thelike.

Examples of the “cycloalkyl” include C₃₋₇ cycloalkyl (e.g., cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc.) and the like.

Examples of the “aryl” include C₆₋₁₄ aryl (e.g., phenyl, 1-naphthyl,2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.)and the like.

Examples of the “aralkyl” include C₇₋₁₆ aralkyl (e.g., phenyl-C₁₋₆alkyl, naphthyl-C₁₋₆ alkyl or diphenyl-C₁₋₄ alkyl etc. such as benzyl,phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl,2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl and thelike) and the like.

When the above-mentioned “hydrocarbon group” of the “hydrocarbon groupoptionally having substituent(s)” for R^(7b), R^(8b), R^(9b), R^(10b),R^(11b) or R^(12b) is alkyl, alkenyl or alkynyl, the group may besubstituted by 1 to 3 substituents selected from (1) a halogen atom(e.g., fluorine atom, chlorine atom, bromine atom, iodine atom etc.),(2) nitro, (3) cyano, (4) hydroxy, (5) C₁₋₆ alkoxy optionally having 1to 3 halogen atoms (e.g., fluorine atom, chlorine atom, bromine atom,iodine atom) (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy,isobutoxy, sec-butoxy, pentyloxy, hexyloxy, fluoromethoxy etc.), (6)C₆₋₁₄ aryloxy (e.g., phenyloxy, naphthyloxy etc.), (7) C₇₋₁₆ aralkyloxy(e.g., benzyloxy, phenethyloxy, diphenylmethyloxy, 1-naphthylmethyloxy,2-naphthylmethyloxy, 2,2-diphenylethyloxy, 3-phenylpropyloxy,4-phenylbutyloxy, 5-phenylpentyloxy etc.), (8) mercapto, (9) C₁₋₆alkylthio optionally having 1 to 3 halogen atoms (e.g., fluorine atom,chlorine atom, bromine atom, iodine atom) (e.g., methylthio,difluoromethylthio, trifluoromethylthio, ethylthio, propylthio,isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio,hexylthio etc.), (10) C₆₋₁₄ arylthio (e.g., phenylthio, naphthylthioetc.), (11) C₇₋₁₆ aralkylthio (e.g., benzylthio, phenethylthio,diphenylmethylthio, 1-naphthylmethylthio, 2-naphthylmethylthio,2,2-diphenylethylthio, 3-phenylpropylthio, 4-phenylbutylthio,5-phenylpentylthio etc.) (12) amino, (13) mono-C₁₋₆ alkylamino (e.g.,methylamino, ethylamino etc.), (14) mono-C₆₋₁₄ arylamino (e.g.,phenylamino, 1-naphthylamino, 2-naphthylamino etc.), (15) mono-C₇₋₁₆aralkylamino (e.g., benzylamino etc.), (16) di-C₁₋₆ alkylamino (e.g.,dimethylamino, diethylamino etc.), (17) di-C₆₋₁₄ arylamino (e.g.,diphenylamino etc.), (18) di-C₇₋₁₆ aralkylamino (e.g., dibenzylaminoetc.), (19) formyl, (20) C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyletc.), (21) C₆₋₁₄ aryl-carbonyl (e.g., benzoyl, 1-naphthoyl, 2-naphthoyletc.), (22) carboxyl, (23) C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl etc.), (24) C₆₋₁₄aryloxy-carbonyl (e.g., phenoxycarbonyl etc.), (25) carbamoyl, (26)thiocarbamoyl, (27) mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl,ethylcarbamoyl etc.), (28) di-C₁₋₆ alkyl-carbamoyl (e.g.,dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl etc.), (29)C₆₋₁₄ aryl-carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl,2-naphthylcarbamoyl etc.), (30) C₁₋₆ alkylsulfonyl (e.g.,methylsulfonyl, ethylsulfonyl etc.), (31) C₆₋₁₄ arylsulfonyl (e.g.,phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl etc.), (32) C₁₋₆alkylsulfinyl (e.g., methylsulfinyl, ethylsulfinyl etc.), (33) C₆₋₁₄arylsulfinyl (e.g., phenylsulfinyl, 1-naphthylsulfinyl,2-naphthylsulfinyl etc.), (34) formylamino, (35) C₁₋₆alkyl-carbonylamino (e.g., acetylamino etc.), (36) C₆₋₁₄aryl-carbonylamino (e.g., benzoylamino, naphthoylamino etc.), (37) C₁₋₆alkoxy-carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino,propoxycarbonylamino, butoxycarbonylamino etc.), (38) C₁₋₆alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino etc.),(39) C₆₋₁₄ arylsulfonylamino (e.g., phenylsulfonylamino,2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.), (40) C₁₋₆alkyl-carbonyloxy (e.g., acetoxy, propionyloxy etc.), (41) C₆₋₁₄aryl-carbonyloxy (e.g., benzoyloxy, naphthylcarbonyloxy etc.), (42) C₁₋₆alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy,propoxycarbonyloxy, butoxycarbonyloxy etc.), (43) mono-C₁₋₆alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy etc.),(44) di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy,diethylcarbamoyloxy etc.), (45) C₆₋₁₄ aryl-carbamoyloxy (e.g.,phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), (46) a 5- to 7-memberedsaturated cyclic amino optionally containing, besides one nitrogen atomand carbon atom, 1 or 2 kinds of 1 to 4 hetero atoms selected from anitrogen atom, a sulfur atom and an oxygen atom (e.g., pyrrolidin-1-yl,piperidino, piperazin-1-yl, morpholino, thiomorpholino,hexahydroazepin-1-yl etc.), (47) a 5- to 10-membered aromaticheterocyclic group containing, besides carbon atom, 1 or 2 kinds of 1 to4 hetero atoms selected from a nitrogen atom, a sulfur atom and anoxygen atom (e.g., 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl,4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl,1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl,2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl,3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), (48) C₁₋₃alkylenedioxy (e.g., methylenedioxy, ethylenedioxy etc.), (49) C₃₋₇cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl etc.) and the like.

In addition, when the “hydrocarbon group” of the “hydrocarbon groupoptionally having substituent(s)” for R^(7b), R^(8b), R^(9b), R^(10b),R^(11b) or R^(12b) is cycloalkyl, aryl or aralkyl, the group may besubstituted by 1 to 5 (preferably 1 to 3) substituents selected from (1)halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodineatom etc.), (2) nitro, (3) cyano, (4) hydroxy, (5) C₁₋₆ alkoxyoptionally having 1 to 3 halogen atoms (e.g., fluorine atom, chlorineatom, bromine atom, iodine atom) (e.g., methoxy, ethoxy, propoxy,isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy,fluoromethoxy etc.), (6) C₆₋₁₄ aryloxy (e.g., phenyloxy, naphthyloxyetc.), (7) C₇₋₁₆ aralkyloxy (e.g., benzyloxy, phenethyloxy,diphenylmethyloxy, 1-naphthylmethyloxy, 2-naphthylmethyloxy,2,2-diphenylethyloxy, 3-phenylpropyloxy, 4-phenylbutyloxy,5-phenylpentyloxy etc.), (8) mercapto, (9) C₁₋₆ alkylthio optionallyhaving 1 to 3 halogen atoms (e.g., fluorine atom, chlorine atom, bromineatom, iodine atom) (e.g., methylthio, difluoromethylthio,trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio,4,4,4-trifluorobutylthio, pentylthio, hexylthio etc.), (10) C₆₋₁₄arylthio (e.g., phenylthio, naphthylthio etc.), (11) C₇₋₁₆ aralkylthio(e.g., benzylthio, phenethylthio, diphenylmethylthio,1-naphthylmethylthio, 2-naphthylmethylthio, 2,2-diphenylethylthio,3-phenylpropylthio, 4-phenylbutylthio, 5-phenylpentylthio etc.), (12)amino, (13) mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino etc.),(14) mono-C₆₋₁₄ arylamino (e.g., phenylamino, 1-naphthylamino,2-naphthylamino etc.), (15) mono-C₇₋₁₆ aralkylamino (e.g., benzylaminoetc.), (16) di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino etc.),(17) di-C₆₋₁₄ arylamino (e.g., diphenylamino etc.), (18) di-C₇₋₁₆aralkylamino (e.g., dibenzylamino etc.), (19) formyl, (20) C₁₋₆alkyl-carbonyl (e.g., acetyl, propionyl etc.), (21) C₆₋₁₄ aryl-carbonyl(e.g., benzoyl, 1-naphthoyl, 2-naphthoyl etc.), (22) carboxyl, (23) C₁₋₆alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,tert-butoxycarbonyl etc.), (24) C₆₋₁₄ aryloxy-carbonyl (e.g.,phenoxycarbonyl etc.), (25) carbamoyl, (26) thiocarbamoyl, (27)mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl etc.),(28) di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl,ethylmethylcarbamoyl etc.), (29) C₆₋₁₄ aryl-carbamoyl (e.g.,phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), (30)C₁₋₆ alkylsulfonyl optionally having 1 to 3 halogen atoms (e.g.,fluorine atom, chlorine atom, bromine atom, iodine atom) (e.g.,methylsulfonyl, ethylsulfonyl, trifluoromethylsulfonyl etc.), (31) C₆₋₁₄arylsulfonyl (e.g., phenylsulfonyl, 1-naphthylsulfonyl,2-naphthylsulfonyl etc.), (32) C₁₋₆ alkylsulfinyl (e.g., methylsulfinyl,ethylsulfinyl etc.). (33) C₆₋₁₄ arylsulfinyl (e.g., phenylsulfinyl,1-naphthylsulfinyl, 2-naphthylsulfinyl etc.), (34) formylamino, (35)C₁₋₆ alkyl-carbonylamino (e.g., acetylamino etc.), (36) C₆₋₁₄aryl-carbonylamino (e.g., benzoylamino, naphthoylamino etc.), (37) C₁₋₆alkoxy-carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino,propoxycarbonylamino, butoxycarbonylamino etc.), (38) C₁₋₆alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino etc.),(39) C₆₋₁₄ arylsulfonylamino (e.g., phenylsulfonylamino,2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.), (40) C₁₋₆alkyl-carbonyloxy (e.g., acetoxy, propionyloxy etc.), (41) C₆₋₁₄aryl-carbonyloxy (e.g., benzoyloxy, naphthylcarbonyloxy etc.), (42) C₁₋₆alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy,propoxycarbonyloxy, butoxycarbonyloxy etc.), (43) mono-C₁₋₆alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy etc.),(44) di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy,diethylcarbamoyloxy etc.), (45) C₆₋₁₄ aryl-carbamoyloxy (e.g.,phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), (46) a 5- to 7-memberedsaturated cyclic amino optionally containing, besides one nitrogen atomand carbon atom, 1 or 2 kinds of 1 to 4 hetero atoms selected from anitrogen atom, a sulfur atom and an oxygen atom (e.g., pyrrolidin-1-yl,piperidino, piperazin-1-yl, morpholino, thiomorpholino,hexahydroazepin-1-yl etc.), (47) a 5- to 10-membered aromaticheterocyclic group containing, besides carbon atom, 1 or 2 kinds of 1 to4 hetero atoms selected from a nitrogen atom, a sulfur atom and anoxygen atom (e.g., 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl,4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl,1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl,2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl,3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), (48) C₁₋₃alkylenedioxy (e.g., methylenedioxy, ethylenedioxy etc.), (49) C₃₋₇cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl etc.), (50) a C₁₋₆ alkyl group (e.g., methyl, ethyl,n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,sec-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl etc.) optionallyhaving 1 to 3 halogen atoms (e.g., fluorine atom, chlorine atom, bromineatom, iodine atom) or hydroxy group, (51) a C₂₋₆ alkenyl group (e.g.,allyl, isopropenyl, isobutenyl, 1-methylallyl, 2-pentenyl, 2-hexenyletc.) optionally having 1 to 3 halogen atoms (e.g., fluorine atom,chlorine atom, bromine atom, iodine atom), (52) C₂₋₆ alkynyl group(e.g., propargyl, 2-butynyl, 3-butynyl, 3-pentynyl, 3-hexynyl etc.),(53) mono-C₃₋₇ cycloalkyl-carbamoyl (e.g., cyclopropylcarbamoyl,cyclobutylcarbamoyl etc.), and (54) a 5- or 10-memberedheterocyclyl-carbonyl containing, besides carbon atom, 1 or 2 kinds of 1to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and anoxygen atom (e.g., 4-morpholinocarbonyl etc.) (hereinafter to bereferred to as substituent group D) and the like.

Examples of the “heterocyclic group” of the “heterocyclic groupoptionally having substituent(s)” for R^(7b), R^(8b), R^(9b), R^(10b),R^(11b) or R^(12b) include a 3- to 8-membered heterocyclic group(preferably a 5- or 6-membered heterocyclic group) containing 1 to 4hetero atoms selected from a nitrogen atom (optionally oxidized), anoxygen atom, a sulfur atom (optionally mono- or di-oxidized) and thelike, or a group wherein a 3- to 8-membered heterocyclic group(preferably a 5- or 6-membered heterocyclic group) containing 1 to 4hetero atoms selected from a nitrogen atom (optionally oxidized), anoxygen atom, a sulfur atom (optionally mono- or di-oxidized) and thelike is condensed with a benzene ring or a 3- to 8-membered ring group(preferably a 5- or 6-membered ring group) containing 1 to 4 heteroatoms selected from a nitrogen atom (optionally oxidized), an oxygenatom, a sulfur atom (optionally mono- or di-oxidized) and the like,preferably a group wherein the 5- or 6-membered heterocyclic group iscondensed with a 5- or 6-membered ring optionally containing 1 to 4hetero atoms selected from a nitrogen atom (optionally oxidized), anoxygen atom, a sulfur atom (optionally mono- or di-oxidized) and thelike.

Specific examples thereof include aziridinyl (e.g., 1- or 2-aziridinyl),azirinyl (e.g., 1- or 2-azirinyl), azetyl (e.g., 2-, 3- or 4-azetyl),azetidinyl (e.g., 1-, 2- or 3-azetidinyl), perhydroazepinyl (e.g., 1-,2-, 3- or 4-perhydroazepinyl), perhydroazocinyl (e.g., 1-, 2-, 3-, 4- or5-perhydroazocinyl), pyrrolyl (e.g., 1-, 2- or 3-pyrrolyl), pyrazolyl(e.g., 1-, 3-, 4- or 5-pyrazolyl), imidazolyl (e.g., 1-, 2-, 4- or5-imidazolyl), triazolyl (e.g., 1,2,3-triazol-1-, 4- or -5-yl,1,2,4-triazol-1-, 3-, 4- or 5-yl), tetrazolyl (e.g., tetrazol-1-, 2- or5-yl), furyl (e.g., 2- or 3-furyl), thienyl (e.g., 2- or 3-thienyl),thienyl wherein the sulfur atom is oxidized (e.g., 2- or3-thienyl-1,1-dioxide), oxazolyl (e.g., 2-, 4- or 5-oxazolyl),isoxazolyl (e.g., 3-, 4- or 5-isoxazolyl), oxadiazolyl (e.g.,1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl,1,2,5-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl), thiazolyl (e.g., 2-, 4- or5-thiazolyl), isothiazolyl (e.g., 3-, 4- or 5-isothiazolyl),thiadiazolyl (e.g., 1,2,3-thiadiazol-4- or 5-yl, 1,2,4-thiadiazol-3- or5-yl, 1,2,5-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl), pyrrolidinyl (e.g.,1-, 2- or 3-pyrrolidinyl), pyridyl (e.g., 2-, 3- or 4-pyridyl), pyridylwherein the nitrogen atom is oxidized (e.g., 2-, 3- or4-pyridyl-N-oxide), pyridazinyl (e.g., 3- or 4-pyridazinyl), pyridazinylwherein one or both of the nitrogen atoms are oxidized (e.g., 3-, 4-, 5-or 6-pyridazinyl-N-oxide), pyrimidinyl (e.g., 2-, 4- or 5-pyrimidinyl),pyrimidinyl wherein one or both of the nitrogen atoms are oxidized(e.g., 2-, 4-, 5- or 6-pyrimidinyl-N-oxide), pyrazinyl, piperidinyl(e.g., 1-, 2-, 3- or 4-piperidinyl), piperazinyl (e.g., 1- or2-piperazinyl), indolyl (e.g., 3H-indole-2-, 3-, 4-, 5-, 6- or 7-yl),pyranyl (e.g., 2-, 3- or 4-pyranyl), thiopyranyl (e.g., 2-, 3- or4-thiopyranyl), thiopyranyl wherein the sulfur atom is oxidized (e.g.,2-, 3- or 4-thiopyranyl-1,1-dioxide), morpholinyl (e.g., 2-, 3- or4-morpholinyl), thiomorpholinyl, quinolyl (e.g., 2-, 3-, 4-, 5-, 6-, 7-or 8-quinolyl), isoquinolyl, pyrido[2,3-d]pyrimidinyl (e.g.,pyrido[2,3-d]pyrimidin-2-yl), naphthyridinyl such as 1,5-, 1,6-, 1,7-,1,8-, 2,6- or 2,7-naphthyridinyl and the like (e.g., 1,5-naphthyridin-2-or 3-yl), thieno[2,3-d]pyridyl (e.g., thieno[2,3-d]pyridin-3-yl),pyrazinoquinolyl (e.g., pyrazino[2,3-d]quinolin-2-yl), chromenyl (e.g.,2H-chromen-2- or 3-yl), 2-benzo[b]thienyl, 3-benzo[b]thienyl,2-benzo[b]furanyl, 3-benzo[b]furanyl and the like.

Examples of the “substituent” of the heterocyclic group include thosesimilar to the substituents selected from the above-mentionedsubstituent group D. The number of the substituents is 1 to 5,preferably 1 to 3.

Of the above-mentioned group, the electron withdrawing group ispreferably a halogen atom, a cyano group, an acyl group or atrifluoromethyl group.

Examples of the electron donating group include a C₁₋₆ alkyl group(e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,tert-butyl, pentyl, hexyl etc.), a C₁₋₆ alkylthio group (e.g.,methylthio, ethylthio, propylthio, isopropylthio, butylthio, pentylthio,hexylthio etc.), a C₁₋₆ alkoxy group (e.g., methoxy, ethoxy, propoxy,isopropoxy, butoxy, pentyloxy, hexyloxy etc.), a group represented bythe —NR^(13b)R^(14b) wherein R^(13b) and R^(14b) are the same ordifferent and each is a hydrogen atom or an alkyl group, and the like.Examples of the alkyl group for R^(13b) or R^(14b) include a C₁₋₆ alkylgroup such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl and the like, particularlypreferably a C₁₋₃ alkyl group.

Of the above-mentioned group, the electron donating group is preferablya C₁₋₃ alkyl, a C₁₋₃ alkylthio, or a group represented by the formula—NR^(13b)R^(14b) wherein each symbol is as defined above.

Of the aforementioned group, the “substituent” for R^(2b) is preferably,for example, an electron withdrawing group or electron donating grouphaving not more than 7 atoms and comparatively low molecular weightshown above.

In the formula (A4), R^(3b) is an optionally substituted alkyl group, anacyl group, an optionally substituted hydroxy group, an optionallysubstituted amino group, a halogen atom, a cyano group or a nitro group.R^(3b) is preferably an alkyl group optionally substituted by halogen,an acyl group, a halogen atom, a cyano group or a nitro group.

R^(4b) and R^(5b) are the same or different and each is a hydrogen atom,an optionally substituted alkyl group, an acyl group, an optionallysubstituted hydroxy group, an optionally substituted amino group, ahalogen atom, a cyano group or a nitro group. Preferably, R^(4b) andR^(5b) are the same or different and each is a hydrogen atom, an alkylgroup optionally substituted by halogen, an acyl group, a halogen atom,a cyano group or a nitro group.

Examples of the “alkyl group” in the “optionally substituted alkylgroup” for R^(3b), R^(4b) or R^(5b) include a C₁₋₆ alkyl group such asmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,tert-butyl, pentyl, hexyl and the like. Examples of the “substituent” ofthe alkyl include those similar to the substituents that theabove-mentioned “hydrocarbon group” for R^(7b), R^(8b), R^(9b), R^(10b),R^(11b) or R^(12b) may have when it is alkyl, alkenyl or alkynyl. Thenumber of the substituents is 1 to 5, preferably 1 to 3.

Preferable examples of the substituent of the alkyl group for R^(3b),R^(4b) or R^(5b) include halogen (e.g., a fluorine atom, a chlorineatom, a bromine atom, an iodine atom). The number of the halogen atom asa substituent is 1 to 5, preferably 1 to 3.

Examples of the “acyl group” for R^(3b), R^(4b) or R^(5b) include acylgroups having 1 to 20 carbon atoms, which is derived from organiccarboxylic acids, for example, C₁₋₇ alkanoyl groups (e.g., formyl; C₁₋₆alkyl-carbonyl such as acetyl, propionyl, butyryl, isobutyryl,pentanoyl, hexanoyl, heptanoyl and the like; etc.), C₆₋₁₄ aryl-carbonylgroups (e.g., benzoyl, naphthalenecarbonyl etc.), C₁₋₆ alkoxy-carbonylgroups (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl,sec-butoxycarbonyl, tert-butoxycarbonyl etc.), C₆₋₁₄ aryloxy-carbonylgroups (e.g., phenoxycarbonyl group), C₇₋₁₉ aralkyl-carbonyl groups(e.g., phenyl-C₁₋₄ alkylcarbonyl such as benzylcarbonyl,phenethylcarbonyl, phenylpropylcarbonyl and the like, naphthyl-C₁₋₄alkylcarbonyl such as benzhydrylcarbonyl, naphthylethylcarbonyl and thelike, etc.), C₇₋₁₉ aralkyloxy-carbonyl groups (e.g., phenyl-C₁₋₄alkyloxycarbonyl such as benzyloxycarbonyl and the like, etc.), 5- or6-membered heterocyclyl-carbonyl groups or condensedheterocyclyl-carbonyl groups thereof (e.g., pyrrolylcarbonyl such as 2-or 3-pyrrolylcarbonyl and the like; pyrazolylcarbonyl such as 3-, 4- or5-pyrazolylcarbonyl and the like; imidazolylcarbonyl such as 2-, 4- or5-imidazolylcarbonyl and the like; triazolylcarbonyl such as1,2,3-triazol-4-ylcarbonyl, 1,2,4-triazol-3-ylcarbonyl and the like;tetrazolylcarbonyl such as 1H- or 2H-tetrazol-5-ylcarbonyl and the like;furylcarbonyl such as 2- or 3-furylcarbonyl and the like;thienylcarbonyl such as 2- or 3-thienylcarbonyl and the like;oxazolylcarbonyl such as 2-, 4- or 5-oxazolylcarbonyl and the like;isoxazolylcarbonyl such as 3-, 4- or 5-isoxazolylcarbonyl and the like;oxadiazolylcarbonyl such as 1,2,3-oxadiazol-4- or 5-ylcarbonyl,1,2,4-oxadiazol-3- or 5-ylcarbonyl, 1,2,5-oxadiazol-3- or 4-ylcarbonyl,1,3,4-oxadiazol-2-ylcarbonyl and the like; thiazolylcarbonyl such as 2-,4- or 5-thiazolylcarbonyl and the like; isothiazolylcarbonyl such as 3-,4- or 5-isothiazolylcarbonyl and the like; thiadiazolylcarbonyl such as1,2,3-thiadiazol-4- or 5-ylcarbonyl, 1,2,4-thiadiazol-3- or5-ylcarbonyl, 1,2,5-thiadiazol-3- or 4-ylcarbonyl,1,3,4-thiadiazol-2-ylcarbonyl and the like; pyrrolidinylcarbonyl such as2- or 3-pyrrolidinylcarbonyl and the like; pyridylcarbonyl such as 2-,3- or 4-pyridylcarbonyl and the like; pyridylcarbonyl wherein thenitrogen atom is oxidized, such as 2-, 3- or 4-pyridyl-N-oxidocarbonyland the like; pyridazinylcarbonyl such as 3- or 4-pyridazinylcarbonyland the like; pyridazinyl wherein one or both of the nitrogen atoms areoxidized, such as 3-, 4-, 5- or 6-pyridazinyl-N-oxidocarbonyl and thelike; pyrimidinylcarbonyl such as 2-, 4- or 5-pyrimidinylcarbonyl andthe like; pyrimidinylcarbonyl wherein one or both of the nitrogen atomsare oxidized, such as 2-, 4-, 5- or 6-pyrimidinyl-N-oxidocarbonyl andthe like; pyrazinylcarbonyl; piperidinylcarbonyl such as 2-, 3- or4-piperidinylcarbonyl and the like; piperazinylcarbonyl; indolylcarbonylsuch as 3H-indol-2- or 3-ylcarbonyl and the like; pyranylcarbonyl suchas 2-, 3- or 4-pyranylcarbonyl and the like; thiopyranylcarbonyl such as2-, 3- or 4-thiopyranylcarbonyl and the like; quinolylcarbonyl such as3-, 4-, 5-, 6-, 7- or 8-quinolylcarbonyl and the like;isoquinolylcarbonyl; pyrido[2,3-d]pyrimidinylcarbonyl (e.g.,pyrido[2,3-d]pyrimidin-2-ylcarbonyl); naphthyridinylcarbonyl (e.g.,1,5-naphthyridin-2- or 3-ylcarbonyl) such as 1,5-, 1,6-, 1,7-, 1,8-,2,6- or 2,7-naphthyridinylcarbonyl and the like;thieno[2,3-d]pyridylcarbonyl (e.g., thieno[2,3-d]pyridin-3-ylcarbonyl);pyrazinoquinolylcarbonyl (e.g., pyrazino[2,3-b]quinolin-2-ylcarbonyl);5- or 6-membered heterocyclyl-carbonyl groups (e.g., 5- or 6-memberedheterocyclylcarbonyl group containing 1 to 4 hetero atoms such as anitrogen atom (optionally oxidized), an oxygen atom, a sulfur atom(optionally mono- or di-oxidized) and the like, such aschromenylcarbonyl (e.g., 2H-chromen-2- or 3-ylcarbonyl etc.) and thelike), 5- or 6-membered heterocyclyl-acetyl groups (e.g., 5- or6-membered heterocyclyl-acetyl groups containing 1 to 4 hetero atomssuch as a nitrogen atom (optionally oxidized), an oxygen atom, a sulfuratom (optionally mono- or di-oxidized) and the like such as2-pyrrolylacetyl, 3-imidazolylacetyl, 5-isoxazolylacetyl and the like),and the like can be used.

As regards the substituent of acyl group, for example, when theabove-mentioned acyl group is an alkanoyl group or an alkoxy-carbonylgroup, it is optionally substituted by 1 to 3 alkylthio groups (e.g.,C₁₋₄ alkylthio such as methylthio, ethylthio, n-propylthio,isopropylthio and the like, and the like), halogen (e.g., fluorine,chlorine, bromine, iodine), an alkoxy group (e.g., C₁₋₆ alkoxy such asmethoxy, ethoxy, n-propoxy, tert-butoxy, n-hexyloxy and the like, andthe like), a nitro group, an alkoxy-carbonyl group (e.g., C₁₋₆alkoxy-carbonyl such as methoxycarbonyl, ethoxycarbonyl,n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl,isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl and the like,and the like), an alkylamino group (e.g., mono- or di-C₁₋₆ alkylaminosuch as methylamino, ethylamino, n-propylamino, n-butylamino,tert-butylamino, n-pentylamino, n-hexylamino, dimethylamino,diethylamino, methylethylamino, di-(n-propyl)amino, di-(n-butyl)aminoand the like, and the like), an alkoxyimino group (e.g., C₁₋₆alkoxyimino such as methoxyimino, ethoxyimino, n-propoxyimino,tert-butoxyimino, n-hexyloxy-imino and the like, and the like) orhydroxyimino.

When the above-mentioned acyl group is an aryl-carbonyl group, anaryloxy-carbonyl group, an aralkyl-carbonyl group, an aralkyloxycarbonylgroup, a 5- or 6-membered heterocyclyl-carbonyl group or a 5- or6-membered heterocyclyl-acetyl group, it is optionally substituted by 1to 5 (preferably 1 to 3) alkyl group (e.g., C₁₋₆ alkyl such as methyl,ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,n-pentyl, sec-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and thelike, C₃₋₆ cycloalkyl such as cyclohexyl and the like, and the like), analkenyl group (e.g., C₂₋₆ alkenyl such as allyl, isopropenyl,isobutenyl, 1-methylallyl, 2-pentenyl, 2-hexenyl and the like, and thelike), an alkynyl group (e.g., C₂₋₆ alkynyl such as propargyl,2-butynyl, 3-butynyl, 3-pentynyl, 3-hexynyl and the like, and the like),an alkoxy group (e.g., C₁₋₆ alkoxy such as methoxy, ethoxy, n-propoxy,tert-butoxy, n-hexyloxy and the like, and the like), an acyl group[e.g., C₁₋₇ alkanoyl such as formyl, acetyl, propionyl, butyryl,isobutyryl, pentanoyl, hexanoyl, heptanoyl and the like; C₆₋₁₄aryl-carbonyl such as benzoyl, naphthalenecarbonyl and the like; C₁₋₆alkoxy-carbonyl such as methoxycarbonyl, ethoxycarbonyl,propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl,sec-butoxycarbonyl, tert-butoxycarbonyl and the like; C₆₋₁₄aryloxy-carbonyl such as phenoxycarbonyl and the like; C₇₋₁₉aralkyl-carbonyl such as phenyl-C₁₋₄ alkyl-carbonyl (e.g.,benzylcarbonyl, phenethylcarbonyl, phenylpropylcarbonyl and the like)and the like; C₇₋₁₉ aralkyloxy-carbonyl such as phenyl-C₁₋₄alkyloxy-carbonyl (e.g., benzyloxycarbonyl and the like) and the like,and the like], nitro, amino, hydroxy, cyano, sulfamoyl, mercapto,halogen (e.g., fluorine, chlorine, bromine, iodine) or an alkylthiogroup (C₁₋₄ alkylthio such as methylthio, ethylthio, n-propylthio,isobutylthio and the like, and the like).

Examples of the “optionally substituted hydroxy group” for R^(3b),R^(4b) or R^(5b) include a group represented by —OR^(16b) whereinR^(16b) is a hydrogen atom, an optionally substituted hydrocarbon group,an optionally substituted heterocyclic group or an acyl group.

Examples of the “optionally substituted hydrocarbon group” for R^(16b)include those similar to the “optionally substituted hydrocarbon group”for the above-mentioned R^(7b), R^(8b), R^(9b), R^(10b), R^(11b) orR^(12b).

Examples of the “optionally substituted heterocyclic group” for R^(16b)include those similar to the “optionally substituted heterocyclic group”for the above-mentioned R^(7b), R^(8b), R^(9b), R^(10b), R^(11b) orR^(12b).

Examples of the “acyl group” for R^(16b) include those similar to the“acyl group” exemplified as the above-mentioned “substituent” forR^(2b).

Examples of the “optionally substituted amino group” for R^(3b), R^(4b)or R^(5b) include a group represented by —NR^(17b)R^(18b) whereinR^(17b) and R^(18b) are the same or different and each is a hydrogenatom, an optionally substituted hydrocarbon group, an optionallysubstituted heterocyclic group or an acyl group.

Examples of the “optionally substituted hydrocarbon group” for R^(17b)or R^(18b) include those similar to the “optionally substitutedhydrocarbon group” for the above-mentioned R^(7b), R^(8b), R^(9b),R^(10b), R^(11b) or R^(12b).

Examples of the “optionally substituted heterocyclic group” for R^(17b)or R^(18b) include those similar to the “optionally substitutedheterocyclic group” for the above-mentioned R^(7b), R^(8b), R^(9b),R^(10b), R^(11b) or R^(12b).

Examples of the “optionally substituted acyl group” for R^(17b) orR^(18b) include those similar to the “acyl group” exemplified as theabove-mentioned “substituent” for R^(2b).

Examples of the “halogen atom” for R^(3b), R^(4b) or R^(5b) includefluorine, chlorine, bromine and iodine.

In the formula (A4), R^(3b) is optionally substituted at anysubstitutable position of the pyridine ring. The number (i.e., n) ofsubstituent R^(3b) is 0 to 3. When n is 2 or 3, each of R^(3b) is thesame or different.

Preferably, n is 0.

Preferably, R^(4b) and R^(5b) are the same or different and each is ahydrogen atom or a halogen atom.

Examples of the “alkyl group” for R^(6b) or R^(6b′) include a C₁₋₆ alkylgroup such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, hexyl and the like, preferably a C₁₋₃alkyl group, particularly preferably methyl.

Preferable embodiment of the partial structure of the formula (A4):

wherein R^(6b) is an alkyl group.

When the compound represented by the above-mentioned formula (A4) hasisomers such as optical isomer, stereoisomer, positional isomer,rotational isomer and the like, any isomers and mixtures are encompassedin the compound (A4). For example, when compound (A4) has an opticalisomer, an optical isomer separated from a racemate is also encompassedin the compound (A4). These isomers can be obtained as independentproducts by a synthesis means or a separation means (e.g.,concentration, solvent extraction, column chromatography,recrystallization and the like), and the like known per se.

The compound (A4) may be a crystal, and both a single crystal andcrystal mixtures are encompassed in the compound (A4). Crystals can beproduced by crystallization according to crystallization methods knownper se.

The compound (A4) may be a solvate (e.g., hydrate etc.) or anon-solvate, both of which are encompassed in the compound (A4).

A compound labeled with an isotope (e.g., ³H, ¹⁴ _(C,) ³⁵S, ¹²⁵I and thelike) is also encompassed in the compound (A4).

The compound represented by the above-mentioned formula (A4) can beproduced, for example, according to the method described in WO2008/108380.

In the pharmaceutical composition of the present invention, preferableexamples of the nonpeptidic pharmaceutically active ingredient having aprimary or secondary amino group include the following compounds.

-   N-methyl-1-{1-[(4-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   1-{1-[(4-fluorophenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-(methylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(4-methoxyphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(4-fluorophenyl)sulfonyl]-2-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{5-(4-fluorophenyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{5-(3-methylphenyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-{5-(3-fluorophenyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-{1-[(2-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-(5-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-{1-[(4-fluoro-2-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N,N-dimethyl-1-(5-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-[5-(4-fluorophenyl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylphenyl)-1-(4-methylphenylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{5-(4-fluorophenyl)-1-[(4-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-(5-(4-fluorophenyl)-1-{[4-(trifluoromethyl)phenyl]sulfonyl}-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   1-[1-[(4-fluorophenyl)sulfonyl]-5-(4-methoxyphenyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(4-fluorophenyl)sulfonyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{1-(4-methylphenyl)sulfonyl}-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[2-methyl-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{5-(2,4-difluorophenyl)-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-[(4-methoxyphenyl)sulfonyl]-5-(4-phenoxyphenyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-[(4-methoxyphenyl)sulfonyl]-5-(2-naphthyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-{1-[(4-methoxyphenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}aniline    or a salt thereof,-   1-{1-[(4-methoxyphenyl)sulfonyl]-5-pyridin-3-yl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(4-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-{4-methyl-1-[(4-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   3-{4-[(methylamino)methyl]-1-[(4-methylphenyl)sulfonyl]-1H-pyrrol-2-yl}benzonitrile    or a salt thereof,-   4-{4-[(methylamino)methyl]-1-[(4-methylphenyl)sulfonyl]-1H-pyrrol-2-yl}benzonitrile    or a salt thereof,-   N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{1-[(4-fluorophenyl)sulfonyl]-5-(3-thienyl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(3-chlorophenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-[(3-chlorophenyl)sulfonyl]-5-(3-thienyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-[(3-chlorophenyl)sulfonyl]-5-(4-fluorophenyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(4-chlorophenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(3,4-difluorophenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-(butylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine or    a salt thereof,-   1-{1-[(4-isopropoxyphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(3-methoxyphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(3-thienylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(3-furyl)-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(2,5-dichloro-3-thienyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-(2-chloro-5-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   1-{1-[(3-chlorophenyl)sulfonyl]-2-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-(5-phenyl-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[2-methyl-1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(4-fluorophenyl)-2-methyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-ethyl-1-[5-(4-fluorophenyl)-2-methyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methylamine    or a salt thereof,-   1-[2,4-dimethyl-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(phenylsulfonyl)-4-propyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[4,5-diphenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[2-chloro-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[2-fluoro-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[2-chloro-4-fluoro-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{2-methyl-1-[(3-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[1-(2-methylpyrimidin-5-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-{4-methyl-[1-(3-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   1-{[1-(4-fluorophenyl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[2-methyl-1-(pyridin-3-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[4-chloro-2-methyl-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-butyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or    a salt thereof,-   1-[5-cyclohexyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-cyclopropyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-(1-{[3-(methylsulfonyl)phenyl]sulfonyl}-5-phenyl-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-(1-{[3-(ethylsulfonyl)phenyl]sulfonyl}-5-phenyl-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   1-[1-(2,3-dihydro-1,4-benzodioxyn-6-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   2-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   4-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   methyl    2-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzoate    or a salt thereof,-   methyl    2-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzoate    or a salt thereof,-   methyl    3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzoate    or a salt thereof,-   methyl    3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzoate    or a salt thereof,-   2-chloro-4-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   [1-(1,3-benzothiazol-6-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(1,1-dioxide-2,3-dihydro-1-benzothien-6-yl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-(1-benzothien-2-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-(1-{[4-(methylsulfonyl)phenyl]sulfonyl}-5-phenyl-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-[3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)phenyl]ethanone    or a salt thereof,-   N-methyl-1-{1-[(3-nitrophenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{1-[(6-methoxypyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[1-(4-methylaminopyridin-3-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[1-(2-methylaminopyridin-3-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[1-(2-methylaminopyrimidin-5-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-{[3-(methylsulfonyl)phenyl]sulfonyl}-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-{[3-(ethylsulfonyl)phenyl]sulfonyl}-5-(2-fluorophenyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   2-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}benzonitrile    or a salt thereof,-   4-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}benzonitrile    or a salt thereof,-   1-{5-(2-fluorophenyl)-1-[(2-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-(1-{[3-(methylsulfonyl)phenyl]sulfonyl}-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   N-methyl-1-{1-(pyridin-3-ylsulfonyl)-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylphenyl)-1-{[3-(methylsulfonyl)phenyl]sulfonyl}-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[1-(phenylsulfonyl)-5-(pyridin-2-yl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{1-[(3,4-difluorophenyl)sulfonyl]-5-(pyridin-2-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-(2,3-dihydro-1,4-benzodioxyn-5-ylsulfonyl)-4-methyl-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(2,5-dimethoxyphenyl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-(2,3-dihydro-1,4-benzodioxyn-6-ylsulfonyl)-4-methyl-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-(1-{[3-(methylsulfonyl)phenyl]sulfonyl}-4-methyl-5-phenyl-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{4-methyl-5-phenyl-1-(3-thienylsulfonyl)-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[4-methyl-1-(pyridin-3-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[4-methyl-1-(pyridin-2-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   [5-(2-fluorophenyl)-4-methyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-[2-methyl-1-(phenylsulfonyl)-5-(3-pyridyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-[2-methyl-5-(1-methyl-1H-pyrazol-4-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[4-methyl-1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-phenyl-1-({4-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-phenyl-1-({3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-({3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[4-methyl-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{1-[(3-chlorophenyl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   5-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)pyrimidin-2-amine    or a salt thereof,-   1-[(imidazo[1,2-a]pyrimidin-6-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[1-(pyridazin-3-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N,N-dimethyl-1-[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N,N-dimethyl-1-[5-phenyl-1-(3-thienylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N,N-dimethyl-1-{5-phenyl-1-(3-pyridinesulfonyl)-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   1-[4-ethyl-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-isopropyl-5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   2-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzoic    acid or a salt thereof,-   3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzoic    acid or a salt thereof,-   3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzamide    or a salt thereof,-   N-cyclopropyl-3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzamide    or a salt thereof,-   N-methyl-3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzamide    or a salt thereof,-   N,N-dimethyl-3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzamide    or a salt thereof,-   N-methyl-1-(1-{[3-(morpholin-4-ylcarbonyl)phenyl]sulfonyl}-5-phenyl-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   2-[3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl]sulfonyl)phenyl}propan-2-ol    or a salt thereof,-   2-fluoro-4-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   N-methyl-1-(5-phenyl-1-{[3-(1H-tetrazol-5-yl)phenyl]sulfonyl}-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   2-({4-[(methylamino)methyl]-2-(pyridin-3-yl)-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   N-methyl-1-(1-{[3-(methylsulfonyl)phenyl]sulfonyl}-5-(3-thienyl)-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   N-methyl-1-(1-{[3-(methylsulfonyl)phenyl]sulfonyl}-5-(pyridin-3-yl)-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-[1-(2-chloropyridin-3-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[1-(5-methyl-3-pyridinesulfonyl)-5-phenyl-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   5-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)pyridin-2-ol    or a salt thereof,-   5-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)pyridine-2-carbonitrile    or a salt thereof-   N-methyl-1-{1-[(6-methylpyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[1-(pyridin-3-ylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(4-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(4-fluoro-2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   3-[4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl]benzonitrile    or a salt thereof,-   1-[5-(2-chlorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2,4-difluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2,5-difluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(4-chloro-2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(3-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[1-(phenylsulfonyl)-5-(pyrimidin-5-yl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[1-(phenylsulfonyl)-5-(pyridin-3-yl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   {1-[5-(2-fluorophenyl)-2-methyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   2,2,2-trifluoro-N-({1-[(4-methylphenyl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methyl)ethaneamine    or a salt thereof,-   N-methyl-1-{1-[6-(methylamino)pyridin-3-ylsulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-{1-[2-(methylamino)pyridin-3-ylsulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-{1-[2-(methylamino)pyrimidin-3-ylsulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-[2-methyl-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[1-(2-methylpyrimidin-5-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-methanamine    or a salt thereof,-   N-methyl-1-[4-methyl-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[4-methyl-5-phenyl-1-(pyridin-2-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(pyridazin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-(5-phenyl-1-{[5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   N-methyl-1-{1-[(2-methylpyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   1-[5-(2,6-difluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(4-cyclohexylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-(pyridin-2-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-(2-fluorophenyl)-1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[4-chloro-5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[2-chloro-5-(2,6-difluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[2-chloro-5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(5-bromopyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   5-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)nicotinonitrile    or a salt thereof,-   methyl    5-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)nicotinate    or a salt thereof,-   N-methyl-1-{1-[(5-methylpyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   1-[5-(2,4-dimethylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{5-[4-(methylsulfonyl)phenyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   (2-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}phenyl)methanol    or a salt thereof,-   N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-(5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-[5-mesityl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{5-[2-(methylthio)phenyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   N-methyl-1-{5-[2-(methylsulfonyl)phenyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   2-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}benzonitrile    or a salt thereof,-   1-[5-(2,6-dimethylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-{5-[2-(methylsulfinyl)phenyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl}methanamine    or a salt thereof,-   2-(2-fluorophenyl)-4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbonitrile    or a salt thereof,-   5-(2-fluorophenyl)-3-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-2-carbonitrile    or a salt thereof,-   4-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}benzonitrile    or a salt thereof,-   4-fluoro-3-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}benzonitrile    or a salt thereof,-   1-[5-(2-fluoro-5-methoxyphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-(2-fluoro-3-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}phenyl)ethanone    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(3-fluoropyridin-4-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-chloropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(6-chloropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(6′-chloro-2,3′-bipyridin-5-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-(2-fluoropyridin-3-yl)-1-[(6-methoxypyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   (2-fluoro-3-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}phenyl)methanol    or a salt thereof,-   1-(2-fluoro-3-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}phenyl)ethanol    or a salt thereof,-   1-[5-(2-fluoro-3-methoxyphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoro-6-methoxyphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-[4-(difluoromethoxy)phenyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(4-methylpyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylpyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-{5-(2-fluoropyridin-3-yl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-chloro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[1-(pyridin-3-ylsulfonyl)-5-(2-thienyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[5-(3-methylpyridin-2-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   2-fluoro-3-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}benzonitrile    or a salt thereof,-   4-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}thiophene-3-carbonitrile    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(2-fluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(2-furylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-(5-(2-fluoropyridin-3-yl)-1-[[3-(methylsulfonyl)phenyl]sulfonyl]-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-(1,3-benzodioxol-5-ylsulfonyl)-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-(4-chloro-5-(2-fluoropyridin-3-yl)-1-[[3-(methylsulfonyl)phenyl]sulfonyl]-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-(2-chloropyridin-3-yl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   3-{1-[(3-fluorophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   1-{5-(2-fluoropyridin-3-yl)-1-[(3-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(3-fluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoro-6-methylpyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-{4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   1-[5-(2-chloropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-{4-[(methylamino)methyl]-1-(phenylsulfonyl)-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(3-thienylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-({2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   1-[3-({2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl)phenyl}ethanone    or a salt thereof,-   1-{1-[(4-fluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(2,3-difluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(3,4-difluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(3-fluoro-4-methylphenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(2,5-difluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-4-methyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-4-methyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-1-(phenylsulfonyl)-5-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-1-(pyridin-3-ylsulfonyl)-5-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-chloropyridin-3-yl)-4-fluoro-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-[3-fluoro-4-[(methylamino)methyl]-1-(phenylsulfonyl)-1H-pyrrol-2-yl]pyridine-2-carbonitrile    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(3-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-1-[(3-fluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{5-(2-chloropyridin-3-yl)-4-fluoro-1-[(3-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[5-(2-chloropyridin-3-yl)-4-fluoro-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-(2-chloropyridin-3-yl)-4-fluoro-1-[(3-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   3-({2-(2-chloropyridin-3-yl)-3-fluoro-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   3-{3-fluoro-1-[(3-methoxyphenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{3-fluoro-1-[(3-fluorophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(3-cyanophenyl)sulfonyl]-3-fluoro-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-[3-fluoro-4-[(methylamino)methyl]-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-2-yl]pyridine-2-carbonitrile    or a salt thereof,-   3-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-{[3-(methylsulfonyl)phenyl]sulfonyl}-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   3-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-N-(2-hydroxyethyl)benzamide    or a salt thereof,-   [3-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl)phenyl}methanol    or a salt thereof,-   3-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)benzyl    acetate or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(3-furylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(3-furylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-({3-[(methylsulfonyl)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-{[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]sulfonyl}-1H-pyrrol-3-yl)-N-methylmethanamine    or a salt thereof,-   3-({2-(2-chloropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   1-[1-(cyclohexylsulfonyl)-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(piperidin-1-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{1-[(2,6-difluorophenyl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{4-chloro-5-(2-fluoropyridin-3-yl)-1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(2-furylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(3-thienylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   Methyl    5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furoate    or a salt thereof,-   [5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furyl]methanol    or a salt thereof,-   [5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furyl]methyl    acetate or a salt thereof,-   1-[4-fluoro-1-{[5-(fluoromethyl)-2-furyl]sulfonyl}-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furamide    or a salt thereof,-   5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furonitrile    or a salt thereof,-   1-[1-{[5-(difluoromethyl)-2-furyl]sulfonyl}-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furyl]ethanol    or a salt thereof,-   1-[5-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)-2-furyl]ethanone    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(2-methylfuran-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-[(5-chloro-2-thienyl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-[(5-bromo-2-thienyl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-[(4-bromo-3-thienyl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   4-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)thiophene-3-carbonitrile    or a salt thereof,-   Methyl    3-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)thiophene-2-carboxylate    or a salt thereof,-   1-{5-(2-fluoropyridin-3-yl)-1-[(5-isoxazol-5-yl-2-thienyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(1-ethyl-1H-pyrazol-4-yl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{1-[(1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-{[1-(difluoromethyl)-1H-pyrazol-4-yl]sulfonyl}-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(1,3-thiazol-2-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(6-methoxypyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-2-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[1-[(2-chloropyridin-3-yl)sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   2-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)benzonitrile    or a salt thereof,-   4-({3-fluoro-2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl}sulfonyl)phenol    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(morpholin-4-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyrrolidin-1-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(1,3-thiazol-2-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-{1-(2-furylsulfonyl)-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-(3-furylsulfonyl)-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-[4-[(methylamino)methyl]-1-(2-thienylsulfonyl)-1H-pyrrol-2-yl]pyridine-2-carbonitrile    or a salt thereof,-   3-[4-[(methylamino)methyl]-1-(3-thienylsulfonyl)-1H-pyrrol-2-yl]pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(2,6-difluorophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(2,4-difluorophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{4-[(methylamino)methyl]-1-[(2-methylphenyl)sulfonyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(2-chlorophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(2-fluorophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(2-cyanophenyl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   3-{1-[(6-methoxypyridin-3-yl)sulfonyl]-4-[(methylamino)methyl]-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof,-   1-methyl-3-{4-[(methylamino)methyl]-1-(phenylsulfonyl)-1H-pyrrol-2-yl}pyridin-2(1H)-one    or a salt thereof,-   3-{4-[(dimethylamino)methyl]-1-(phenylsulfonyl)-1H-pyrrol-2-yl}-1-methylpyridin-2(1H)-one    or a salt thereof,-   3-[4-[(methylamino)methyl]-1-(phenylsulfonyl)-1H-pyrrol-2-yl]pyridin-2(1H)-one    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(6-fluoropyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(6-methoxypyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(6-methylpyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof.

In addition, the compounds shown in the following Tables 1-1 to 1-4 andsalts thereof are also preferable as a pharmaceutically activeingredient having a primary or secondary amino group in thepharmaceutical composition of the present invention.

TABLE 1-1

LC/MS HPLC m/e Ar R^(q) purity (%) (M⁺ + 1) 3-pyridyl methoxy 97 3583-thienyl methoxy 96 363 p-tolyl methoxy 96 371 4-cyanophenyl methoxy100 382 3,5-dimethylphenyl methoxy 96 385 4-methoxyphenyl methoxy 97 3874-chlorophenyl methoxy 91 391 4-acetylphenyl methoxy 98 3993-acetylphenyl methoxy 97 399 4-aminocarbonylphenyl methoxy 98 4004-(N,N-dimethylamino)phenyl methoxy 98 400 4-(methylthio)phenyl methoxy81 403 benzo[b]thiophen-2-yl methoxy 99 413 3-(acetylamino)phenylmethoxy 93 414 2,4-dimethoxyphenyl methoxy 97 4173-(trifluoromethyl)phenyl methoxy 94 425 4-(trifluoromethoxy)phenylmethoxy 87 441 2-isopropoxyphenyl methoxy 99 415 3-(6-methoxy)pyridylmethoxy 93 388 3-cyanophenyl methoxy 98 382 3-furyl methyl 98 331

TABLE 1-2

LC/MS HPLC m/e Ar R^(q) purity (%) (M⁺ + 1) 3-pyridyl methyl 100 3423-thienyl methyl 99 347 p-tolyl methyl 96 355 4-cyanophenyl methyl 98366 3,5-dimethylphenyl methyl 93 369 4-methoxyphenyl methyl 99 3714-chlorophenyl methyl 93 375 4-acetylphenyl methyl 98 383 3-acetylphenylmethyl 98 383 4-aminocarbonylphenyl methyl 98 3844-(N,N-dimethylamino)phenyl methyl 99 384 4-(methylthio)phenyl methyl 96387 benzo[b]thiophen-2-yl methyl 99 397 3-(acetylamino)phenyl methyl 89398 2,4-dimethoxyphenyl methyl 99 401 3-(trifluoromethyl)phenyl methyl81 409 4-(trifluoromethoxy)phenyl methyl 89 425 2-isopropoxyphenylmethyl 92 399 3-(hydroxymethyl)phenyl methyl 91 371 3-(6-methoxy)pyridylmethyl 99 372 3-cyanophenyl methyl 98 366

TABLE 1-3

LC/MS HPLC m/e R^(r) purity (%) (M⁺ + 1) 4-biphenyl 100 403 m-toluyl 100341 2,4-dichlorophenyl 100 395 2-methoxy-4-methylphenyl 100 3712-chlorophenyl 100 361 4-carboxyphenyl 99 371 3,5-dimethylphenyl 100 3553,5-dichlorophenyl 93 395 4-tert-butylphenyl 99 383 n-propyl 99 293ethyl 100 279 3,4-dimethoxyphenyl 95 387 3-chlorophenyl 100 3614-cyanophenyl 98 352 3-cyanophenyl 98 352 2-cyanophenyl 99 3522,1,3-benzothiadiazol-4-yl 96 385 3,4-dichlorophenyl 99 395 3-thienyl 96333 phenyl 100 327

TABLE 1-4

LC/MS HPLC m/e R^(r) purity (%) (M⁺ + 1) 1-naphthyl 97 377 p-styryl 99353 4-ethylphenyl 100 355 2,5-dichlorophenyl 99 395 isopropyl 100 2932-(1-naphthyl)ethyl 99 405 2-naphthyl 99 377 2,4,6-trimethylphenyl 100369 4-bromophenyl 99 405

Of these, preferred are the following compounds.

-   N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-[5-phenyl-1-(3-thienylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   N-methyl-1-(1-{[3-(methylsulfonyl)phenyl]sulfonyl}-5-phenyl-1H-pyrrol-3-yl)methanamine    or a salt thereof,-   1-[1-(1-benzothien-2-ylsulfonyl)-5-phenyl-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-{[3-(methylsulfonyl)phenyl]sulfonyl}-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{5-(2-fluorophenyl)-1-[(2-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   N-methyl-3-({4-[(methylamino)methyl]-2-phenyl-1H-pyrrol-1-yl}sulfonyl)benzamide    or a salt thereof,-   1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-[5-(2-chloropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   3-{4-[(methylamino)methyl]-1-(phenylsulfonyl)-1H-pyrrol-2-yl}pyridine-2-carbonitrile    or a salt thereof, or-   1-{1-[(4-fluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(3-furylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(2-methylfuran-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[1-{[1-(difluoromethyl)-1H-pyrazol-4-yl]sulfonyl]-4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-2-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof.

Most preferred as a pharmaceutically active ingredient having a primaryor secondary amino group in the pharmaceutical composition of thepresent invention are

-   1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof, and-   1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof, and more preferred are-   1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine    or a salt thereof,-   1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof,-   N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof,-   1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine    or a salt thereof, and-   N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine    or a salt thereof.

Examples of the salt of the above-mentioned “nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup” include metal salt, ammonium salt, salt with organic base, saltwith inorganic acid, salt with organic acid, salt with basic or acidicamino acid and the like.

Preferable examples of the metal salt include alkali metal salts such assodium salt, potassium salt and the like; alkaline earth metal saltssuch as calcium salt, magnesium salt, barium salt and the like; aluminumsalt and the like. Preferable examples of the salt with an organic baseinclude salts with trimethylamine, triethylamine, pyridine, picoline,2,6-lutidine, ethanolamine, diethanolamine, triethanolamine,cyclohexylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine and thelike. Preferable examples of the salt with an inorganic acid includesalts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuricacid, phosphoric acid and the like. Preferable examples of the salt withan organic acid include salts with adipic acid, ascorbic acid, benzoicacid, oleic acid, succinic acid, acetic acid, tartaric acid, sorbicacid, fumaric acid, lactic acid, maleic acid, malonic acid, citricanhydride, maleic anhydride, phthalic acid, phthalic anhydride, malicacid, formic acid, trifluoroacetic acid, oxalic acid, methanesulfonicacid, benzenesulfonic acid, p-toluenesulfonic acid and the like.Preferable examples of the salt with a basic amino acid include saltswith arginine, lysine, ornithine and the like, and preferable examplesof the salt with an acidic amino acid include salts with aspartic acid,glutamic acid and the like.

Of these, a salt with an organic acid is preferable for thepharmaceutical composition of the present invention. Examples of thesalt with an organic acid for such nonpeptidic pharmaceutically activeingredient having a primary or secondary amino group include salts withadipic acid, ascorbic acid, benzoic acid, oleic acid, succinic acid,acetic acid, tartaric acid, sorbic acid, fumaric acid, lactic acid,maleic acid, malonic acid, citric anhydride, maleic anhydride, phthalicanhydride, malic acid and the like. In addition, of the organic acidsalts, a salt with an unsaturated carboxylic acid is particularlypreferably used. Examples of the salt with such unsaturated carboxylicacid include salts with fumaric acid, sorbic acid, maleic acid, oleicacid, succinic acid, tartaric acid and the like. Of these, the saltswith fumaric acid, succinic acid and tartaric acid are preferable.

In the whole pharmaceutical composition of the present invention (apharmaceutical composition containing at least a nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup, an excipient and an acidic compound), the content (%) of the“pharmaceutically active ingredient having a primary or secondary aminogroup or a salt thereof” is preferably 0.1-80%, further preferably0.1-60%, particularly preferably 0.1-50% (in the present specification,“%” means weight percent unless otherwise specified).

[2. Excipient (Second Component)]

As the “excipient”, which is the second component of the pharmaceuticalcomposition of the present invention, preferred is an excipient havingpH 4.5 or above when dissolved or dispersed in water.

Examples of such excipient include mannitol, croscarmellose sodium,hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethyleneglycol, polyvinylpyrrolidone, crystalline cellulose, lactose, sucrose,starch, cornstarch, titanium oxide (TiO₂), light anhydrous silicic acidand the like. These excipients may be used alone or two or more kindsthereof may be used in combination. Of these, as the excipient,mannitol, hydroxypropylcellulose and crystalline cellulose arepreferable.

The content (%) of the excipient in the whole pharmaceutical compositionof the present invention is preferably 20-99.8%, further preferably40-99.8%, particularly preferably 50-99.8%.

In the pharmaceutical composition of the present invention, the mixingratio of the “excipient” to the “nonpeptidic pharmaceutically activeingredient having a primary or secondary amino group or a salt thereof”(to be abbreviated as “pharmaceutically active ingredient”) ispreferably pharmaceutically active ingredient:excipient=1:0.25-1:998,further preferably 1:0.67-1:998, particularly preferably 1:1-1:998. Theabove-mentioned mixing ratio is a weight ratio.

[3. Acidic Compound (Third Component)]

Here, the term acidic compound has a general meaning. Specifically, forexample, the term can be defined based on the value of pKa (logarithm ofreciprocal of acid dissociation constant) of the compound. The “acidiccompound” means a compound having a partial structure having pKa of notmore than 6.5 (preferably not more than 5.5). The acidic compound to beused in the present invention may be either a solid or a liquid atambient temperature (15-25° C.). The above-mentioned “partial structurehaving pKa” refers to a partial structure that releases H⁺.

The above-mentioned “nonpeptidic pharmaceutically active ingredienthaving a primary or secondary amino group (first component)” has a“primary or secondary amino group having high nucleophilicity”. Thus,when a trace amount of a basic component is contained in the excipient,the basic component acts as a basic catalyst and highly possibly causesproblems of Michael addition of, for example, fumaric acid and the liketo an α or β-unsaturated carbonyl compound (nucleophilic additionreaction of a carbon at the end of a conjugated system in conjugationwith an electron-withdrawing substituent) and the like.

Examples of the above-mentioned basic compound which is contained in theexcipient and having a possibility of acting as a basic catalyst includea basic salt, oxide and hydroxide, such as metal carbonates such asalkali metal hydrogen carbonates (e.g., sodium hydrogen carbonate etc.),alkali metal carbonates (e.g., sodium carbonate, potassium carbonateetc.), alkaline earth metal carbonates (e.g., calcium carbonate,magnesium carbonate etc.) and the like; di-salt hydrogen phosphate suchas di-alkali metal salt hydrogen phosphates (e.g., disodium hydrogenphosphate, dipotassium hydrogen phosphate, etc.) and the like; silicatessuch as calcium silicate, magnesium silicate and the like; metal oxidessuch as magnesium oxide and the like; metal hydroxides such as sodiumhydroxide, calcium hydroxide, magnesium hydroxide, aluminum hydroxideand the like; citrates such as sodium citrate and the like; tartratessuch as sodium dl- and l-tartrates and the like; pantothenates such ascalcium pantothenate etc, and the like.

Therefore, a stabilizer is added to the pharmaceutical composition ofthe present invention. The stabilizer stabilizes the pharmaceuticalcomposition by preventing a reaction of an amino group in thenonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group with an α□ or β-unsaturated carbonyl compound. Asthe stabilizer, any substance can be used as long as it is an acidiccompound which can protonate, by releasing H⁺, the amino group of thenonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group, preferably an organic acid or a salt thereof(particularly organic acid).

Specifically, the pharmaceutical composition of the present inventioncharacteristically contains an acidic compound (third component) as thestabilizer in addition to a pharmaceutical composition containing anonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group (first component) and an excipient (secondcomponent).

As the “acidic compound” to be used in the present invention, aninorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid,sulfuric acid, phosphoric acid and the like, or an organic acid similarto the organic acid exemplified in the explanation of theabove-mentioned “salt with an organic acid of a nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup” can be used. Particularly preferable examples thereof includeedible organic acids such as adipic acid, ascorbic acid, benzoic acid,oleic acid, succinic acid, acetic acid, tartaric acid, sorbic acid,fumaric acid, lactic acid, maleic acid, malonic acid, citric anhydride,maleic anhydride, phthalic anhydride, malic acid and the like. Inaddition, an organic acid such as formic acid, trifluoroacetic acid,phthalic acid, oxalic acid, methanesulfonic acid, benzenesulfonic acid,p-toluenesulfonic acid and the like can also be used for the object ofstabilization of the pharmaceutical composition.

The organic acid may be a salt. Examples of the salt with an organicacid include sodium ascorbate, sodium fumarate, and those similar to thesalts exemplified in the above-mentioned “salt with an organic acid of anonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group”. Of these, those similar to the salts exemplifiedin the above-mentioned “salt with an organic acid of a nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup” are preferable. In addition, the salt with an organic acidsimilar to the above-mentioned respective organic acids are preferable.

These organic acids and salts thereof may be used alone or two or morekinds thereof may be used simultaneously. In addition, the organic acidto be used for the above-mentioned “salt with an organic acid of anonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group” and an organic acid to be used as a stabilizermay be the same or different.

As the organic acid to be used for the above-mentioned “salt with anorganic acid of a nonpeptidic pharmaceutically active ingredient havinga primary or secondary amino group”, preferred are fumaric acid, malonicacid, citric anhydride, maleic anhydride, succinic acid and tartaricacid, more preferred are fumaric acid, citric anhydride, succinic acid,tartaric acid, and still more preferred are fumaric acid, succinic acidand tartaric acid.

The pH of an excipient or acidic compound is measured under thefollowing conditions. To be specific, the pH of an aqueous solution ordispersion obtained by dissolving or dispersing an excipient in water at1% w/v is measured at 25° C. with a commercially available pH meter.

In the pharmaceutical composition of the present invention, the pKavalue of the “nonpeptidic pharmaceutically active ingredient having aprimary or secondary amino group” is preferably higher for stabilizationof the pharmaceutical composition than that of the “organic acid or asalt thereof” to be added.

Particularly, the difference between the pKa value of the “nonpeptidicpharmaceutically active ingredient having a primary or secondary aminogroup” and that of the “organic acid” is preferably not less than 4,further preferably not less than 5, particularly preferably not lessthan 6.

For example, when the pharmaceutically active ingredient is representedby the formula (A2), an “organic acid” is preferably used as an acidiccompound. Examples of the “organic acid” include edible organic acidssuch as adipic acid, ascorbic acid, benzoic acid, oleic acid, succinicacid, acetic acid, tartaric acid, sorbic acid, fumaric acid, lacticacid, maleic acid, malonic acid, citric acid, malic acid and the like.In addition, organic acids such as formic acid, trifluoroacetic acid,phthalic acid, oxalic acid, methanesulfonic acid, benzenesulfonic acid,p-toluenesulfonic acid and the like can also be used for stabilizing thepharmaceutical composition. Of these, fumaric acid is particularlypreferable.

The content (%) of the acidic compound in the whole pharmaceuticalcomposition of the present invention is preferably 0.1-20% (morepreferably 0.1-19%), further preferably 1-10%, particularly preferably2-10%. In another embodiment, it is 0.01-50%, preferably 0.05-19%, morepreferably 0.1-10%.

In the pharmaceutical composition of the present invention, the mixingratio of the “acidic compound” to the “nonpeptidic pharmaceuticallyactive ingredient having a primary or secondary amino group” (to beabbreviated as a “pharmaceutically active ingredient”) is preferablypharmaceutically active ingredient:acidic compound=1:0.00125-1:200,further preferably 1:0.0167-1:200, particularly preferably 1:0.04-1:100.

In the pharmaceutical composition of the present invention, the mixingratio of the “acidic compound” to the “excipient” is preferablyexcipient:acidic compound=1:0.0001-1:1, further preferably 1:0.01-1:0.5,particularly preferably 1:0.02-1:0.2.

When producing the pharmaceutical composition of the present invention,the “acidic compound” may be added as a powder in a granulation step ora mixing step. In addition, an acidic compound can be sprayed bydissolving or dispersing in a binder solution in the granulation step orin a film coating solution in a film coating step.

The above-mentioned “binder solution” is prepared by dissolving a binderin an aqueous solution. Examples of the “binder” includehydroxypropylcellulose, hydroxypropylmethylcellulose, crystallinecellulose, starch, polyvinylpyrrolidone, gum arabic powder, gelatin,pullulan, low-substituted hydroxypropylcellulose and the like.

The above-mentioned “film coating solution” is prepared, for example, bydissolving or suspending a film coating polymer in a solvent. The filmcoating solution may further contain a colorant (preferably, diirontrioxide and yellow ferric oxide), a light shielding agent (preferably,titanium oxide) and the like. Examples of the “film coating polymer”include hydroxypropylmethylcellulose, ethylcellulose,hydroxymethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose acetate succinate, acrylic resin(methacrylic acid-acrylic acid copolymer, aminoalkylmethacrylatecopolymer etc.), shellac, polyvinyl acetate phthalate, gum arabic,cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate,carboxymethylethyl cellulose and the like. Examples of the “solvent”include water, alcohols (e.g., ethanol, isopropyl alcohol, n-propylalcohol, methanol, etc.), acetone, ethyl acetate, dichloromethane,chloroform, hexane, toluene, heptane and the like. The amount of the“film coating polymer” to be used can be determined according to thekind of the solid preparation. For example, when the solid preparationis a tablet, the amount is about 0.5-10 wt % of the tablet. The spraytemperature is generally 25-80° C., the spray time is generally 5 min-24hr, and the drying conditions are generally at 30-80° C. for about 1min-24 hr. The film coating layer of the present invention can begenerally formed at ratio of 1-10 parts by weight, preferably 2-6 partsby weight, per 100 parts by weight of the solid preparation (preferablytablet, more preferably ellipse or round tablet) of the presentinvention.

To use the pharmaceutical composition of the present invention as a morestable pharmaceutical composition, the content of the decomposed productof the pharmaceutically active ingredient in the whole pharmaceuticalcomposition does not desirably exceed, according to the ICH guideline, alower of 1.0% and a total daily ingestion amount of 5 μg when thepharmaceutically active ingredient to be administered per day is <1 mg,a lower of 0.5% and a total daily ingestion amount of 20 μg when thepharmaceutically active ingredient to be administered per day is 1 mg-10mg, a lower of 0.2% and a total daily ingestion amount of 2 mg when thepharmaceutically active ingredient to be administered per day is >10mg-2 g, 0.10% when the pharmaceutically active ingredient to beadministered per day is >2 g, a lower of 1.0% and a total dailyingestion amount of 50 μg when the pharmaceutically active ingredient tobe administered per day is <10 mg, a lower of 0.5% and a total dailyingestion amount of 200 μg when the pharmaceutically active ingredientto be administered per day is 10 mg-100 mg, a lower of 0.2% and a totaldaily ingestion amount of 3 mg when the pharmaceutically activeingredient to be administered per day is >100 mg-2 g, and 0.15% when thepharmaceutically active ingredient to be administered per day is >2 g.

The preservation environment of a pharmaceutical product after beingplaced in the market by a manufacturer is difficult to control. Tomaintain the quality of a pharmaceutical product, therefore, the contentof the decomposed product is preferably as small as possible under anytemperature and humidity conditions (60° C., 40° C., 75% RH, 30° C., 65%RH etc.) and in any packaging form (open bottle, closed bottle etc.).

The pharmaceutical composition of the present invention shows a smallcontent of a decomposed product under any conditions (60° C., 40° C.,75% RH, 30° C., 65% RH etc.) whether in an open bottle or a closedbottle.

Therefore, the pharmaceutical composition of the present invention canretain preservation stability and can maintain high quality under anyconditions.

The pharmaceutical composition of the present invention has lowtoxicity, and can be safely administered orally or parenterally (e.g.,topical, rectal, intravenous administration etc.) as it is or in theform of a pharmaceutical composition containing a pharmacologicallyacceptable carrier according to a method known per se, for example,preparations such as tablet (core tablet, sugar-coated tablet,film-coated tablet etc.), powder, granule, capsule (including softcapsule), orally disintegrating tablet, liquid, injection, suppository,sustained-release preparation, plaster and the like. The pharmaceuticalcomposition of the present invention is preferably administered as anoral preparation such as tablet, granule, capsule and the like. Ofthese, a solid preparation such as tablet, capsule and the like ispreferable, a sugar-coated tablet, a film-coated tablet and the like areespecially preferable, and a film-coated tablet is particularlypreferable.

Examples of the pharmacologically acceptable carrier that can be usedfor the production of the pharmaceutical composition of the presentinvention include various organic or inorganic carrier substancesconventionally used as preparation materials. For example, filler,lubricant, binder, disintegrant, water-soluble polymer and basicinorganic salt for solid preparations; solvent, solubilizing agent,suspending agent, isotonicity agent, buffering agent and soothing agentfor liquid preparation and the like can be mentioned. Where necessary,general additives such as preservative, antioxidant, colorant,sweetening agent, foaming agent, flavor and the like can also be used.

Examples of the “lubricant” include magnesium stearate, sucrose fattyacid ester, polyethylene glycol, talc, stearic acid and the like.

Examples of the “binder” include hydroxypropylcellulose,hydroxypropylmethylcellulose, crystalline cellulose, starch,polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan,low-substituted hydroxypropylcellulose and the like.

Examples of the “disintegrant” include (1) crospovidone, (2)disintegrants referred to as super disintegrants such as croscarmellosesodium (FMC-Asahi Kasei), carmellose calcium (Gotoku Yakuhin) and thelike, (3) sodium carboxymethyl starch (e.g., manufactured by MatsutaniChemical Industry Co., Ltd.), (4) low-substituted hydroxypropylcellulose(e.g., manufactured by Shin-Etsu Chemical Co., Ltd.), (5) cornstarch andthe like. The “crospovidone” may be any crosslinked polymer having achemical name of 1-ethenyl-2-pyrrolidinone homopolymer includingpolyvinylpolypyrrolidone (PVPP) and 1-vinyl-2-pyrrolidinone homopolymer.Specific examples thereof include Kollidon CL (manufactured by BASF),Polyplasdone XL (manufactured by ISP), Polyplasdone XL-10 (manufacturedby ISP), Polyplasdone INF-10 (manufactured by ISP) and the like.

Examples of the “water-soluble polymer” include ethanol-solublewater-soluble polymer [e.g., cellulose derivatives such ashydroxypropylcellulose (hereinafter to be sometimes indicated as HPC)and the like, polyvinylpyrrolidone and the like], ethanol-insolublewater-soluble polymer [e.g., cellulose derivative such ashydroxypropylmethylcellulose (hereinafter to be sometimes indicated asHPMC), methylcellulose, carboxymethylcellulose sodium and the like,sodium polyacrylate, polyvinyl alcohol, sodium alginate, guar gum andthe like] and the like.

Examples of the “basic inorganic salt” include basic inorganic salts ofsodium, potassium, magnesium and/or calcium. Preferred are basicinorganic salts of magnesium and/or calcium. More preferred is a basicinorganic salt of magnesium. Examples of the basic inorganic salt ofsodium include sodium carbonate, sodium hydrogen carbonate, disodiumhydrogen phosphate and the like. Examples of the basic inorganic salt ofpotassium include potassium carbonate, potassium hydrogen carbonate andthe like. Examples of the basic inorganic salt of magnesium includeheavy magnesium carbonate, magnesium carbonate, magnesium oxide,magnesium hydroxide, magnesium aluminometasilicate, magnesium silicate,magnesium aluminate, synthetic hydrotalcite [Mg₆Al₂(OH)₁₆CO₃.4H₂O] andalumina magnesium hydroxide, preferably, heavy magnesium carbonate,magnesium carbonate, magnesium oxide, magnesium hydroxide and the like.Examples of the basic inorganic salt of calcium include precipitatedcalcium carbonate, calcium hydroxide and the like.

Examples of the “solvent” include water for injection, alcohol,propylene glycol, macrogol, sesame oil, corn oil, olive oil and thelike.

Examples of the “solubilizing agent” include polyethylene glycol,propylene glycol, benzyl benzoate, ethanol, trisaminomethane,cholesterol, triethanolamine, sodium carbonate, sodium citrate and thelike.

Examples of the “suspending agent” include surfactants such asstearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionicacid, lecithin, benzalkonium chloride, benzethonium chloride, glycerolmonostearate and the like; hydrophilic polymers such as polyvinylalcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose,methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose and the like, and the like.

Examples of the “isotonicity agent” include glucose, D-sorbitol, sodiumchloride, glycerol, D-mannitol and the like.

Examples of the “buffering agent” include buffers such as phosphate,acetate, carbonate, citrate and the like, and the like.

Examples of the “soothing agent” include benzyl alcohol and the like.

Examples of the “preservative” include paraoxybenzoates, chlorobutanol,benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid andthe like.

Examples of the “antioxidant” include sulfite, ascorbic acid,α-tocopherol and the like.

Examples of the “colorant” include food colors such as Food Color YellowNo. 5, Food Color Red No. 2, Food Color Blue No. 2 and the like; foodlake colors, ferric oxide red, yellow ferric oxide and the like.

Examples of the “sweetening agent” include saccharin sodium, dipotassiumglycyrrhizinate, aspartame, stevia, thaumatin and the like.

Examples of the “foaming agent” include sodium bicarbonate and the like.

As the “flavor”, any of synthetic substance and naturally-occurringsubstance may be used. Examples thereof include flavors such as lemon,lime, orange, menthol, strawberry and the like.

The pharmaceutical composition of the present invention does not have tocontain a souring agent.

The pharmaceutical composition of the present invention can beformulated into a preparation for oral administration (film-coatedtablet) by, for example, adding a pharmacologically acceptable carriersuch as binder, disintegrant, lubricant and the like as necessary to agranulated powder containing the above-mentioned first to thirdcomponents, tableting the obtained mixture by a method known per se(preparation of core tablet (core)) and, where necessary, coating thetablet by a method known per se for masking of taste, enteric coating orsustained release. When the pharmaceutical composition of the presentinvention is, for example, formulated into an orally disintegratingtablet, the above-mentioned composition containing the first to thirdcomponents can be produced by a method known per se. Moreover, suchtablet can be produced by a method including coating a core containingcrystalline cellulose and lactose with the pharmaceutical composition ofthe present invention, forming an enteric coating layer by a methodknown per se to give fine granules, mixing the obtained fine granulesand an additive and molding the mixture.

A film-coated tablet is more preferable.

In addition, a core material containing an acidic compound and a layercontaining a pharmaceutically active ingredient do not need to beseparated by a separating layer.

Examples of the above-mentioned “enteric coating layer” include a layercomprised of a mixture of one or more kinds from aqueous enteric polymerbase such as cellulose acetate phthalate (CAP),hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetatesuccinate, methacrylic acid copolymer [for example, Eudragit L30D-55(trade name; manufactured by Roehm), Kollicoat MAE30DP (trade name;manufactured by BASF), Polyquid PA30 (trade name; manufactured by

Sanyo chemical industries, Ltd.) etc.], carboxymethylethylcellulose,shellac and the like; sustained-release base such as methacrylic acidcopolymer [for example, Eudragit NE30D (trade name), Eudragit RL30D(trade name), Eudragit RS30D (trade name) etc.] and the like;water-soluble polymer; plasticizer such as triethyl citrate,polyethylene glycol, acetylated monoglyceride, triacetine, castor oiletc. and the like.

Examples of the above-mentioned “additive” include water-soluble sugaralcohol (e.g., sorbitol, mannitol and maltitol, reduced starchsaccharides, xylitol, reduced paratinose, erythritol etc.), crystallinecellulose (e.g., Ceolus KG 801, Avicel PH 101, Avicel PH 102, Avicel PH301, Avicel PH 302, Avicel RC-591 (crystalline cellulose, carmellosesodium) etc.), low-substituted hydroxypropylcellulose (e.g., LH-22,LH-32, LH-23, LH-33 (Shin-Etsu Chemical Co., Ltd.) and a mixture thereofetc.) and the like. Furthermore, binder, foaming agent, sweeteningagent, flavor, lubricant, colorant, stabilizer, excipient, disintegrantand the like can also be used.

The pharmaceutical composition of the present invention is superior inthe preservation stability. Particularly, when the pharmaceuticalcomposition of the present invention contains a compound represented bythe above-mentioned formula (A2) or (A3) as a pharmaceutically activeingredient, such pharmaceutical composition is useful for the treatmentor prophylaxis of peptic ulcer (e.g., gastric ulcer, ulcer due topostoperative stress, duodenal ulcer, anastomotic ulcer, ulcer caused bynon-steroidal anti-inflammatory agent etc.); Zollinger-Ellison syndrome;gastritis; erosive esophagitis; reflux esophagitis such as erosivereflux esophagitis and the like; symptomatic gastroesophageal refluxdisease (Symptomatic GERD) such as nonerosive esophageal reflux,esophageal reflux unaccompanied by esophagitis and the like; functionaldyspepsia; Barrett esophagus; gastric cancer (including gastric cancerassociated with promoted production of interleukin-1β due to genepolymorphism of interleukin-1); stomach MALT lymphoma; hyperacidity;upper gastrointestinal hemorrhage caused by peptic ulcer, acute stressulcer, hemorrhagic gastritis, invasive stress (e.g., stress caused bymajor surgery requiring post-operative intensive management, orcerebrovascular disorder, head trauma, multiple organ failure orextensive burn requiring intensive treatment) and the like; airwaydisorders; asthma; and the like in mammals (e.g., human, monkey, sheep,bovine, horse, dog, cat, rabbit, rat, mouse etc.), pre-anestheticadministration, eradication or assistant to eradication of Helicobacterpylori and the like.

While the dose of the pharmaceutical composition of the presentinvention varies depending on the subject of administration,administration route, disease and the like, for oral administration toan adult (60 kg) as, for example, an antiulcerogenic drug, it ispreferably administered in an amount of about 0.5-about 1500 mg/day,preferably about 5-about 150 mg/day, as a pharmaceutically activeingredient. The pharmaceutical composition of the present invention maybe administered once a day or in 2-3 portions a day.

The pharmaceutical composition of the present invention may be used incombination with other active ingredient as long as the activity of thenonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group is not impaired.

Examples of the “other active ingredient” include anti-AM Helicobacterpylori active substance, imidazole compound, bismuth salt, quinolonecompound and the like.

Examples of the “anti-Helicobacter pylori active substance” includepenicillin antibiotic (e.g., amoxicillin, benzyl penicillin,piperacillin, mecillinam, ampicillin, temocillin, bacampicillin,aspoxicillin, sultamicillin, lenampicillin, etc.), cephem antibiotic(e.g., cefixime, cefaclor, etc.), macrolide antibiotic (e.g.,erythromycin, clarithromycin, roxithromycin, rokitamycin,flurithromycin, telithromycin, etc.), tetracycline antibiotic (e.g.,tetracycline, minocycline, streptomycin etc.), aminoglycoside antibiotic(e.g., gentamicin, amikacin etc.), imipenem and the like. Of these,penicillin antibiotic, macrolide antibiotic and the like are preferable.

Examples of the “imidazole compound” include metronidazole, miconazoleand the like.

Examples of the “bismuth salt” include bismuth acetate, bismuth citrate,bithmuth subsalicylate and the like.

Examples of the “quinolone compound” include ofloxacin, ciploxacin andthe like.

Particularly, for Helicobacter pylori eradication, in the pharmaceuticalcomposition of the present invention wherein the pharmaceutically activeingredient is a compound represented by the above-mentioned (A2), (A3)or (A4), a penicillin antibiotic (e.g., amoxicillin etc.) and anerythromycin antibiotic (e.g., clarithromycin etc.) are preferably used.For Helicobacter pylori eradication, while the pharmaceuticalcomposition of the present invention has an anti-H. pylori action(bacteriostatic or eradication action) by itself, it can enhance anantibacterial action of other antibiotics by regulating its pH in thestomach and the like, thus acting as an aid for the eradication effectbased on the action of the antibiotic to be used in combination.

In addition, the pharmaceutical composition of the present invention maybe used in combination with a gastric motility enhancer, a drug actingon the lower esophageal sphincter (e.g., transient lower esophagealsphincter relaxation inhibitor, etc.), C1C-2 channel opener (intestinaljuice secretion accelerating agent), histamine H2 receptor antagonist,antacid, sedative, stomachic or non-steroidal anti-inflammatory drug(NSAID).

Examples of the “gastric motility enhancer” include domperidone,metoclopramide, mosapride, itopride, tegaserod and the like.

Examples of the “drug acting on the lower esophageal sphincter” includeGABA-B receptor agonists such as baclofen, an optically active formthereof and the like, and the like.

Examples of the “C1C-2 channel opener (intestinal juice secretionaccelerating agent)” include lubiprostone and the like.

Examples of the “histamine H2 receptor antagonist” include cimetidine,ranitidine, famotidine, roxatidine, nizatidine, lafutidine and the like.

Examples of the “antacid” include sodium hydrogen carbonate, aluminumhydroxide and the like.

Examples of the “sedative” include diazepam, chlordiazepoxide and thelike.

Examples of the “stomachic” include Gentiana lutea, swertia japonica,diastase and the like.

Examples of the “non-steroidal anti-inflammatory drug” include aspirin,indomethacin, ibuprofen, mefenamic acid, diclofenac, etodolac,piroxicam, celecoxib and the like.

The pharmaceutical composition of the present invention may also be usedin combination with the following medicaments.

(i) proton pump inhibitor, e.g., omeprazole, esomeprazole, pantoprazole,rabeprazole, tenatoprazole, ilaprazole and lansoprazole;

(ii) oral antacid-combination agent, e.g., Maalox (registered trademark), Aludrox (registered trade mark) and Gaviscon (registered trademark);

(iii) mucous membrane protector, e.g., polaprezinc, ecabet sodium,rebamipide, teprenone, cetraxate, sucralfate, chlorophylline-copper andplaunotol;

(iv) anti-gastrin agent, e.g., anti-gastrin vaccine, itriglumide andZ-360;

(v) 5-HT₃ antagonist, e.g., dolasetron, palonosetron, alosetron,azasetron, ramosetron, mitrazapine, granisetron, tropisetron, E-3620,ondansetron and indisetron;

(vi) 5-HT₄ agonist, e.g., tegaserod, mosapride, cinitapride andoxitriptane;

(vii) laxative, e.g., Trifyba (registered trade mark), Fybogel(registered trade mark), Konsyl (registered trade mark), Isogel(registered trade mark), Regulan (registered trade mark), Celevac(registered trade mark) and Normacol (registered trade mark);

(viii) GABA_(B) agonist, e.g., baclofen and AZD-3355;

(ix) GABA_(B) antagonist, e.g., GAS-360 and SGS-742;

(x) calcium channel blocker, e.g., aranidipine, lacidipine, falodipine,azelnidipine, clinidipine, lomerizine, diltiazem, gallopamil,efonidipine, nisoldipine, amlodipine, lercanidipine, bevantolol,nicardipine, isradipine, benidipine, verapamil, nitrendipine,barnidipine, propafenone, manidipine, bepridil, nifedipine, nilvadipine,nimodipine and fasudil;

(xi) dopamine antagonist, e.g., metoclopramide, domperidone andlevosulpiride;

(xii) tachykinin (NK) antagonist, particularly, NK-3, NK-2 and NK-1antagonist, e.g., nepadutant, saredutant, talnetant,(αR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione(TAK-637),5-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one(MK-869), lanepitant, dapitant and3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenyl-piperidine(2S,3S);

(xiii) nitric oxide synthase inhibitor, e.g., GW-274150, tilarginine,P54, guanidioethyldisulfide and nitroflurbiprofen;

(xiv) vanilloid receptor 1 antagonist, e.g., AMG-517 and GW-705498;

(xv) ghrelin agonist, e.g., capromorelin and TZP-101;

(xvi) AchE release stimulant, e.g., Z-338 and KW-5092;

(xvii) therapeutic agent for insomnia (etizolam, zopiclone, triazolam,zolpidem, ramelteon, indiplon etc.),

(xviii) potassium ion competitive acid secretion blocker (P-CAB),

(xix) melatonin agonist,

(xx) melatonin, and the like.

The above-mentioned medicaments (i)-(xx) may be used in combination byadding to the pharmaceutical composition of the present invention.Alternatively, the above-mentioned medicaments (i)-(xx) and thepharmaceutical composition of the present invention may be separatelyproduced and simultaneously administered or administered in a staggeredmanner to the same subject.

Next, the second invention of the present invention is explained indetail by referring to a specific embodiment.

The solid preparation of the second invention of the present inventioncontains a pharmaceutically active ingredient, titanium oxide, aplasticizer and a chain organic acid, and is characteristically a solidpreparation improved in the stability during light irradiation.

When a pharmaceutically active ingredient unstable to light irradiationis formulated into a preparation, titanium oxide (TiO₂) is generallyused together with a film coating agent (also referred to as a coatingagent) for shielding to ensure light-stability of the preparation.However, TiO₂ shows a shielding function due to its high refractiveindex, but also shows a strong oxidation action caused by holegeneration during light irradiation. The cause is presumed to be that 1)titanium oxide in a coating agent develops a free radical due to UVlight, 2) the drug and alcohols in the coating agent such aspolyethylene glycol and the like are decomposed due to free radical, 3)a decomposed product of alcohols (e.g., polyethylene glycol and thelike), for example, aldehydes such as formaldehyde, acetoaldehyde andthe like, an acid such as formic acid and the like, and peroxide in thecoating agent further cause decomposition of the drug. To improve thelight-stability of the preparation, therefore, it is necessary tosuppress the decomposed product due to its strong oxidation action whileutilizing the light shielding effect of TiO₂. Conventionally, as a meansto suppress an increase in the decomposed product, a method includingforming an intermediate layer between a film coating and a core tabletand a method including removing PEG (plasticizer) from a film coatingcomponent have generally been employed. However, these methods maydecrease the productivity during film coating, which may influence thefinal appearance of a film-coated tablet.

The present inventors have found an effect of suppressing a decomposedproduct during light irradiation by adding a chain organic acid to thesolid preparation (either core or film), without decreasing theproductivity during film coating. The solid preparation of the presentinvention improved in the light stability is explained in the following.

[Pharmaceutically Active Ingredient (Component I)]

The form of the pharmaceutically active ingredient to be used in thepresent invention may be any of solid, powder, crystal, oil, solutionand the like, and its efficacy is not particularly limited. For example,one or more kinds of components selected from nutritional supplement,antipyretic analgesic antiphlogistic drug, psychotropic drug,antianxiety drug, antidepressant, hypnosedative, anticonvulsant drug,central nervous system neural active agent, brain metabolism improvingagent, brain circulation improving agent, antiepilepsy agent,sympathetic nerve stimulant, digestive medicine, antacid, anti-ulceragent, antitussive expectorant, antiemetic, respiratory stimulant,bronchodilator, antiallergic agent, dental and oral drug, antihistamineagent, cardiotonic agent, antiarrhythmic agent, diuretic,antihypertensive agent, vasoconstrictor, coronary vasodilator,peripheral vasodilator, lipid-lowering agent, cholagogue, antibiotic,chemotherapeutic agent, diabetes agent, osteoporosis agent,anti-rheumatic drug, skeleton muscle relaxants, hormone agent, narcoticalkaloid, sulfa drug, gout a therapeutic drug for, anticoagulant,anti-malignant tumor agent, therapeutic drug for Alzheimer's disease,potassium ion competitive acid secretion inhibitor and the like can beused.

Examples of the nutritional supplement include vitamins such as vitaminA, vitamin D, vitamin E (d-α-tocopherol acetate and the like), vitaminB1 (dibenzoylthiamine, fursultiamine hydrochloride and the like),vitamin B2 (riboflavin butyrate and the like), vitamin B6 (pyridoxinehydrochloride and the like), vitamin C (ascorbic acid, sodiumL-ascorbate and the like), vitamin B12 (hydroxocobalamin acetate,cyanocobalamin and the like), mineral such as calcium, magnesium, ironand the like, protein, amino acid, oligosaccharide, crude drug and thelike.

Examples of the antipyretic analgesic antiphlogistic drug includeaspirin, acetaminophen, ethenzamide, ibuprofen, diphenhydraminehydrochloride, dl-chlorpheniramine maleate, dihydrocodeine phosphate,noscapine, methylephedrine hydrochloride, phenylpropanolaminehydrochloride, caffeine, anhydrous caffeine, serrapeptase, lysozymechloride, tolfenamic acid, mefenamic acid, diclofenac sodium, flufenamicacid, salicylamide, aminopyrine, ketoprofen, indomethacin, bucolome,pentazocine and the like.

Examples of the psychotropic drug include chlorpromazine, reserpine andthe like.

Examples of the antianxiety drug include alprazolam, chlordiazepoxide,diazepam and the like.

Examples of the antidepressant include imipramine, maprotilinehydrochloride, amphetamine and the like.

Examples of the hypnosedatives include estazolam, nitrazepam, diazepam,perlapine, phenobarbital sodium and the like.

Examples of the anticonvulsant include scopolamine hydrobromide,diphenhydramine hydrochloride, papaverine hydrochloride, meclizinehydrochloride, dimenhydrinate and the like.

Examples of the central nervous system neural active agent includeciticoline and the like.

Examples of the brain metabolism improving agent include meclofenoxatehydrochloride and the like.

Examples of the brain circulation improving agent include vinpocetineand the like.

Examples of the antiepilepsy agent include phenyloin, carbamazepine andthe like.

Examples of the sympathetic nerve stimulant include isoproterenolhydrochloride and the like.

Examples of the digestive medicine include stomachics and digestivessuch as diastase, saccharated pepsin, scopolia extract, cellulose AP3,lipase AP, cassia oil and the like, antiflatulent such as berberinechloride, resistant lactobacilli, bifidobacteria and the like, and thelike.

Examples of the antacid include magnesium carbonate, sodium hydrogencarbonate, magnesium alumino metasilicate, synthetic hydrotalcite,precipitated calcium carbonate, magnesium oxide and the like.

Examples of the anti-ulcer agent include lansoprazole, omeprazole,rabeprazole, pantoprazole, ilaprazole, tenatoprazole, famotidine,cimetidine, ranitidine hydrochloride and the like.

Examples of the antitussive expectorant include cloperastinehydrochloride, dextromethorphan hydrobromide, theophylline, potassiumguaiacolsulfonate, guaifenesin, codeine phosphate and the like.

Examples of the antiemetic include difenidol hydrochloride,metoclopramide and the like.

Examples of the respiratory stimulant include levallorphan tartrate andthe like.

Examples of the bronchodilator include theophylline, salbutamol sulfateand the like.

Examples of the antiallergic agent include amlexanox, seratrodust andthe like.

Examples of the dental and oral drug include oxytetracycline,triamcinolone acetonide, chlorhexidine hydrochloride, lidocain and thelike.

Examples of the antihistamine agent include diphenhydraminehydrochloride, promethazine, isothipendyl hydrochloride,dl-chlorpheniramine maleate and the like.

Examples of the cardiotonic agent include caffeine, digoxin and thelike.

Examples of the antiarrhythmic agent include procaineamidehydrochloride, propranolol hydrochloride, pindolol and the like.

Examples of the diuretic include thiazide such as isosorbide,furosemide, HCTZ and the like, and the like.

Examples of the antihypertensive agent include delapril hydrochloride,captopril, hexamethonium bromide, hydralazine hydrochloride, labetalolhydrochloride, manidipine hydrochloride, candesartancilexetil,methyldopa, losartan, valsartan, eprosartan, irbesartan, tasosartan,telmisartan and the like.

Examples of the vasoconstrictor include phenylephrine hydrochloride andthe like.

Examples of the coronary vasodilator include carbochromenehydrochloride, molsidomine, verapamil hydrochloride and the like.

Examples of the peripheral vasodilator include cinnarizinee and thelike.

Examples of the lipid-lowering agent include cerivastatin sodium,simvastatin, pravastatin sodium and the like.

Examples of the cholagogue include dehydrocholic acid, trepibutone andthe like.

Examples of the antibiotic include cephem antibiotics such as cefalexin,cefaclor, amoxicillin, pivmecillinam hydrochloride, cefotiam hexetilhydrochloride, cefadroxil, cefixime, cefditoren pivoxil, cefterampivoxil, cefpodoxime proxetil, cefotiam hydrochloride, cefozopranhydrochloride, cefmenoxime hydrochloride, cefsulodin sodium and thelike, synthetic antibacterial agents such as ampicillin, ciclacillin,sulbenicillin sodium, naldixic acid, enoxacin and the like, monobactumantibiotics such as carumonam sodium and the like, penem and carbapenemantibiotics and the like.

Examples of the chemotherapeutic agent include sufamethizol,sufamethizol hydrochloride, thiazosulfone and the like.

Examples of the diabetes agent include tolbutamide, pioglitazonehydrochloride, voglibose, glibenclamide, troglitazone, rosiglitazonemaleate, acarbose, miglitol, emiglitate and the like.

Examples of the osteoporosis agent include ipriflavone and the like.

Examples of the skeleton muscle relaxant include methocarbamol and thelike.

Examples of the anti-rheumatic drug include methotrexate, bucillamineand the like.

Examples of the hormone agent include liothyronine sodium, dexamethasonesodium phosphate, prednisolone, oxendolone, leuprorelin acetate and thelike.

Examples of the narcotic alkaloid include opium, morphine hydrochloride,ipecac, oxycodon hydrochloride, opium alkaloid hydrochloride, cocainehydrochloride and the like.

Examples of the sulfa drug include sulfamin, sulfisomidine, sufamethizoland the like.

Examples of the therapeutic drug for gout include allopurinol,colchicine and the like.

Examples of the anticoagulant include dicoumarol and the like.

Examples of the anti-malignant tumor agent include 5-fluorouracil,uracil, mitomycin and the like.

Examples of the therapeutic drug for Alzheimer's disease includeidebenone, vinpocetine and the like.

Examples of the potassium ion competitive acid secretion blocker (P-CAB)include a compound represented by the above-mentioned formula (A1), theformula (A2), the formula (A3) or the formula (A4) and the like.

Of the aforementioned pharmaceutically active ingredients, apharmaceutically active ingredient that can particularly enjoy theeffect of the invention is a pharmaceutically active ingredient unstableto light irradiation. For example, the present invention is particularlyeffective for a pharmaceutically active ingredient represented by theabove-mentioned formula (A1), the formula (A2), the formula (A3) or theformula (A4), which belongs to the “pharmaceutically active ingredientunstable to light irradiation”. That is, the present invention has aremarkable effect for improving the stability of a pharmaceuticallyactive ingredient represented by the above-mentioned formula (A1), theformula (A2), the formula (A3) or the formula (A4) to light irradiation.

[Titanium Oxide (Component II)]

In the present invention, titanium oxide has a superior shielding effectagainst light. The particle size of titanium oxide to be used in thepresent invention is generally about 0.01-about 1.5 μm, preferably about0.1-about 0.7 μm. When titanium oxide is added to a coating agent forfilm-coated tablets and the like, the content of titanium oxide is suchan amount capable of achieving the object of shielding of thepharmaceutical preparation, which is preferably about 5-about 30 wt %,more preferably about 5-about 20 wt %, of the coating agent.

[Plasticizer (Component III)]

Examples of the “plasticizer” to be used in the present inventioninclude plasticizers generally used in a pharmaceutical preparation.Specifically, for example, esters such as triethyl citrate, medium-chaintriglyceride, diethyl phthalate, dibutyl phthalate, triacetine(triacetyl glycerol), butyl phthalyl butyl glycolate, glyceryl caprylateand the like; alcohols such as glycerol, propylene glycol, polyethyleneglycol and the like, and the like. As the plasticizer, a compound of thechemical formula [HOCH₂(CH₂OCH₂)_(n)CH₂OH (n=integer of 2-870)] ispreferable, and polyethylene glycol (PEG) is particularly preferable.Examples of PEG actually used as the plasticizer include macrogol(manufactured by Sanyo chemical industries, Ltd.). While the averagemolecular weight of PEG is not particularly limited, it is preferablynot less than 200, more preferably 200-20000, since a smaller averagemolecular weight increases hygroscopicity. When PEG is added to acoating agent for a film-coated tablet and the like, the content of PEGis preferably about 5-about 30 wt %, especially about 10-25 wt %, morepreferably about 10-about 20 wt %, of the coating agent.

[Chain Organic Acid (Component IV)]

In the solid preparation of the present invention, titanium oxide isused for shielding. However, it is known that since titanium oxide has astrong oxidation action as mentioned above, when a coating agentcontaining a light shielding agent such as titanium oxide and the likeand a plasticizer such as polyethylene glycol and the like is applied toa drug-containing tablet during formulation of a preparation of a drugunstable to light, the obtained film-coated tablet becomes inferior tothe tablet before a coating treatment in the stability to light. Thepresent invention effectively suppresses, without decreasing theproductivity during film coating, generation of a decomposed productduring light irradiation by adding an organic acid, particularly a chainorganic acid, together with titanium oxide to, for example, a solidpreparation such as a film coating agent and the like. Examples of thechain organic acid include adipic acid, oleic acid, succinic acid,acetic acid, tartaric acid, sorbic acid, fumaric acid, lactic acid,maleic acid, malonic acid, citric acid, malic acid and the like. Theseorganic acids may be used alone, or two or more kinds thereof may beused simultaneously. The chain organic acid preferably has pH 6.0 orbelow when dissolved or dispersed in water. The chain organic acid ispreferably fumaric acid, citric acid, succinic acid or tartaric acid,more preferably fumaric acid, succinic acid or tartaric acid.

The pH of a chain organic acid is measured under the followingconditions. To be specific, the pH of an aqueous solution or dispersionobtained by dissolving or dispersing a measurement target in water at 1%w/v is measured at 25° C. with a commercially available pH meter.

The content (%) of the chain organic acid in the whole pharmaceuticalcomposition of the present invention is preferably 0.1-20% (morepreferably 0.1-19%), further preferably 1-10%, particularly preferably2-10%. In another embodiment, it is 0.01-50%, preferably 0.05-19%, morepreferably 0.1-10%.

When producing the pharmaceutical composition of the present invention,the “chain organic acid” may be added as a powder in a granulation stepor a mixing step. In addition, a chain organic acid can be sprayed bydissolving or dispersing in a binder solution in the granulation step orin a film coating solution in a film coating step.

The solid preparation containing the pharmaceutically active ingredientof the present invention has low toxicity, and can be safelyadministered orally or parenterally (e.g., topical, rectal, intravenousadministration etc.) as it is or in the form of a pharmaceuticalcomposition containing a pharmacologically acceptable carrier accordingto a method known per se, for example, as preparations such as tablet(core tablet, sugar-coated tablet, film-coated tablet etc.), powder,granule, capsule (including soft capsule), orally disintegrating tablet,suppository, sustained-release preparation and the like. Thepharmaceutical composition of the present invention is preferablyadministered as an oral preparation such as tablet, granule, capsule andthe like. Of these, tablet and capsule are preferable, and asugar-coated tablet and a film-coated tablet are especially preferable.

As the pharmacologically acceptable carrier that can be used for theproduction of the pharmaceutical composition of the present invention,those similar to the examples recited for the first invention can bementioned.

The pharmaceutical composition of the present invention does not have tocontain a souring agent.

Now, as one embodiment of the present invention, an example wherein asolid preparation containing a pharmaceutically active ingredient,titanium oxide, a plasticizer and a chain organic acid, as explainedabove, is applied to a film-coated tablet is explained in the following.The film-coated tablet is obtained by coating a core tablet (core)containing a pharmaceutically active ingredient with a film coatinglayer comprising the following film coating polymer. Generally, apharmaceutically active ingredient is contained in a core, but titaniumoxide, a chain organic acid and a plasticizer may be contained in eitheror both of a core or(and) a film coating layer. Particularly, titaniumoxide and a plasticizer are preferably contained in a film coatinglayer. In addition, a core material containing a chain organic acid anda layer containing an active ingredient do not need to be separated by aseparating layer.

A film coating solution is sprayed on a solid preparation (preferablytablet, more preferably ellipse or round tablet), and dried asnecessary. The “film coating solution” is prepared by, for example,dissolving or suspending a film coating polymer in a solvent. The filmcoating solution may further contain, for example, a colorant(preferably, diiron trioxide and yellow ferric oxide), a light shieldingagent (preferably, titanium oxide) and the like. Examples of the “filmcoating polymer” include hydroxypropylmethylcellulose, ethylcellulose,hydroxymethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose acetate succinate, acrylic resin(methacrylic acid-acrylic acid copolymer, aminoalkylmethacrylatecopolymer etc.), shellac, polyvinyl acetatephthalate, gum arabic,cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate,carboxymethylethylcellulose and the like. Examples of the “solvent”include water, alcohols (e.g., ethanol, isopropyl alcohol, n-propylalcohol, methanol and the like), acetone, ethyl acetate,dichloromethane, chloroform, hexane, toluene, heptane and the like. Theamount of the “film coating polymer” to be used can be selectedaccording to the kind of the solid preparation and, when the solidpreparation is a tablet, it is, for example, about 0.5-10 wt % of atablet. The spraying temperature is generally 25-80° C., the sprayingtime is generally 5 min-24 hr, and the drying conditions are generally30-80° C. for about 1 min-24 hr. The film coating layer of the presentinvention can be formed at a ratio of generally 1-10 parts by weight,preferably 2-6 parts by weight, per 100 parts by weight of the solidpreparation (preferably tablet, more preferably ellipse or round tablet)of the present invention.

The pharmaceutical composition of the present invention can beformulated into a preparation for oral administration (film-coatedtablet) by, for example, adding, where necessary, an excipient to theabove-mentioned component I and component IV to give a granulatedpowder, adding, where necessary, a binder, a disintegrant, a lubricantand the like thereto, tableting the obtained mixture by a method knownper se and, where necessary, coating the tablet by a method known per sefor masking of taste, enteric coating or sustained release.

The core tablet of the pharmaceutical composition of the presentinvention can be obtained by adding an excipient and the above-mentionedcomponent IV (chain organic acid) to the above-mentioned component I(pharmaceutically active ingredient), adding, where necessary, a binder,sieving the obtained granulated powder, adding, where necessary, adisintegrant and, where necessary, a lubricant, mixing the mixture, andpunching the obtained mixed powder. The obtained core tablet can beformulated into a film-coated tablet of the pharmaceutical compositionof the present invention by coating the core tablet by a method knownper se.

A binder can be added by spraying an aqueous solution thereof and thelike.

The coating by a method known per se includes, for example, separatelypreparing a coating solution using a disperser or a propeller stirringmachine, and the like, and spraying and coating the solution on tabletscharged in a film coating machine.

Examples of the above-mentioned “excipient”, “binder”, “disintegrant”and “lubricant” respectively include those similar to the examplesrecited for the above-mentioned first invention.

The pharmaceutical composition of the present invention is superior inthe stability during light irradiation. The pharmaceutical compositionof the present invention can be used in the same manner as described inthe above-mentioned first invention.

The pharmaceutical composition of the present invention may have thecharacteristics of both the first invention and the second invention.

EXAMPLES

The present invention is explained in more detail in the following byreferring to Comparative Examples, Examples and Experimental Examples,which are not to be construed as limitative. In the formulationsdescribed as Examples, Pharmacopoeia compatible products and JapanesePharmaceutical Excipients compatible products were used as thecomponents other than the active ingredient (additives). In thefollowing Examples and Comparative Examples, the Japanese Pharmacopoeia15th Edition or Japanese Pharmaceutical Excipients 2003 compatibleproducts were used as the preparation additives (e.g., lactose,D-mannitol, hydroxypropylcellulose, crospovidone, magnesium stearate,crystalline cellulose).

Unless otherwise specified, % in the following means wt %.

Firstly, the results of the stability evaluation of the pharmaceuticalcomposition of the first invention of the present invention, containinga nonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group, an excipient and an acidic compound are explainedby Examples 1-44 and Comparative Examples 1-6.

Comparative Example 1 Sample 1

A plain tablet (core tablet) containing1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate (hereinafter to be referred to as compound A) was produced asfollows at the composition ratio shown in Table 2-1.

That is, compound A (24.491 g), mannitol (4350.0 g) and crystallinecellulose (540.0 g) were placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (2700.0 g) of hydroxypropylcellulose (162.0 g) to givea granulated powder. The obtained granulated powder (4568.0 g) waspassed through a powermill (P-3, manufactured by Showa Kagaku KikaiKosakusho) to give a sized powder. The sized powder (4230.0 g),croscarmellose sodium (225.0 g) and magnesium stearate (45.007 g) wereplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder wastableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 9 mmφ punch to give plain tablets(core tablets, 300 mg per tablet).

TABLE 2-1 Composition of plain tablet (core tablet) containing compoundA (sample 1) composition amount (mg) 1) compound A* 1.336 2) mannitol241.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)croscarmellose sodium 15 6) magnesium stearate 3 total 300.0 *Wherenecessary, the content was amended using mannitol as an adjustmentcomponent.

Comparative Example 2 Sample 2

The plain tablet (core tablet) (sample 1, 3300.0 g) obtained inComparative Example 1 was placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about 312mg per tablet) were obtained while spraying a film coating solution(1372.0 g) having the composition ratio shown in Table 2-2. The obtainedfilm-coated tablet was placed in a glass bottle, tightly sealed andpreserved at 60° C. for 2 weeks, and at 40° C., 75% RH for 2 or 6months. The film-coated tablet was placed in a glass bottle, andpreserved in an open bottle at 40° C., 75% RH for 6 months.

TABLE 2-2 Composition of aqueous film coating solution compositionamount (mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide0.2 4) purified water 108 total 120.0

Example 1 Sample 3

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 3. That is, compound A(4.01 g), mannitol (722.6 g) and crystalline cellulose (90.6 g) wereplaced in a fluidized bed dryer granulator (LAB-1, manufactured byPOWREX CORPORATION), and the mixture was preheated and mixed. Themixture was granulated while spraying an aqueous solution (452.4 g) ofhydroxypropylcellulose (27.0 g) and fumaric acid (2.4 g) to give agranulated powder. The obtained granulated powder was passed through a16M (1000 μm) sieve to give a sized powder. To the sized powder (564.3g) were added croscarmellose sodium (30.00 g) and magnesium stearate(6.000 g) and the mixture was mixed in a bag to give a mixed powder. Themixed powder was tableted by a rotary tableting machine (COLLECT 19K,manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφ punch to giveplain tablets (core tablets, 300 mg per tablet). A part of the obtainedplain tablet (core tablet) was used for preservation measurement. Thatis, the plain tablet (core tablet) was placed in a glass bottle, tightlysealed and preserved at 60° C. for 2 weeks.

TABLE 3 Composition of plain tablet (core tablet) containing compound A(sample 3) composition amount (mg) 1) compound A 1.336 2) mannitol240.864 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 0.8 6) croscarmellose sodium 15 7) magnesium stearate 3total 300.0

Example 2 Sample 4

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 4.

That is, compound A (4.01 g), mannitol (635.2 g), crystalline cellulose(90.0 g) and fumaric acid (90.1 g) were placed in a fluidized bed dryergranulator (LAB-1, manufactured by POWREX CORPORATION), and the mixturewas preheated and mixed. The mixture was granulated while spraying anaqueous solution (450.0 g) of hydroxypropylcellulose (27.0 g) to give agranulated powder. The obtained granulated powder was passed through a16M (1000 μm) sieve to give a sized powder. To the sized powder (564.2g) were added croscarmellose sodium (30.00 g) and magnesium stearate(6.000 g) and the mixture was mixed in a bag to give a mixed powder. Themixed powder was tableted by a rotary tableting machine (COLLECT 19K,manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφ punch to giveplain tablets (core tablets, 300 mg per tablet). A part of the obtainedplain tablet (core tablet) was used for preservation measurement. Thatis, the plain tablet (core tablet) was placed in a glass bottle, tightlysealed and preserved at 60° C. for 2 weeks.

TABLE 4 Composition of plain tablet (core tablet) containing compound A(sample 4) composition amount (mg) 1) compound A 1.336 2) mannitol211.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 30 6) croscarmellose sodium 15 7) magnesium stearate 3total 300.0

Example 3 Sample 5

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 5.

That is, compound A (4.01 g), mannitol (635.0 g), crystalline cellulose(90.0 g) and fumaric acid (87.7 g) were placed in a fluidized bed dryergranulator (LAB-1, manufactured by POWREX CORPORATION), and the mixturewas preheated and mixed. The mixture was granulated while spraying anaqueous solution (452.4 g) of hydroxypropylcellulose (27.0 g) andfumaric acid (2.4 g) to give a granulated powder. The obtainedgranulated powder was passed through a 16M (1000 μm) sieve to give asized powder. To the sized powder (564.1 g) were added croscarmellosesodium (30.20 g) and magnesium stearate (6.000 g) and the mixture wasmixed in a bag to give a mixed powder. The mixed powder was tableted bya rotary tableting machine (COLLECT 19K, manufactured by KikusuiSeisakusho, Ltd.) using a 9 mmφ punch to give plain tablets (coretablets, 300 mg per tablet). The plain tablet (core tablet) was placedin a glass bottle, tightly sealed and preserved at 60° C. for 2 weeks.

TABLE 5 Composition of plain tablet (core tablet) containing compound A(sample 5) composition amount (mg) 1) compound A 1.336 2) mannitol211.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 30 6) croscarmellose sodium 15 7) magnesium stearate 3total 300.0

Example 4 Sample 6

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 6.

That is, compound A (2.6719 g), mannitol (481.8 g), crystallinecellulose (60.0 g) and fumaric acid (1.61 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (300.0 g) of hydroxypropylcellulose (18.0g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder. To thesized powder (507.8 g) were added croscarmellose sodium (27.00 g) andmagnesium stearate (5.4000 g) and the mixture was mixed in a bag to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a9 mmφ punch to give plain tablets (core tablets, 300 mg per tablet).

TABLE 6 Composition of plain tablet (core tablet) containing compound A(sample 6) composition amount (mg) 1) compound A 1.336 2) mannitol240.864 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 0.8 6) croscarmellose sodium 15 7) magnesium stearate 3total 300.0

Example 5 Sample 7

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 7.

That is, compound A (2.6724 g), mannitol (480.3 g), crystallinecellulose (60.0 g) and fumaric acid (3.01 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (300.0 g) of hydroxypropylcellulose (18.0g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder. To thesized powder (507.9 g) were added croscarmellose sodium (27.00 g) andmagnesium stearate (5.4000 g) and the mixture was mixed in a bag to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a9 mmφ punch to give plain tablets (core tablets, 300 mg per tablet).

TABLE 7 Composition of plain tablet (core tablet) containing compound A(sample 7) composition amount (mg) 1) compound A 1.336 2) mannitol240.164 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 1.5 6) croscarmellose sodium 15 7) magnesium stearate 3total 300.0

Example 6 Sample 8

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 8.

That is, compound A (2.6721 g), mannitol (477.3 g), crystallinecellulose (60.0 g) and fumaric acid (6.01 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (300.0 g) of hydroxypropylcellulose (18.0g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder. To thesized powder (507.7 g) were added croscarmellose sodium (27.00 g) andmagnesium stearate (5.4000 g) and the mixture was mixed in a bag to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a9 mmφ punch to give plain tablets (core tablets, 300 mg per tablet).

TABLE 8 Composition of plain tablet (core tablet) containing compound A(sample 8) composition amount (mg) 1) compound A 1.336 2) mannitol238.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 3 6) croscarmellose sodium 15 7) magnesium stearate 3 total300.0

Example 7 Sample 9

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 9.

That is, compound A (2.6715 g), mannitol (469.3 g), crystallinecellulose (60.0 g) and fumaric acid (14.00 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (300.0 g) of hydroxypropylcellulose (18.0g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder. To thesized powder (507.5 g) were added croscarmellose sodium (27.00 g) andmagnesium stearate (5.4000 g) and the mixture was mixed in a bag to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a9 mmφ punch to give plain tablets (core tablets, 300 mg per tablet).

TABLE 9 Composition of plain tablet (core tablet) containing compound A(sample 9) composition amount (mg) 1) compound A 1.336 2) mannitol234.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 7 6) croscarmellose sodium 15 7) magnesium stearate 3 total300.0

Example 8 Sample 10

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 10.

That is, compound A (20.04 g), mannitol (451.0 g), crystalline cellulose(60.0 g) and fumaric acid (15.0 g) were placed in a fluidized bed dryergranulator (LAB-1, manufactured by POWREX CORPORATION), and the mixturewas preheated and mixed. The mixture was granulated while spraying anaqueous solution (300.0 g) of hydroxypropylcellulose (18.0 g) to give agranulated powder. The obtained granulated powder was passed through a16M (1000 μm) sieve to give a sized powder. To the sized powder (526.4g) were added croscarmellose sodium (28.00 g) and magnesium stearate(5.60 g) and the mixture was mixed in a bag to give a mixed powder. Themixed powder was tableted by a rotary tableting machine (COLLECT 19K,manufactured by Kikusui Seisakusho, Ltd.) using a 8 mmφ punch to giveplain tablets (core tablets, 200 mg per tablet).

TABLE 10 Composition of plain tablet (core tablet) containing compound A(sample 10) composition amount (mg) 1) compound A 6.68 2) mannitol150.32 3) crystalline cellulose 20 4) hydroxypropylcellulose 6 5)fumaric acid 5 6) croscarmellose sodium 10 7) magnesium stearate 2 total200.0

Example 9 Sample 11

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 11.

That is, compound A (80.16 g), mannitol (390.9 g), crystalline cellulose(60.0 g) and fumaric acid (15.0 g) were placed in a fluidized bed dryergranulator (LAB-1, manufactured by POWREX CORPORATION), and the mixturewas preheated and mixed. The mixture was granulated while spraying anaqueous solution (300.0 g) of hydroxypropylcellulose (18.0 g) to give agranulated powder. The obtained granulated powder was passed through a16M (1000 μm) sieve to give a sized powder. To the sized powder (526.4g) were added croscarmellose sodium (28.00 g) and magnesium stearate(5.60 g) and the mixture was mixed in a bag to give a mixed powder. Themixed powder was tableted by a rotary tableting machine (COLLECT 19K,manufactured by Kikusui Seisakusho, Ltd.) using a 8 mmφ punch to giveplain tablets (core tablets, 200 mg per tablet).

TABLE 11 Composition of plain tablet (core tablet) containing compound A(sample 11) composition amount (mg) 1) compound A 26.72 2) mannitol130.28 3) crystalline cellulose 20 4) hydroxypropylcellulose 6 5)fumaric acid 5 6) croscarmellose sodium 10 7) magnesium stearate 2 total200.0

Example 10 Sample 12

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 12.

That is, compound A (160.32 g), mannitol (310.7 g), crystallinecellulose (60.6 g) and fumaric acid (15.0 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (300.0 g) of hydroxypropylcellulose (18.0g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder. To thesized powder (526.4 g) were added croscarmellose sodium (28.00 g) andmagnesium stearate (5.60 g) and the mixture was mixed in a bag to give amixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a8 mmφ punch to give plain tablets (core tablets, 200 mg per tablet).

TABLE 12 Composition of plain tablet (core tablet) containing compound A(sample 12) composition amount (mg) 1) compound A 53.44 2) mannitol103.56 3) crystalline cellulose 20 4) hydroxypropylcellulose 6 5)fumaric acid 5 6) croscarmellose sodium 10 7) magnesium stearate 2 total200.0

Example 11 Sample 13

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 13.

That is, compound A (160.32 g), mannitol (265.7 g), crystallinecellulose (60.0 g) and fumaric acid (60.0 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (300.0 g) of hydroxypropylcellulose (18.0g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder. To thesized powder (526.4 g) were added croscarmellose sodium (28.00 g) andmagnesium stearate (5.60 g) and the mixture was mixed in a bag to give amixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a8 mmφ punch to give plain tablets (core tablets, 200 mg per tablet).

TABLE 13 Composition of plain tablet (core tablet) containing compound A(sample 13) composition amount (mg) 1) compound A 53.44 2) mannitol88.56 3) crystalline cellulose 20 4) hydroxypropylcellulose 6 5) fumaricacid 20 6) croscarmellose sodium 10 7) magnesium stearate 2 total 200.0

Example 12 Sample 14

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 14.

That is, compound A (80.890 g), mannitol (4065.0 g), crystallinecellulose (528.0 g) and fumaric acid (132.0 g) were placed in afluidized bed dryer granulator (FD-5S, manufactured by POWREXCORPORATION), and the mixture was preheated and mixed. The mixture wasgranulated while spraying an aqueous solution (2640.0 g) ofhydroxypropylcellulose (158.4 g) to give a granulated powder. Theobtained granulated powder (4550.0 g) was passed through a powermill(P-3, manufactured by Showa Kagaku Kikai Kosakusho) to give a sizedpowder. The sized powder (4239.0 g), croscarmellose sodium (225.5 g) andmagnesium stearate (45.10 g) were placed in a tumbler mixer (TM-15S,manufactured by Showa Kagaku Kikai Kosakusho), and mixed therein to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 12HUK, manufactured by Kikusui Seisakusho, Ltd.) usinga 8 mmφ punch to give plain tablets (core tablets, 220 mg per tablet).

TABLE 14 Composition of plain tablet (core tablet) containing compound A(sample 14) composition amount (mg) 1) compound A* 3.34 2) mannitol169.36 3) crystalline cellulose 22 4) hydroxypropylcellulose 6.6 5)fumaric acid 5.5 6) croscarmellose sodium 11 7) magnesium stearate 2.2total 220.0 *Where necessary, the content was amended using mannitol asan adjustment component.

Example 13 Sample 15

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 15.

That is, compound A (161.8 g), mannitol (3984.0 g), crystallinecellulose (528.0 g) and fumaric acid (132.0 g) were placed in afluidized bed dryer granulator (FD-5S, manufactured by POWREXCORPORATION), and the mixture was preheated and mixed. The mixture wasgranulated while spraying an aqueous solution (2640.0 g) ofhydroxypropylcellulose (158.4 g) to give a granulated powder. Theobtained granulated powder (4550.0 g) was passed through a powermill(P-3, manufactured by Showa Kagaku Kikai Kosakusho) to give a sizedpowder. The sized powder (4239.0 g), croscarmellose sodium (225.5 g) andmagnesium stearate (45.1 g) were placed in a tumbler mixer (TM-15S,manufactured by Showa Kagaku Kikai Kosakusho), and mixed therein to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 12HUK, manufactured by Kikusui Seisakusho, Ltd.) usinga 8 mmφ punch to give plain tablets (core tablets, 220 mg per tablet).

TABLE 15 Composition of plain tablet (core tablet) containing compound A(sample 15) composition amount (mg) 1) compound A* 6.68 2) mannitol166.02 3) crystalline cellulose 22 4) hydroxypropylcellulose 6.6 5)fumaric acid 5.5 6) croscarmellose sodium 11 7) magnesium stearate 2.2total 220.0 *Where necessary, the content was amended using mannitol asan adjustment component.

Example 14 Sample 16

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 16.

That is, compound A (323.5 g), mannitol (3824.0 g), crystallinecellulose (528.0 g) and fumaric acid (132.0 g) were placed in afluidized bed dryer granulator (FD-5S, manufactured by POWREXCORPORATION), and the mixture was preheated and mixed. The mixture wasgranulated while spraying an aqueous solution (2640.0 g) ofhydroxypropylcellulose (158.4 g) to give a granulated powder. Theobtained granulated powder (4550.0 g) was passed through a powermill(P-3, manufactured by Showa Kagaku Kikai Kosakusho) to give a sizedpowder. The sized powder (4239.0 g), croscarmellose sodium (225.5 g) andmagnesium stearate (45.1 g) were placed in a tumbler mixer (TM-15S,manufactured by Showa Kagaku Kikai Kosakusho), and mixed therein to givea mixed powder. The mixed powder was tableted by a rotary tabletingmachine (COLLECT 12HUK, manufactured by Kikusui Seisakusho, Ltd.) usinga 8 mmφ punch to give plain tablets (core tablets, 220 mg per tablet).

TABLE 16 Composition of plain tablet (core tablet) containing compound A(sample 16) composition amount (mg) 1) compound A* 13.36 2) mannitol159.34 3) crystalline cellulose 22 4) hydroxypropylcellulose 6.6 5)fumaric acid 5.5 6) croscarmellose sodium 11 7) magnesium stearate 2.2total 220.0 *Where necessary, the content was amended using mannitol asan adjustment component.

Example 15 Sample 17

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratios shown in Table 17. That is, compound A(647.1 g), mannitol (3504.0 g), crystalline cellulose (528.0 g) andfumaric acid (132.0 g) were placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (2640.0 g) of hydroxypropylcellulose (158.4 g) to givea granulated powder. The obtained granulated powder (4550.0 g) waspassed through a powermill (P-3, manufactured by Showa Kagaku KikaiKosakusho) to give a sized powder. The sized powder (4239.0 g),croscarmellose sodium (225.5 g) and magnesium stearate (45.1 g) wereplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed therein to give a mixed powder. The mixed powderwas tableted by a rotary tableting machine (COLLECT 12HUK, manufacturedby Kikusui Seisakusho, Ltd.) using a 8 mmφ punch to give plain tablets(core tablets, 220 mg per tablet).

TABLE 17 Composition of plain tablet (core tablet) containing compound A(sample 17) composition amount (mg) 1) compound A* 26.72 2) mannitol145.98 3) crystalline cellulose 22 4) hydroxypropylcellulose 6.6 5)fumaric acid 5.5 6) croscarmellose sodium 11 7) magnesium stearate 2.2total 220.0 *Where necessary, the content was amended using mannitol asan adjustment component.

Example 16 Sample 18

The plain tablet (core tablet) (sample 3, 299.95 g) obtained in Example1 was placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (136.9 g) havingthe composition ratio shown in Table 18. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 18 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 17 Sample 19

The plain tablet (core tablet) (sample 4, 250.0 g) obtained in Example 2was placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (103.1 g) havingthe composition ratio shown in Table 19. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 19 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 18 Sample 20

The plain tablets (core tablets) obtained in Example 3 (sample 5, 300.0g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (126.6 g) havingthe composition ratio shown in Table 20. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 20 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 19 Sample 21

The plain tablets (core tablets) obtained in Example 4 (sample 6, 300.0g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (145.0 g) havingthe composition ratio shown in Table 21. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 21 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 20 Sample 22

The plain tablets (core tablets) obtained in Example 5 (sample 7, 300.1g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (143.5 g) havingthe composition ratio shown in Table 22. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 22 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 21 Sample 23

The plain tablets (core tablets) obtained in Example 6 (sample 8, 300.1g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (158.3 g) havingthe composition ratio shown in Table 23. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 23 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 22 Sample 24

The plain tablets (core tablets) obtained in Example 7 (sample 9, 300.0g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (138.1 g) havingthe composition ratio shown in Table 24. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 or 6 months. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 or 6 months.

TABLE 24 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 23 Sample 25

The plain tablets (core tablets) obtained in Example 8 (sample 10, 350.1g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 209 mg per tablet)were obtained while spraying a film coating solution (192.0 g) havingthe composition ratio shown in Table 25. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 months. The film-coated tablet wasplaced in a glass bottle, and preserved in an open bottle at 40° C., 75%RH for 2 months.

TABLE 25 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.732 2) macrogol 6000 1.350 3) titanium oxide 0.94) diiron trioxide 0.018 5) purified water 90 total 99.0

Example 24 Sample 26

The plain tablets (core tablets) obtained in Example 9 (sample 11, 350.0g) were placed in a film coating machine (HCT-MINI type, manufactured byFreund Corporation), and film-coated tablets (about 209 mg per tablet)were obtained while spraying a film coating solution (182.3 g) havingthe composition ratio shown in Table 26. The obtained film-coated tabletwas placed in a glass bottle, tightly sealed and preserved at 60° C. for2 weeks, and at 40° C., 75% RH for 2 months. The film-coated tablet wasplaced in a glass bottle, and preserved in an open bottle at 40° C., 75%RH for 2 months.

TABLE 26 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.732 2) macrogol 6000 1.350 3) titanium oxide 0.94) diiron trioxide 0.018 5) purified water 90 total 99.0

Example 25 Sample 27

The plain tablets (core tablets) obtained in Example 10 (sample 12,350.1 g) were placed in a film coating machine (HCT-MINI type,manufactured by Freund Corporation), and film-coated tablets (about 209mg per tablet) were obtained while spraying a film coating solution(189.0 g) having the composition ratio shown in Table 27. The obtainedfilm-coated tablet was placed in a glass bottle, tightly sealed andpreserved at 60° C. for 2 weeks, and at 40° C., 75% RH for 2 months. Thefilm-coated tablet was placed in a glass bottle, and preserved in anopen bottle at 40° C., 75% RH for 2 months.

TABLE 27 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.732 2) macrogol 6000 1.350 3) titanium oxide 0.94) diiron trioxide 0.018 5) purified water 90 total 99.0

Example 26 Sample 28

The plain tablets (core tablets) obtained in Example 11 (sample 13,240.1 g) were placed in a film coating machine (HCT-MINI type,manufactured by Freund Corporation), and film-coated tablets (about 209mg per tablet) were obtained while spraying a film coating solution(126.3 g) having the composition ratio shown in Table 28. The obtainedfilm-coated tablet was placed in a glass bottle, tightly sealed andpreserved at 60° C. for 2 weeks, and at 40° C., 75% RH for 2 months. Thefilm-coated tablet was placed in a glass bottle, and preserved in anopen bottle at 40° C., 75% RH for 2 months.

TABLE 28 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.732 2) macrogol 6000 1.350 3) titanium oxide 0.94) diiron trioxide 0.018 5) purified water 90 total 99.0

Example 27 Sample 29

The plain tablets (core tablets) obtained in Example 12 (sample 14,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1480.9 g)having the composition ratio shown in Table 29. The film-coated tabletwas placed in a glass bottle, and preserved in an open bottle at 40° C.,75% RH for 2 months.

TABLE 29 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.6 2) macrogol 6000 1.5 3) titanium oxide 0.75 4)yellow ferric oxide 0.075 5) diiron trioxide 0.075 6) purified water 81total 90.0

Example 28 Sample 30

The plain tablets (core tablets) obtained in Example 13 (sample 15,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1501.0 g)having the composition ratio shown in Table 30. The film-coated tabletwas placed in a glass bottle, and preserved in a closed bottle or anopen bottle at 40° C., 75% RH for 2 months.

TABLE 30 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.6 2) macrogol 6000 1.5 3) titanium oxide 0.75 4)yellow ferric oxide 0.075 5) diiron trioxide 0.075 6) purified water 81total 90.0

Example 29 Sample 31

The plain tablets (core tablets) obtained in Example 14 (sample 16,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1514.0 g)having the composition ratio shown in Table 31. The film-coated tabletwas placed in a glass bottle, and preserved in a closed bottle or anopen bottle at 40° C., 75% RH for 2 months.

TABLE 31 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.6 2) macrogol 6000 1.5 3) titanium oxide 0.75 4)yellow ferric oxide 0.075 5) diiron trioxide 0.075 6) purified water 81total 90.0

Example 30 Sample 32

The plain tablets (core tablets) obtained in Example 15 (sample 17,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1374.0 g)having the composition ratio shown in Table 32. The film-coated tabletwas placed in a glass bottle, and preserved in a closed bottle or anopen bottle at 40° C., 75% RH for 2 months.

TABLE 32 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.6 2) macrogol 6000 1.5 3) titanium oxide 0.75 4)yellow ferric oxide 0.075 5) diiron trioxide 0.075 6) purified water 81total 90.0

Comparative Example 3 Sample 33

A plain tablet (core tablet) containingN-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanaminefumarate (hereinafter to be referred to as compound B) was produced asfollows at the composition ratio shown in Table 33.

That is, compound B (2.680 g), mannitol (483.320 g) and crystallinecellulose (60.0 g) were placed in a fluidized bed dryer granulator(LAB-1, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (300.0 g) of hydroxypropylcellulose (18.0 g) to give agranulated powder. The obtained granulated powder was passed through a16M (1000 μm) sieve to give a sized powder. Croscarmellose sodium (27.00g) and magnesium stearate (5.400 g) were added to the sized powder(507.6 g) and mixed to give a mixed powder. The mixed powder wastableted by a rotary tableting machine (COLLECT 19K, manufactured byKikusui Seisakusho, Ltd.) using a 9 mmφ punch to give plain tablets(core tablets, 300 mg per tablet).

TABLE 33 Composition of plain tablet (core tablet) containing compound Bcomposition amount (mg) 1) compound B 1.340 2) mannitol 241.66 3)crystalline cellulose 30 4) hydroxypropylcellulose 9 5) croscarmellosesodium 15 6) magnesium stearate 3 total 300.0

Comparative Example 4 Sample 34

The plain tablets (core tablets) obtained in Comparative Example 3(sample 33, 200.0 g) were placed in a film coating machine (DRC-200,manufactured by POWREX CORPORATION), and film-coated tablets (about 312mg per tablet) were obtained while spraying a film coating solution(96.8 g) having the composition ratio shown in Table 34. The obtainedfilm-coated tablet was placed in a glass bottle, tightly sealed andpreserved at 40° C., 75% RH for 2 months. The film-coated tablet wasplaced in a glass bottle, and preserved in an open bottle at 40° C., 75%RH for 2 months.

TABLE 34 composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.8 2) polyethylene glycol 2 3) titanium oxide 1 4)diiron trioxide 0.2 5) purified water 108 total 120.0

Example 31 Sample 35

A plain tablet (core tablet) containing compound B was produced asfollows at the composition ratio shown in Table 35.

That is, compound B (24.54 g), mannitol (4223.0 g), crystallinecellulose (540.0 g) and fumaric acid (126.0 g) were placed in afluidized bed dryer granulator (FD-5S, manufactured by POWREXCORPORATION), and the mixture was preheated and mixed. The mixture wasgranulated while spraying an aqueous solution (2700.0 g) ofhydroxypropylcellulose (162.0 g) to give a granulated powder. Theobtained granulated powder (4568.0 g) was passed through a powermill(P-3, manufactured by Showa Kagaku Kikai Kosakusho) to give a sizedpowder. The sized powder (4230.0 g), croscarmellose sodium (225.0 g) andmagnesium stearate (45.00 g) were placed in a tumbler mixer (TM-15S,manufactured by Showa Kagaku Kikai Kosakusho), and mixed to give a mixedpowder. The mixed powder was tableted by a rotary tableting machine(COLLECT 12HUK, manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφpunch to give plain tablets (core tablets, 300 mg per tablet).

TABLE 35 Composition of plain tablet (core tablet) containing compound Bcomposition amount (mg) 1) compound B 1.340 2) mannitol 234.66 3)crystalline cellulose 30 4) hydroxypropylcellulose 9 5) fumaric acid 76) croscarmellose sodium 15 7) magnesium stearate 3 total 300.0

Example 32 Sample 36

The plain tablets (core tablets) obtained in Example 31 (sample 35,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 312 mg pertablet) were obtained while spraying a film coating solution (1432.0 g)having the composition ratio shown in Table 34. The obtained film-coatedtablet was placed in a glass bottle, tightly sealed and preserved at 40°C., 75% RH for 2 months. The film-coated tablet was placed in a glassbottle, and preserved in an open bottle at 40° C., 75% RH for 2 months.

Example 33 Sample 37

A plain tablet (core tablet) containing compound B was produced asfollows at the composition ratio shown in Table 36. That is, compound B(5.360 g), mannitol (479.2 g) and crystalline cellulose (60.00 g) wereplaced in a fluidized bed dryer granulator (LAB-1, manufactured byPOWREX CORPORATION), and the mixture was preheated and mixed. Themixture was granulated while spraying an aqueous solution (301.4 g) ofhydroxypropylcellulose (18.0 g) and fumaric acid (0.60 g) to give agranulated powder. The obtained granulated powder was passed through a16M (1000 μm) sieve to give a sized powder. Croscarmellose sodium (24.75g) and magnesium stearate (4.950 g) were added to the sized powder(465.3 g), and mixed to give a mixed powder. The mixed powder wastableted by a rotary tableting machine (COLLECT 19K, manufactured byKikusui Seisakusho, Ltd.) using a 7 mmφ punch to give plain tablets(core tablets, 150 mg per tablet).

TABLE 36 Composition of plain tablet (core tablet) containing compound Bcomposition amount (mg) 1) compound B 1.340 2) mannitol 119.81 3)crystalline cellulose 15 4) hydroxypropylcellulose 4.5 5) fumaric acid0.35 6) croscarmellose sodium 7.5 7) magnesium stearate 1.5 total 150.0

Example 34 Sample 38

The plain tablets (core tablets) obtained in Example 33 (sample 37,180.3 g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (core tablet, 156.1 mg pertablet) while spraying a film coating solution (75.0 g) having thecomposition ratio shown in Table 37. The obtained film-coated tablet wasplaced in a glass bottle, tightly sealed and preserved at 40° C., 75% RHfor 2 months. The film-coated tablet was placed in a glass bottle, andpreserved in an open bottle at 40° C., 75% RH for 2 months.

TABLE 37 composition of aqueous film coating solution composition amount(mg) 1) hypromellose 4.47 2) macrogol 6000 1.02 3) titanium oxide 0.5084) yellow ferric oxide 0.051 5) diiron trioxide 0.051 6) purified water54.9 total 61.0

Example 35 Sample 39

A plain tablet (core tablet) containing compound B was produced asfollows at the composition ratio shown in Table 38.

That is, compound B (24.54 g), mannitol (4223.0 g), crystallinecellulose (540.0 g) and fumaric acid (126.0 g) were placed in afluidized bed dryer granulator (FD-5S, manufactured by POWREXCORPORATION), and the mixture was preheated and mixed. The mixture wasgranulated while spraying an aqueous solution (2700.0 g) ofhydroxypropylcellulose (162.0 g) to give a granulated powder. Theobtained granulated powder (4568.0 g) was passed through a powermill(P-3, manufactured by Showa Kagaku Kikai Kosakusho) to give a sizedpowder. The sized powder (4230.0 g), croscarmellose sodium (225.0 g) andmagnesium stearate (45.00 g) were placed in a tumbler mixer (TM-15S,manufactured by Showa Kagaku Kikai Kosakusho), and mixed to give a mixedpowder. The mixed powder was tableted by a rotary tableting machine(COLLECT 12HUK, manufactured by Kikusui Seisakusho, Ltd.) using a 7 mmφpunch to give plain tablets (core tablets, 150 mg per tablet).

TABLE 38 Composition of plain tablet (core tablet) containing compound Bcomposition amount (mg) 1) compound B 0.67 2) mannitol 117.33 3)crystalline cellulose 15 4) hydroxypropylcellulose 4.5 5) fumaric acid3.5 6) croscarmellose sodium 7.5 7) magnesium stearate 1.5 total 150.0

Example 36 Sample 40

The plain tablets (core tablets) obtained in Example 35 (sample 39,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 156 mg pertablet) were obtained while spraying a film coating solution (1470.0 g)having the composition ratio shown in Table 34. The obtained film-coatedtablet was placed in a glass bottle, tightly sealed and preserved at 40°C., 75% RH for 2 months. The film-coated tablet was placed in a glassbottle, and preserved in an open bottle at 40° C., 75% RH for 2 months.

Example 37 Sample 41

A plain tablet (core tablet) containing compound B was produced asfollows at the composition ratio shown in Table 39. That is, compound B(245.4 g), mannitol (4003.0 g), crystalline cellulose (540.0 g) andfumaric acid (126.0 g) were placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (2700.0 g) of hydroxypropylcellulose (162.0 g) to givea granulated powder. The obtained granulated powder (4568.0 g) waspassed through a powermill (P-3, manufactured by Showa Kagaku KikaiKosakusho) to give a sized powder. The sized powder (4230.0 g),croscarmellose sodium (225.0 g) and magnesium stearate (45.00 g) wereplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder wastableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 9 mmφ punch to give plain tablets(core tablets, 300 mg per tablet).

TABLE 39 Composition of plain tablet (core tablet) containing compound Bcomposition amount (mg) 1) compound B 13.4 2) mannitol 222.6 3)crystalline cellulose 30 4) hydroxypropylcellulose 9 5) fumaric acid 76) croscarmellose sodium 15 7) magnesium stearate 3 total 300.0

Example 38 Sample 42

The plain tablets (core tablets) obtained in Example 37 (sample 41,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 312 mg pertablet) were obtained while spraying a film coating solution (1425.0 g)having the composition ratio shown in Table 34. The obtained film-coatedtablet was placed in a glass bottle, tightly sealed and preserved at 40°C., 75% RH for 2 months. The film-coated tablet was placed in a glassbottle, and preserved in an open bottle at 40° C., 75% RH for 2 months.

Example 39 Sample 43

A plain tablet (core tablet) containing compound B was produced asfollows at the composition ratio shown in Table 40. That is, compound B(981.5 g), mannitol (3267.0 g), crystalline cellulose (540.0 g) andfumaric acid (126.0 g) were placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (2700.0 g) of hydroxypropylcellulose (162.0 g) to givea granulated powder. The obtained granulated powder (4568.0 g) waspassed through a powermill (P-3, manufactured by Showa Kagaku KikaiKosakusho) to give a sized powder. The sized powder (4230.0 g),croscarmellose sodium (225.0 g) and magnesium stearate (45.00 g) wereplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder wastableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 9 mmφ punch to give plain tablets(core tablets, 300 mg per tablet).

TABLE 40 Composition of plain tablet (core tablet) containing compound Bcomposition amount (mg) 1) compound B 53.6 2) mannitol 182.4 3)crystalline cellulose 30 4) hydroxypropylcellulose 9 5) fumaric acid 76) croscarmellose sodium 15 7) magnesium stearate 3 total 300.0

Example 40 Sample 44

The plain tablets (core tablets) obtained in Example 39 (sample 43,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 312 mg pertablet) were obtained while spraying a film coating solution (1417.2 g)having the composition ratio shown in Table 34. The obtained film-coatedtablet was placed in a glass bottle, tightly sealed and preserved at 40°C., 75% RH for 2 months. The film-coated tablet was placed in a glassbottle, and preserved in an open bottle at 40° C., 75% RH for 2 months.

Comparative Example 5 Sample 45

A plain tablet (core tablet) containing1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate (hereinafter to be referred to as compound C) was produced asfollows at the composition ratio shown in Table 41.

That is, compound C (2.318 g), mannitol (483.7 g) and crystallinecellulose (60.0 g) were placed in a fluidized-bed dryer (LAB-1,manufactured by POWREX CORPORATION), and the mixture was preheated andmixed. The mixture was granulated while spraying an aqueous solution(300.0 g) of hydroxypropylcellulose (18.0 g) to give a granulatedpowder. The obtained granulated powder was passed through a 16M (1000μm) sieve to give a sized powder. Croscarmellose sodium (27.0 g) andmagnesium stearate (5.40 g) were added to the sized powder (507.6 g),and mixed in a bag to give a mixed powder. The mixed powder was tabletedby a rotary tableting machine (COLLECT 19K, manufactured by KikusuiSeisakusho, Ltd.) using a 9 mmφ punch to give plain tablets (coretablets, 300 mg per tablet).

TABLE 41 Composition of plain tablet (core tablet) containing compound Ccomposition amount (mg) 1) compound C 1.159 2) mannitol 238.841 3)crystalline cellulose 30 4) hydroxypropylcellulose 9 5) croscarmellosesodium 15 6) magnesium stearate 3 total 300.0

Comparative Example 6 Sample 46

The plain tablets (core tablets) obtained in Comparative Example 5(sample 45, 200.0 g) were placed in a film coating machine (Hicoatermini, manufactured by Freund Corporation), and film-coated tablets(about 312 mg per tablet) were obtained while spraying a film coatingsolution (136.3 g) having the composition ratio shown in Table 42. Theobtained film-coated tablet was placed in a glass bottle, tightly sealedand preserved at 40° C., 75% RH for 1 month. The film-coated tablet wasplaced in a glass bottle, and preserved in an open bottle at 40° C., 75%RH for 1 month.

TABLE 42 composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.8 2) polyethylene glycol 2 3) titanium oxide 1 4)diiron trioxide 0.2 5) purified water 108 total 120.0

Example 41 Sample 47

A plain tablet (core tablet) containing compound C was produced asfollows at the composition ratio shown in Table 43. That is, compound C(2.318 g), mannitol (482.082 g) and crystalline cellulose (60 g) wereplaced in a fluidized bed dryer granulator (LAB-1, manufactured byPOWREX CORPORATION), preheated and mixed. A granulated powder wasobtained while spraying an aqueous solution (300.0 g) of tartaric acid(1.60 g) and hydroxypropylcellulose (18.0 g). The obtained granulatedpowder was passed through a 16M (1000 μm) sieve to give a sized powder.Croscarmellose sodium (24.08 g) and magnesium stearate (4.81 g) wereadded to the sized powder (451.2 g), and mixed in a bag to give a mixedpowder. The mixed powder was tableted by a rotary tableting machine(COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφpunch to give plain tablets (core tablets, 300 mg per tablet).

TABLE 43 Composition of plain tablet (core tablet) containing compound Ccomposition amount (mg) 1) compound C 1.159 2) mannitol 241.041 3)crystalline cellulose 30 4) hydroxypropylcellulose 9 5) tartaric acid0.8 6) croscarmellose sodium 15 7) magnesium stearate 3 total 300.0

Example 42 Sample 48

The plain tablets (core tablets) obtained in Example 41 (sample 47,200.23 g) were placed in a film coating machine (Hicoater mini,manufactured by Freund Corporation), and film-coated tablets (about 312mg per tablet) were obtained while spraying a film coating solution(101.7 g) having the composition ratio shown in Table 42. The obtainedfilm-coated tablet was placed in a glass bottle, tightly sealed andpreserved at 40° C., 75% RH for 1 month.

Example 43 Sample 49

A plain tablet (core tablet) containing compound C was produced asfollows at the composition ratio shown in Table 44.

That is, compound C (6.954 g), mannitol (477.4 g) and crystallinecellulose (60 g) were placed in a fluidized bed dryer granulator (LAB-1,manufactured by POWREX CORPORATION), preheated and mixed. A granulatedpowder was obtained while spraying an aqueous solution (300.0 g) oftartaric acid (1.60 g) and hydroxypropylcellulose (18.0 g). The obtainedgranulated powder was passed through a 16M (1000 μm) sieve to give asized powder. The sized powder (376.0 g), croscarmellose sodium (20.00g) and magnesium stearate (4.00 g) were added, and mixed to give a mixedpowder. The mixed powder was tableted by a rotary tableting machine(COLLECT 19K, manufactured by Kikusui Seisakusho, Ltd.) using a 6 mmφpunch to give plain tablets (core tablets, 100 mg per tablet).

TABLE 44 Composition of plain tablet (core tablet) containing compound Ccomposition amount (mg) 1) compound C 1.159 2) mannitol 79.5743 3)crystalline cellulose 30 4) hydroxypropylcellulose 3 5) tartaric acid0.2667 6) croscarmellose sodium 5 7) magnesium stearate 1 total 100.0

Example 44 Sample 5

The plain tablets (core tablets) obtained in Example 43 (sample 49,280.03 g) were placed in a film coating machine (Hicoater mini,manufactured by Freund Corporation), and film-coated tablets (about 104mg per tablet) were obtained while spraying a film coating solution(115.4 g) having the composition ratio shown in Table 42. The obtainedfilm-coated tablet was placed in a glass bottle, tightly sealed andpreserved at 40° C., 75% RH for 1 month. The film-coated tablet wasplaced in a glass bottle, and preserved in an open bottle at 40° C., 75%RH for 1 month.

Experimental Example 1 Decomposed Product Measurement Method

The film-coated tablets of Comparative Example 2 and Examples 16-30 andthe core tablets of Examples 1-3 were examined for production ofdecomposed product U-6 of compound A (relative retention time: about0.70) and other decomposed products before preservation (initial) andafter preservation.

The decomposed product was measured by extracting the tablets with 0.05mol/L phosphoric acid/MeCN mixture (19:1) or water/MeCN mixture (19:1)by HPLC. The HPLC test conditions are as follows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm)

column: CAPCELL PAK C18 MGII, 3 μm, 4.6 mm i.d.×150 mm (manufactured byShiseido Co., Ltd.)

column temperature: fixed temperature around 25° C.

mobile phase A: 0.05 mol/L sodium phosphate buffer (pH 6.0)/acetonitrilemixture (95:5)

mobile phase B: 0.05 mol/L sodium phosphate buffer (pH 6.0)/acetonitrilemixture (40:60)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B as follows.

TABLE 45 time (min) after mobile phase A mobile phase B injection (%)(%) 0 100 0 10 80 20 60 70 30 110 0 100 110.1 100 0 120 100 0measurement range of peak area: 110 min

Experiment Results 1

The decomposed products before preservation and after preservation at60° C. for 2 weeks were measured, and the results of total decomposedproduct and U-6 that remarkably increased in the absence of organic acidare shown in Table 46.

TABLE 46 decomposed product after preservation at 60° C. for 2 weekscore tablet organic before preservation after preservation or film-compound A acid total decomposed total decomposed coated concentra-concentra- decomposed product U-6 decomposed product U-6 sample tablettion (%) tion (%) preservation state product (%) (%) product (%) (%)sample 2 film-coated 0.4 0 closed glass bottle 0.68 0.31 2.00 1.48(comparison tablet control) sample 3 core tablet 0.4 0.3 closed glassbottle 0.92 0.27 1.20 0.55 sample 4 core tablet 0.4 10 closed glassbottle 0.90 0.26 1.12 0.48 sample 5 core tablet 0.4 10 closed glassbottle 0.91 0.27 1.16 0.48 sample 18 film-coated 0.4 0.3 closed glassbottle 0.88 0.26 1.15 0.54 tablet sample 19 film-coated 0.4 10 closedglass bottle 0.89 0.26 1.11 0.49 tablet sample 20 film-coated 0.4 10closed glass bottle 0.88 0.26 1.12 0.48 tablet sample 21 film-coated 0.40.3 closed glass bottle 0.91 0.28 1.90 1.28 tablet sample 22 film-coated0.4 0.5 closed glass bottle 0.95 0.28 1.65 1.04 tablet sample 23film-coated 0.4 1.0 closed glass bottle 0.86 0.26 1.41 0.85 tabletsample 24 film-coated 0.4 2.3 closed glass bottle 0.86 0.26 1.07 0.30tablet sample 25 film-coated 3.3 2.5 closed glass bottle 0.76 0.25 0.800.30 tablet sample 26 film-coated 13.4 2.5 closed glass bottle 0.74 0.250.77 0.27 tablet sample 27 film-coated 26.7 2.5 closed glass bottle 0.600.20 0.61 0.20 tablet sample 28 film-coated 26.7 10 closed glass bottle0.61 0.20 0.61 0.20 tablet

Experiment Results 2

The decomposed products before preservation and after preservation at40° C., 75% RH for 2 months were measured, and the results of totaldecomposed product and U-6 that remarkably increased in the absence oforganic acid are shown in Table 47.

TABLE 47 decomposed product after preservation at 40° C., 75% RH for 2months organic before preservation after preservation core tabletcompound A acid total decomposed total decomposed or film-coatedconcentra- concentra- decomposed product U-6 decomposed product U-6sample tablet tion (%) tion (%) preservation state product (%) (%)product (%) (%) sample 2 film-coated  0.4 0   closed glass bottle 0.680.31 1.91 1.38 (comparison tablet control) sample 18 film-coated  0.40.3 closed glass bottle 0.88 0.26 1.11 0.47 tablet open glass bottle0.88 0.26 0.99 0.39 sample 19 film-coated  0.4 10.0  closed glass bottle0.89 0.26 1.03 0.44 tablet open glass bottle 0.89 0.26 1.38 0.37 sample20 film-coated  0.4 10.0  closed glass bottle 0.88 0.26 1.08 0.47 tabletopen glass bottle 0.88 0.26 1.09 0.37 sample 21 film-coated  0.4 0.3closed glass bottle 0.91 0.28 1.90 1.08 tablet open glass bottle 0.910.28 1.17 0.52 sample 22 film-coated  0.4 0.5 closed glass bottle 0.950.28 1.47 0.87 tablet open glass bottle 0.95 0.28 1.00 0.46 sample 23film-coated  0.4 1.0 closed glass bottle 0.86 0.26 1.45 0.74 tablet openglass bottle 0.86 0.26 0.97 0.40 sample 24 film-coated  0.4 2.3 closedglass bottle 0.86 0.26 1.01 0.43 tablet open glass bottle 0.86 0.26 1.080.35 sample 25 film-coated  3.3 2.5 closed glass bottle 0.76 0.25 0.950.32 tablet open glass bottle 0.76 0.25 0.81 0.30 sample 26 film-coated13.4 2.5 closed glass bottle 0.74 0.25 0.84 0.30 tablet open glassbottle 0.74 0.25 0.80 0.28 sample 27 film-coated 26.7 2.5 closed glassbottle 0.60 0.20 0.78 0.30 tablet open glass bottle 0.60 0.20 0.74 0.28sample 28 film-coated 26.7 2.5 closed glass bottle 0.61 0.20 0.87 0.29tablet open glass bottle 0.61 0.20 1.23 0.39 sample 29 film-coated  1.52.5 closed glass bottle 0.74 0.31 0.98 0.45 tablet open glass bottle0.74 0.31 0.75 0.35 sample 30 film-coated  3.0 2.5 closed glass bottle0.71 0.29 0.81 0.34 tablet open glass bottle 0.71 0.29 0.70 0.30 sample31 film-coated  6.1 2.5 closed glass bottle 0.79 0.29 0.83 0.32 tabletopen glass bottle 0.79 0.29 0.75 0.29 sample 32 film-coated 12.1 2.5closed glass bottle 0.68 0.27 0.72 0.29 tablet open glass bottle 0.680.27 0.74 0.27

Experiment Results 3

The decomposed products before preservation and after preservation at40° C., 75% RH for 6 months were measured, and the results of totaldecomposed product and U-6 that remarkably increased in the absence oforganic acid are shown in Table 48.

TABLE 48 decomposed product after preservation at 40° C., 75% RH for 6months organic before preservation after preservation core tabletcompound A acid total decomposed total decomposed or film-coatedconcentra- concentra- decomposed product U-6 decomposed product U-6sample tablet tion (%) tion (%) preservation state product (%) (%)product (%) (%) sample 2 film-coated 0.4 0   closed glass bottle 0.680.31 2.80 2.07 (comparison tablet open glass bottle 0.68 0.31 3.19 2.1 control) sample 18 film-coated 0.4 0.3 closed glass bottle 0.88 0.261.45 0.65 tablet open glass bottle 0.88 0.26 1.18 0.50 sample 19film-coated 0.4 10.0  closed glass bottle 0.89 0.26 1.03 0.54 tabletopen glass bottle 0.89 0.26 1.49 0.46 sample 20 film-coated 0.4 10.0 closed glass bottle 0.88 0.26 1.21 0.58 tablet open glass bottle 0.880.26 1.77 0.48 sampel 21 film-coated 0.4 0.3 closed glass bottle 0.910.28 2.66 1.77 tablet open glass bottle 0.91 0.28 1.59 0.87 sample 22film-coated 0.4 0.5 closed glass bottle 0.95 0.28 2.32 1.45 tablet openglass bottle 0.95 0.28 1.50 0.66 sample 23 film-coated 0.4 1.0 closedglass bottle 0.86 0.26 1.92 1.12 tablet open glass bottle 0.86 0.26 1.160.58 sample 24 film-coated 0.4 2.3 closed glass bottle 0.86 0.26 1.290.65 tablet open glass bottle 0.86 0.26 1.15 0.49

By the addition of an organic acid, an increase in the decomposedproduct U-6 was suppressed irrespective of the preservation conditionsand preservation state. Particularly, an increase in the decomposedproduct U-6, which strikingly increases in the absence of an organicacid, was remarkably suppressed.

U-6 was remarkably suppressed when fumaric acid was added duringgranulation by any of solution/dispersion addition including dissolvingor dispersing fumaric acid in water and spraying the solution ordispersion, powder addition including addition of organic acid as apowder, and a combination of solution/dispersion addition and powderaddition.

An increase in the decomposed product was suppressed as theconcentration of the organic acid in the tablet became higher. When theorganic acid concentration was 1% or above, an increase in U-6 wasstrikingly suppressed. When it was 2% or above, the suppressive effectwas still more remarkable.

By the addition of an organic acid, a remarkable decomposed productsuppressive effect was observed in both a plain tablet (core tablet) anda film-coated tablet, and the plain tablet (core tablet) and thefilm-coated tablet showed no difference in the amount of increase.

By the addition of an organic acid, a decomposed product suppressiveeffect was observed irrespective of the concentration of compound A.

Experimental Example 2 Measurement Method of Decomposed Product

The film-coated tablets of Comparative Example 4 were examined for theproduction of compound B decomposed product U-1 (relative retentiontime: about 0.75) and other decomposed products, before preservation(initial) and after preservation (sample 34). The decomposed product wasmeasured by extracting the tablets with water/MeCN mixture (1:3) byHPLC. The HPLC test conditions are as follows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm)

column: CAPCELL PAK C18 MGII, 3 μm, 4.6 mm i.d.×100 mm (manufactured byShiseido Co., Ltd.)

column temperature: fixed temperature around 40° C.

mobile phase A: 0.05 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (9:1)

mobile phase B: 0.05 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (2:3)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B as follows.

TABLE 49 time (min) after injection mobile phase A (%) mobile phase B(%) 0 100 0 100 0 100 100.1 100 0 110 100 0 measurement range of peakarea: 100 min

Experimental Example 3 Measurement Method of Decomposed Product

The film-coated tablets of Examples 32, 34, 36, 38 and 40 were examinedfor the production of compound B decomposed product U-1 (relativeretention time: about 0.75) and other decomposed products, beforepreservation (initial) and after preservation. The decomposed productwas measured by extracting the tablets with water/MeCN mixture (1:3) byHPLC. The HPLC test conditions are as follows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm)

column: CAPCELL PAK C18 MGII, 3 μm, 4.6 mm i.d.×100 mm (manufactured byShiseido Co., Ltd.)

column temperature: fixed temperature around 40° C.

mobile phase A: 0.03 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (9:1)

mobile phase B: 0.03 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (2:3)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B in the same manner asin Table 49.

Experiment Results 4

The decomposed products before preservation and after preservation inclosed bottle or open bottle at 40° C., 75% RH for 2 months weremeasured, and the results of total decomposed product and U-1 thatremarkably increased in the absence of organic acid are shown in Table50.

TABLE 50 decomposed product after preservation at 40° C., 75% RH for 2months organic before preservation after preservation core tabletcompound B acid total decomposed total decomposed or film-coatedconcentra- concentra- decomposed product U-1 decomposed product U-1sample tablet tion (%) tion (%) preservation state product (%) (%)product (%) (%) sample 34 film-coated 0.4 0   closed glass bottle 2.450.86 5.06 3.14 (comparison tablet open glass bottle control) sample 36film-coated 0.4 2.3 closed glass bottle 2.25 0.79 4.56 2.01 tablet openglass bottle 2.36 0.87 3.14 1.36 sample 38 film-coated 0.9 0.2 closedglass bottle 1.86 0.71 2.75 1.22 tablet open glass bottle 1.86 0.71 2.371.10 sample 40 film-coated 0.4 2.3 closed glass bottle 2.33 0.81 5.182.11 tablet open glass bottle 2.33 0.81 3.34 1.27 sample 42 film-coated4.5 2.3 closed glass bottle 2.23 0.78 2.60 0.92 tablet open glass bottle2.23 0.78 2.18 0.81 sample 44 film-coated 17.9  2.3 closed glass bottle2.25 0.80 2.40 0.90 tablet open glass bottle 2.25 0.80 2.21 0.79

By the addition of an organic acid, irrespective of the preservationconditions and preservation state, an increase in the decomposed productU-1 was suppressed. Particularly, an increase in the decomposed productU-1, which strikingly increases in the absence of an organic acid, wasremarkably suppressed.

U-1 was remarkably suppressed when fumaric acid was added duringgranulation by any of solution/dispersion addition including dissolvingor dispersing fumaric acid in water and spraying the solution ordispersion, powder addition including addition of organic acid as apowder, and a combination of solution/dispersion addition and powderaddition.

By the addition of an organic acid, a decomposed product suppressiveeffect was observed irrespective of the concentration of compound B.

Experimental Example 4 Measurement Method of Decomposed Product

The film-coated tablets of Comparative Example 6 and Examples 42 and 44were examined for production of compound C decomposed product, beforepreservation (initial) and after preservation. The decomposed productU-2 (relative retention time: about 0.6), decomposed product U-3(relative retention time: about 0.8) and other decomposed products weremeasured by extracting the tablets with 0.02 mol/L phosphate buffer (pH7.0)/acetonitrile mixture (2:1) by HPLC. The HPLC test conditions are asfollows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm)

column: Zorbax Eclipse XDB-C18, 5 μm, 4.6 mm i.d.×150 mm (manufacturedby Agilent)

column temperature: fixed temperature around 25° C.

mobile phase A: 0.02 mol/L phosphate buffer (pH 7.0)/acetonitrilemixture (19:1)

mobile phase B: acetonitrile/0.02 mol/L phosphate buffer (pH 7.0)mixture (3:2)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B as follows.

TABLE 51 time (min) after injection mobile phase A (%) mobile phase B(%) 0 100 0 5 100 0 80 0 100 81 100 0 90 100 0 measurement range of peakarea: 80 min

Experiment Results 5

The decomposed products were measured before preservation and afterpreservation in a closed glass bottle at 40° C., 75% RH for 1 month, andthe total decomposed product and the amounts of U-2 and U-3 thatremarkably increased in the absence of organic acid are shown in Table52.

TABLE 52 decomposed product after preservation at 40° C., 75% RH for 1month before preservation after preservation compound organic acid totaldecomposed decomposed total decomposed decomposed concentra- concentra-preservation decomposed product U-2 product U-3 decomposed product U-2product U-3 sample tion (%) tion (%) state product (%) (%) (%) product(%) (%) (%) sample 46 0.4 0   closed glass bottle 3.23 0.54 1.55 12.472.99 7.50 (comparison open glass bottle 3.23 0.54 1.55  7.68 2.38 3.76control) sample 48 0.4 0.3 closed glass bottle 0.87 0.10 0.10  2.39 0.310.98 sample 50 1.2 0.3 closed glass bottle 1.13 0.11 0.13  3.89 0.381.62 open glass bottle 1.13 0.11 0.13  4.32 0.63 2.29

By the addition of an organic acid, an increase in the decomposedproducts U-2 and U-3 was suppressed irrespective of the preservationconditions and preservation state. Particularly, an increase in thedecomposed products U-2 and U-3 that remarkably increase in the absenceof organic acid was markedly suppressed.

By the addition of an organic acid, a decomposed product suppressiveeffect was observed irrespective of the concentration of compound C.

The solid preparation of the present invention containing apharmaceutically active ingredient, titanium oxide, a plasticizer and achain organic acid, which is the second invention of the presentinvention, was evaluated for the stability during light irradiation. Theresults are now explained by Examples 45-71 and Comparative Examples7-9.

Example 45 Sample 51

A plain tablet (core tablet) containing1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate (hereinafter to be referred to as compound A) was produced asfollows at the composition ratio shown in Table 53.

That is, compound A (24.340 g), mannitol (4350.2 g) and crystallinecellulose (540.1 g) were placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (2700.0 g) of hydroxypropylcellulose (162.1 g) to givea granulated powder. The obtained granulated powder (4568.1 g) waspassed through a powermill (P-3, manufactured by Showa Kagaku KikaiKosakusho) to give a sized powder (Batch 1).

Compound A (24.341 g), mannitol (4350.0 g) and crystalline cellulose(540.0 g) were placed in a fluidized bed dryer granulator (FD-5S,manufactured by POWREX CORPORATION), and the mixture was preheated andmixed. The mixture was granulated while spraying an aqueous solution(2700.0 g) of hydroxypropylcellulose (162.0 g) to give a granulatedpowder. The obtained granulated powder (4568.1 g) was passed through apowermill (P-3, manufactured by Showa Kagaku Kikai Kosakusho) to give asized powder (Batch 2).

The sized powders (Batch 1 and Batch 2, 8460.0 g), croscarmellose sodium(450.0 g) and magnesium stearate (90.007 g) were placed in a tumblermixer (TM-60S, manufactured by Showa Kagaku Kikai Kosakusho), and mixedto give a mixed powder. The mixed powder was tableted by a rotarytableting machine (AQUARIUS 08242L2JI, manufactured by KikusuiSeisakusho, Ltd.) using a 9 mmφ punch to give plain tablets (coretablets, 300 mg per tablet).

TABLE 53 composition of plain tablet (core tablet) containing compound A(sample 51) composition amount (mg) 1) compound A* 1.336 2) mannitol241.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)croscarmellose sodium 15 6) magnesium stearate 3 total 300.0 *Wherenecessary, the content was amended using mannitol as an adjustmentcomponent.

Example 46 Sample 52

The plain tablets (core tablets) obtained in Example 45 (sample 51, 30.0g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (65.9 g) having thecomposition ratio shown in Table 54. The obtained film-coated tabletswere arranged on a plastic petri dish (45 sample cup, manufactured byShinwa Kagaku), and exposed to xenon light (1200000 Lux/hr) by a xenonfade meter (SX75, manufactured by Suga Test Instruments).

TABLE 54 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.8 2) macrogol 6000 2 3) titanium oxide 1 4)diiron trioxide 0.2 5) purified water 108 total 120.0

Example 47 Sample 53

The plain tablets (core tablets) obtained in Example 45 (sample 51, 30.0g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (66.2 g) having thecomposition ratio shown in Table 55. The obtained film-coated tabletswere arranged on a plastic petri dish (45 sample cup, manufactured byShinwa Kagaku), and samples shielded with aluminum foil and non-shieldedsamples were exposed to xenon light (1200000 Lux/hr).

TABLE 55 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.595 2) macrogol 6000 1.953 3) titanium oxide0.977 4) diiron trioxide 0.195 5) fumaric acid 0.28 6) purified water108 total 120.0

Example 48 Sample 54

The plain tablets (core tablets) obtained in Example 45 (sample 51, 30.0g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (75.1 g) having thecomposition ratio shown in Table 56. The obtained film-coated tabletswere arranged on a plastic petri dish (45 sample cup, manufactured byShinwa Kagaku), and exposed to xenon light (1200000 Lux/hr) by a xenonfade meter (SX75, manufactured by Suga Test Instruments).

TABLE 56 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.389 2) macrogol 6000 1.907 3) titanium oxide0.953 4) diiron trioxide 0.191 5) fumaric acid 0.56 6) purified water108 total 120.0

Example 49 Sample 55

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratio shown in Table 57.

That is, compound A (2.4074 g), mannitol (432.3 g), crystallinecellulose (54.0 g) and fumaric acid (2.70 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (270.0 g) of hydroxypropylcellulose (16.2g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder.Croscarmellose sodium (22.50 g) and magnesium stearate (4.5011 g) wereadded to the sized powder (423.0 g), and mixed to give a mixed powder.The mixed powder was tableted by a rotary tableting machine (COLLECT19K, manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφ punch togive plain tablets (core tablets, 300 mg per tablet).

TABLE 57 composition of plain tablet (core tablet) containing compound A(sample 55) composition amount (mg) 1) compound A* 1.336 2) mannitol240.164 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 1.5 6) croscarmellose sodium 15 7) magnesium stearate 3total 300.0 *Where necessary, the content was amended using mannitol asan adjustment component.

Example 50 Sample 56

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratio shown in Table 58.

That is, compound A (2.4080 g), mannitol (429.6 g), crystallinecellulose (54.0 g) and fumaric acid (5.40 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (270.0 g) of hydroxypropylcellulose (16.2g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder.Croscarmellose sodium (22.50 g) and magnesium stearate (4.5012 g) wereadded to the sized powder (423.0 g), and mixed to give a mixed powder.The mixed powder was tableted by a rotary tableting machine (COLLECT19K, manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφ punch togive plain tablets (core tablets, 300 mg per tablet).

TABLE 58 composition of plain tablet (core tablet) containing compound A(sample 56) composition amount (mg) 1) compound A* 1.336 2) mannitol238.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 3 6) croscarmellose sodium 15 7) magnesium stearate 3 total300.0 *Where necessary, the content was amended using mannitol as anadjustment component.

Example 51 Sample 57

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratio shown in Table 59.

That is, compound A (2.4095 g), mannitol (422.4 g), crystallinecellulose (54.0 g) and fumaric acid (12.60 g) were placed in a fluidizedbed dryer granulator (LAB-1, manufactured by POWREX CORPORATION), andthe mixture was preheated and mixed. The mixture was granulated whilespraying an aqueous solution (270.0 g) of hydroxypropylcellulose (16.2g) to give a granulated powder. The obtained granulated powder waspassed through a 16M (1000 μm) sieve to give a sized powder.Croscarmellose sodium (22.50 g) and magnesium stearate (4.5017 g) wereadded to the sized powder (423.0 g), and mixed to give a mixed powder.The mixed powder was tableted by a rotary tableting machine (COLLECT19K, manufactured by Kikusui Seisakusho, Ltd.) using a 9 mmφ punch togive plain tablets (core tablets, 300 mg per tablet).

TABLE 59 composition of plain tablet (core tablet) containing compound A(sample 57) composition amount (mg) 1) compound A* 1.336 2) mannitol234.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)fumaric acid 7 6) croscarmellose sodium 15 7) magnesium stearate 3 total300.0 *Where necessary, the content was amended using mannitol as anadjustment component.

Example 52 Sample 58

The plain tablets (core tablets) obtained in Example 49 (sample 55,100.0 g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (49.2 g) having thecomposition ratio shown in Table 60. The obtained film-coated tabletswere arranged on a plastic petri dish (45 sample cup, manufactured byShinwa Kagaku), and exposed to xenon light (1200000 Lux/hr) by a xenonfade meter (SX75, manufactured by Suga Test Instruments).

TABLE 60 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.8 2) macrogol 6000 2 3) titanium oxide 1 4)diiron trioxide 0.2 5) purified water 108 total 120.0

Example 53 Sample 59

The plain tablets (core tablets) obtained in Example 50 (sample 56,100.0 g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (61.4 g) having thecomposition ratio shown in Table 61. The obtained film-coated tabletswere arranged on a plastic petri dish (45 sample cup, manufactured byShinwa Kagaku), and exposed to xenon light (1200000 Lux/hr) by a xenonfade meter (SX75, manufactured by Suga Test Instruments).

TABLE 61 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.8 2) macrogol 6000 2 3) titanium oxide 1 4)diiron trioxide 0.2 5) purified water 108 total 120.0

Example 54 Sample 60

The plain tablets (core tablets) obtained in Example 51 (sample 57,100.0 g) were placed in a film coating machine (DRC-200, manufactured byPOWREX CORPORATION), and film-coated tablets (about 312 mg per tablet)were obtained while spraying a film coating solution (59.5 g) having thecomposition ratio shown in Table 62. The obtained film-coated tabletswere arranged on a plastic petri dish (45 sample cup, manufactured byShinwa Kagaku), and exposed to xenon light (1200000 Lux/hr) by a xenonfade meter (SX75, manufactured by Suga Test Instruments).

TABLE 62 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 8.8 2) macrogol 6000 2 3) titanium oxide 1 4)diiron trioxide 0.2 5) purified water 108 total 120.0

Comparative Example 7 Sample 61

A plain tablet (core tablet) containing compound A was produced asfollows at the composition ratio shown in Table 63.

That is, compound A (24.491 g), mannitol (4350.0 g) and crystallinecellulose (540.0 g) were placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture waspreheated and mixed. The mixture was granulated while spraying anaqueous solution (2700.0 g) of hydroxypropylcellulose (162.0 g) to givea granulated powder. The obtained granulated powder (4568.0 g) waspassed through a powermill (P-3, manufactured by Showa Kagaku KikaiKosakusho) to give a sized powder. The sized powder (4230.0 g),croscarmellose sodium (225.0 g) and magnesium stearate (45.007 g) wereplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder wastableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 9 mmφ punch to give plain tablets(core tablets, 300 mg per tablet).

TABLE 63 composition of plain tablet (core tablet) containing compound A(sample 61) composition amount (mg) 1) compound A* 1.336 2) mannitol241.664 3) crystalline cellulose 30 4) hydroxypropylcellulose 9 5)croscarmellose sodium 15 6) magnesium stearate 3 total 300.0 *Wherenecessary, the content was amended using mannitol as an adjustmentcomponent.

Comparative Example 8 Sample 62

The plain tablets (core tablets) obtained in Comparative Example 7(sample 61, 3300.0 g) were placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about 312mg per tablet) were obtained while spraying a film coating solution(1372.0 g) having the composition ratio shown in Table 64. The obtainedfilm-coated tablets were arranged on a plastic petri dish (45 samplecup, manufactured by Shinwa Kagaku), and exposed to xenon light (1200000Lux/hr) by a xenon fade meter (SX75, manufactured by Suga TestInstruments).

TABLE 64 Composition of aqueous film coating solution composition amount(mg) 1) hypromellose 10.8 2) titanium oxide 1 3) diiron trioxide 0.2 4)purified water 108 total 120.0

Example 55 Sample 63

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 65.

That is, compound A (641.28 g), mannitol (3503.52 g), fumaric acid(132.0 g) and crystalline cellulose (528.0 g) are placed in a fluidizedbed dryer granulator (FD-5S, manufactured by POWREX CORPORATION), andthe mixture is preheated and mixed. The mixture is granulated whilespraying an aqueous solution (2640.0 g) of hydroxypropylcellulose (158.4g) to give a granulated powder. The obtained granulated powder (4653.0g) is passed through a powermill (P-3, manufactured by Showa KagakuKikai Kosakusho) to give a sized powder. The sized powder (4342.8 g),croscarmellose sodium (231.0 g) and magnesium stearate (46.2 g) areplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder istableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 6.5 mmφ punch to give plain tablets(core tablets, 110 mg per tablet). The obtained plain tablets (coretablets, 3300.0 g) are placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about114.4 mg per tablet) are obtained while spraying a film coating solution(1380.0 g) having the composition ratio shown in Table 66.

TABLE 65 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 13.36 2) mannitol 72.99 3)crystalline cellulose 11 4) hydroxypropylcellulose 3.3 5) fumaric acid2.75 6) croscarmellose sodium 5.5 7) magnesium stearate 1.1 total 110.0

TABLE 66 composition of aqueous film coating solution composition amount(mg) 1) hypromellose 6.6 2) macrogol 6000 1.5 3) titanium oxide 0.75 4)yellow ferric oxide 0.075 5) diiron trioxide 0.075 6) purified water 81total 90.0

Example 56 Sample 64

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 67.

That is, compound A (641.28 g), mannitol (3503.52 g), fumaric acid(132.0 g) and crystalline cellulose (528.0 g) are placed in a fluidizedbed dryer granulator (FD-5S, manufactured by POWREX CORPORATION), andthe mixture is preheated and mixed. The mixture is granulated whilespraying an aqueous solution (2640.0 g) of hydroxypropylcellulose (158.4g) to give a granulated powder. The obtained granulated powder (4653.0g) is passed through a powermill (P-3, manufactured by Showa KagakuKikai Kosakusho) to give a sized powder. The sized powder (4342.8 g),croscarmellose sodium (231.0 g) and magnesium stearate (46.2 g) areplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder istableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 7 mmφ punch to give plain tablets(core tablets, 165 mg per tablet). The obtained plain tablets (coretablets, 3300.0 g) are placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about171.6 mg per tablet) are obtained while spraying a film coating solution(1380.0 g) having the composition ratio shown in Table 66.

TABLE 67 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 20.04 2) mannitol 109.485 3)crystalline cellulose 16.5 4) hydroxypropylcellulose 4.95 5) fumaricacid 4.125 6) croscarmellose sodium 8.25 7) magnesium stearate 1.65total 165.0

Example 57 Sample 65

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 68.

That is, compound A (641.28 g), mannitol (3503.52 g), fumaric acid(132.0 g) and crystalline cellulose (528.0 g) are placed in a fluidizedbed dryer granulator (FD-5S, manufactured by POWREX CORPORATION), andthe mixture is preheated and mixed. The mixture is granulated whilespraying an aqueous solution (2640.0 g) of hydroxypropylcellulose (158.4g) to give a granulated powder. The obtained granulated powder (4653.0g) is passed through a powermill (P-3, manufactured by Showa KagakuKikai Kosakusho) to give a sized powder. The sized powder (4342.8 g),croscarmellose sodium (231.0 g) and magnesium stearate (46.2 g) areplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder istableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 9.5 mmφ punch to give plain tablets(core tablets, 330 mg per tablet). The obtained plain tablets (coretablets, 3300.0 g) is placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about343.2 mg per tablet) is obtained while spraying a film coating solution(1380.0 g) having the composition ratio shown in Table 66.

TABLE 68 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 40.08 2) mannitol 218.97 3)crystalline cellulose 33 4) hydroxypropylcellulose 9.9 5) fumaric acid8.25 6) croscarmellose sodium 16.5 7) magnesium stearate 3.3 total 330.0

Example 58 Sample 66

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 69.

That is, compound A (641.28 g), mannitol (3503.52 g), fumaric acid(132.0 g) and crystalline cellulose (528.0 g) are placed in a fluidizedbed dryer granulator (FD-5S, manufactured by POWREX CORPORATION), andthe mixture is preheated and mixed. The mixture is granulated whilespraying an aqueous solution (2640.0 g) of hydroxypropylcellulose (158.4g) to give a granulated powder. The obtained granulated powder (4653.0g) is passed through a powermill (P-3, manufactured by Showa KagakuKikai Kosakusho) to give a sized powder. The sized powder (4342.8 g),croscarmellose sodium (231.0 g) and magnesium stearate (46.2 g) areplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder istableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 14×8 mmφ punch to give plain tablets(core tablets, 440 mg per tablet). The obtained plain tablets (coretablets, 3300.0 g) are placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about457.6 mg per tablet) are obtained while spraying a film coating solution(1380.0 g) having the composition ratio shown in Table 66.

TABLE 69 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 53.44 2) mannitol 291.96 3)crystalline cellulose 44 4) hydroxypropylcellulose 13.2 5) fumaric acid11 6) croscarmellose sodium 22 7) magnesium stearate 4.4 total 440

Example 59 Sample 67

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 70.

That is, compound A (881.76 g), mannitol (3263.04 g), fumaric acid(132.0 g) and crystalline cellulose (528.0 g) are placed in a fluidizedbed dryer granulator (FD-5S, manufactured by POWREX CORPORATION), andthe mixture is preheated and mixed. The mixture is granulated whilespraying an aqueous solution (2640.0 g) of hydroxypropylcellulose (158.4g) to give a granulated powder. The obtained granulated powder (4653.0g) is passed through a powermill (P-3, manufactured by Showa KagakuKikai Kosakusho) to give a sized powder. The sized powder (4342.8 g),croscarmellose sodium (231.0 g) and magnesium stearate (46.2 g) areplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder istableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 6.5 mmφ punch to give plain tablets(core tablets, 120 mg per tablet). The obtained plain tablets (coretablets, 3300.0 g) are placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about124.8 mg per tablet) are obtained while spraying a film coating solution(1380 g) having the composition ratio shown in Table 66.

TABLE 70 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 20.04 2) mannitol 74.16 3)crystalline cellulose 12 4) hydroxypropylcellulose 3.6 5) fumaric acid 36) croscarmellose sodium 6 7) magnesium stearate 1.2 total 120

Example 60 Sample 68

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 71. That is, compound A(881.76 g), mannitol (3263.04 g), fumaric acid (132.0 g) and crystallinecellulose (528.0 g) are placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture ispreheated and mixed. The mixture is granulated while spraying an aqueoussolution (2640.0 g) of hydroxypropylcellulose (158.4 g) to give agranulated powder. The obtained granulated powder (4653.0 g) is passedthrough a powermill (P-3, manufactured by Showa Kagaku Kikai Kosakusho)to give a sized powder. The sized powder (4342.8 g), croscarmellosesodium (231.0 g) and magnesium stearate (46.2 g) are placed in a tumblermixer (TM-15S, manufactured by Showa Kagaku Kikai Kosakusho), and mixedto give a mixed powder. The mixed powder is tableted by a rotarytableting machine (COLLECT 12HUK, manufactured by Kikusui Seisakusho,Ltd.) using a 7 mmφ punch to give plain tablets (core tablets, 160 mgper tablet). The obtained plain tablets (core tablets, 3300.0 g) areplaced in a film coating machine (DRC-500, manufactured by POWREXCORPORATION), and film-coated tablets (about 166.4 mg per tablet) areobtained while spraying a film coating solution (1380 g) having thecomposition ratio shown in Table 66.

TABLE 71 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 26.72 2) mannitol 98.88 3)crystalline cellulose 16 4) hydroxypropylcellulose 4.8 5) fumaric acid 46) croscarmellose sodium 8 7) magnesium stearate 1.6 total 160

Example 61 Sample 69

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 72.

That is, compound A (881.76 g), mannitol (3263.04 g), fumaric acid(132.0 g) and crystalline cellulose (528.0 g) are placed in a fluidizedbed dryer granulator (FD-5S, manufactured by POWREX CORPORATION), andthe mixture is preheated and mixed. The mixture is granulated whilespraying an aqueous solution (2640.0 g) of hydroxypropylcellulose (158.4g) to give a granulated powder. The obtained granulated powder (4653.0g) is passed through a powermill (P-3, manufactured by Showa KagakuKikai Kosakusho) to give a sized powder. The sized powder (4342.8 g),croscarmellose sodium (231.0 g) and magnesium stearate (46.2 g) areplaced in a tumbler mixer (TM-15S, manufactured by Showa Kagaku KikaiKosakusho), and mixed to give a mixed powder. The mixed powder istableted by a rotary tableting machine (COLLECT 12HUK, manufactured byKikusui Seisakusho, Ltd.) using a 8 mmφ punch to give plain tablets(core tablets, 240 mg per tablet). The obtained plain tablets (coretablets, 3300.0 g) are placed in a film coating machine (DRC-500,manufactured by POWREX CORPORATION), and film-coated tablets (about249.6 mg per tablet) are obtained while spraying a film coating solution(1380 g) having the composition ratio shown in Table 66.

TABLE 72 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 40.08 2) mannitol 148.32 3)crystalline cellulose 24 4) hydroxypropylcellulose 7.2 5) fumaric acid 66) croscarmellose sodium 12 7) magnesium stearate 2.4 total 240

Example 62 Sample 70

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 73. That is, compound A(881.76 g), mannitol (3263.04 g), fumaric acid (132.0 g) and crystallinecellulose (528.0 g) are placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture ispreheated and mixed. The mixture is granulated while spraying an aqueoussolution (2640.0 g) of hydroxypropylcellulose (158.4 g) to give agranulated powder. The obtained granulated powder (4653.0 g) is passedthrough a powermill (P-3, manufactured by Showa Kagaku Kikai Kosakusho)to give a sized powder. The sized powder (4342.8 g), croscarmellosesodium (231.0 g) and magnesium stearate (46.2 g) are placed in a tumblermixer (TM-15S, manufactured by Showa Kagaku Kikai Kosakusho), and mixedto give a mixed powder. The mixed powder is tableted by a rotarytableting machine (COLLECT 12HUK, manufactured by Kikusui Seisakusho,Ltd.) using a 9.5 mmφ punch to give plain tablets (core tablets, 320 mgper tablet). The obtained plain tablets (core tablets, 3300.0 g) areplaced in a film coating machine (DRC-500, manufactured by POWREXCORPORATION), and film-coated tablets (about 332.8 mg per tablet) areobtained while spraying a film coating solution (1380 g) having thecomposition ratio shown in Table 66.

TABLE 73 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 53.44 2) mannitol 197.76 3)crystalline cellulose 32 4) hydroxypropylcellulose 9.6 5) fumaric acid 86) croscarmellose sodium 16 7) magnesium stearate 3.2 total 320

Example 63 Sample 71

A plain tablet (core tablet) containing compound A is produced asfollows at the composition ratio shown in Table 74. That is, compound A(961.92 g), mannitol (3182.88 g), fumaric acid (132.0 g) and crystallinecellulose (528.0 g) are placed in a fluidized bed dryer granulator(FD-5S, manufactured by POWREX CORPORATION), and the mixture ispreheated and mixed. The mixture is granulated while spraying an aqueoussolution (2640.0 g) of hydroxypropylcellulose (158.4 g) to give agranulated powder. The obtained granulated powder (4653.0 g) is passedthrough a powermill (P-3, manufactured by Showa Kagaku Kikai Kosakusho)to give a sized powder. The sized powder (4342.8 g), croscarmellosesodium (231.0 g) and magnesium stearate (46.2 g) are placed in a tumblermixer (TM-15S, manufactured by Showa Kagaku Kikai Kosakusho), and mixedto give a mixed powder. The mixed powder is tableted by a rotarytableting machine (COLLECT 12HUK, manufactured by Kikusui Seisakusho,Ltd.) using a 8 mmφ punch to give plain tablets (core tablets, 220 mgper tablet). The obtained plain tablets (core tablets, 3300.0 g) areplaced in a film coating machine (DRC-500, manufactured by POWREXCORPORATION), and film-coated tablets (about 228.8 mg per tablet) areobtained while spraying a film coating solution (1380 g) having thecomposition ratio shown in Table 66.

TABLE 74 composition of plain tablet (core tablet) containing compound Acomposition amount (mg) 1) compound A 40.08 2) mannitol 132.62 3)crystalline cellulose 22 4) hydroxypropylcellulose 6.6 5) fumaric acid5.5 6) croscarmellose sodium 11 7) magnesium stearate 2.2 total 220

Example 64 Sample 72

The plain tablets (core tablets) obtained in Example 12 (sample 14,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1480.9 g)having the composition ratio shown in Table 29. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Example 65 Sample 73

The plain tablets (core tablets) obtained in Example 13 (sample 15,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1501.0 g)having the composition ratio shown in Table 30. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Example 66 Sample 74

The plain tablets (core tablets) obtained in Example 14 (sample 16,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1514.0 g)having the composition ratio shown in Table 31. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Example 67 Sample 75

The plain tablets (core tablets) obtained in Example 15 (sample 17,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 229 mg pertablet) were obtained while spraying a film coating solution (1374.0 g)having the composition ratio shown in Table 32. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Comparative Example 9 Sample 76

The plain tablets (core tablets) obtained in Comparative Example 3(sample 33, 200.0 g) were placed in a film coating machine (DRC-200,manufactured by POWREX CORPORATION), and film-coated tablets (about 312mg per tablet) were obtained while spraying a film coating solution(96.8 g) having the composition ratio shown in Table 34. The obtainedfilm-coated tablets were exposed to xenon light (1200000 Lux/hr) by afade meter (SX75, manufactured by Suga Test Instruments).

Example 68 Sample 77

The plain tablets (core tablets) obtained in Example 31 (sample 35,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 312 mg pertablet) were obtained while spraying a film coating solution (1432.0 g)having the composition ratio shown in Table 34. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Example 69 Sample 78

The plain tablets (core tablets) obtained in Example 35 (sample 39,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 156 mg pertablet) were obtained while spraying a film coating solution (1470.0 g)having the composition ratio shown in Table 37. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Example 70 Sample 79

The plain tablets (core tablets) obtained in Example 37 (sample 41,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 312 mg pertablet) were obtained while spraying a film coating solution (1425.0 g)having the composition ratio shown in Table 37. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Example 71 Sample 80

The plain tablets (core tablets) obtained in Example 39 (sample 43,3300.0 g) were placed in a film coating machine (DRC-500, manufacturedby POWREX CORPORATION), and film-coated tablets (about 312 mg pertablet) were obtained while spraying a film coating solution (1417.2 g)having the composition ratio shown in Table 37. The obtained film-coatedtablets were exposed to xenon light (1200000 Lux/hr) by a fade meter(SX75, manufactured by Suga Test Instruments).

Experimental Example 5 Measurement Method of Decomposed Product

The film-coated tablets of Examples 46-48, Examples 52-54, Examples64-67 and Comparative Example 8 were examined for the production ofcompound A decomposed product, before xenon light irradiation and afterxenon light irradiation. The decomposed product U-6 was measured byextracting the tablets with 0.05 mol/L phosphoric acid/MeCN mixture(19:1) or water/MeCN mixture (19:1) by HPLC. The HPLC test conditionsare as follows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm)

column: CAPCELL PAK C18 MGII, 3 μm, 4.6 mm i.d.×150 mm (manufactured byShiseido Co., Ltd.)

column temperature: fixed temperature around 25° C.

mobile phase A: 0.05 mol/L sodium phosphate buffer (pH 6.0)/acetonitrilemixture (95:5)

mobile phase B: 0.05 mol/L sodium phosphate buffer (pH 6.0)/acetonitrilemixture (40:60)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B as follows.

TABLE 75 time (min) after mobile mobile phase injection phase A (%) B(%) 0 100 0 10 80 20 60 70 30 110 0 100 110.1 100 0 120 100 0measurement range of peak area: 110 min

Experiment Results 6

The compound A decomposed product U-6 (relative retention time: about0.7) and other decomposed products were measured before xenon lightirradiation and after xenon light irradiation, and the results of thetotal decomposed products are shown in Table 76.

TABLE 76 organic acid compound concentration (%) total decomposedproduct (%) PEG addition concentra- core tablet film before xenon afterxenon sample to film part tion (%) part part light irradiation lightirradiation sample 52 added 0.4 0   0   0.70 1.59 sample 53 added 0.40   2.3 0.71 1.05 sample 54 added 0.4 0   4.7 0.85 0.84 sample 58 added0.4 0.5 0   0.84 1.15 sample 59 added 0.4 1.0 0   0.85 1.03 sample 60added 0.4 2.3 0   0.83 0.92 sample 72 added 1.5 2.5 0   0.74 0.76 sample73 added 3.0 2.5 0   0.71 0.73 sample 74 added 6.1 2.5 0   0.79 0.74sample 75 added 12.1  2.5 0   0.68 0.70 sample 62 not added 0.4 0   0  1.00 1.12 Comparative Example * organic acid concentration (%) of coretablet part = (organic acid mass contained in core tablet part/coretablet mass) × 100 * organic acid concentration (%) of film part =(organic acid mass contained in film part/film mass) × 100 * compoundconcentration (%) = (added compound weight/core tablet weight) × 100

Even when PEG was added to film coating component, production of adecomposed product after light irradiation was suppressed by theaddition of an organic acid.

Even when organic acid was added to the core tablet part or the filmpart, a decomposed product suppressive effect was observed. When addedto the core tablet part, a remarkable suppression was observed with 2.3%or above. When added to the film part, a remarkable suppression wasobserved with 4.7% or above.

Even when PEG was added to a film coating component, stabilization wasachieved to a level equal to or higher than the absence of PEG by theaddition of an organic acid.

Since the production of a decomposed product can be suppressed by theaddition of an organic acid, suppression of change in the appearanceafter light irradiation is sufficiently predicted. Hence, a high qualitypharmaceutical composition superior in light-stability can be provided.

Experimental Example 6 Measurement Method of Decomposed Product

The film-coated tablet (sample 76) obtained in Comparative Example 9 wasexamined for the production of compound B total decomposed productbefore xenon light irradiation and after xenon light irradiation. Thedecomposed product was measured by extracting the tablet with water/MeCNmixture (1:3) by HPLC. The HPLC test conditions are as follows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm) column: CAPCELL PAK C18 MGII, 3 μm, 4.6 mm i.d.×100mm (manufactured by Shiseido Co., Ltd.)

column temperature: fixed temperature around 40° C.

mobile phase A: 0.05 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (9:1)

mobile phase B: 0.05 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (2:3)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B as follows.

TABLE 77 time (min) after injection mobile phase A (%) mobile phase B(%) 0 100 0 100 0 100 100.1 100 0 110 100 0 measurement range of peakarea: 100 min

Experimental Example 7 Measurement Method of Decomposed Product

The film-coated tablets obtained Examples 68-71 (samples 77, 78, 79 and80) were examined for the production of compound B total decomposedproduct before xenon light irradiation and after xenon lightirradiation. The decomposed products were measured by extracting thetablets with water/MeCN mixture (1:3) by HPLC. The HPLC test conditionsare as follows.

detector: ultraviolet absorption spectrophotometer (measurementwavelength: 230 nm) column: CAPCELL PAK C18 MGII, 3 μm, 4.6 mm i.d.×100mm (manufactured by Shiseido Co., Ltd.)

column temperature: fixed temperature around 40° C.

mobile phase A: 0.03 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (9:1)

mobile phase B: 0.03 mol/L sodium phosphate buffer (pH 7.0)/acetonitrilemixture (2:3)

mobile phase delivery: density gradient was controlled by changingmixing ratio of mobile phase A and mobile phase B as follows.

TABLE 78 time (min) after injection mobile phase A (%) mobile phase B(%) 0 100 0 100 0 100 100.1 100 0 110 100 0 measurement range of peakarea: 100 min

Experiment Results 7

The decomposed products of film-coated tablets were measured beforexenon light irradiation and after xenon light irradiation, and theresults of the total decomposed products are shown in Table 79.

TABLE 79 decomposed products after xenon light irradiation organic acidcore tablet compound concentration (%) before preservation afterpreservation or film- concentra- core tablet total decomposed totaldecomposed sample coated tablet tion (%) part film part product (%)product (%) sample 76 film-coated 0.4 0   0 2.45 2.87 (comparison tabletcontrol) sample 77 film-coated 0.4 2.3 0 2.36 2.65 tablet sample 78film-coated 0.4 2.3 0 2.33 2.55 tablet sample 79 film-coated 4.5 2.3 02.23 2.24 tablet sample 80 film-coated 17.9  2.3 0 2.25 2.29 tablet

Since the production of a decomposed product can be suppressed by theaddition of an organic acid, suppression of change in the appearanceafter light irradiation is sufficiently predicted. Hence, a high qualitypharmaceutical composition superior in light-stability can be provided.

INDUSTRIAL APPLICABILITY

According to the first invention of the present invention, a stabilizedpharmaceutical composition comprising a nonpeptidic pharmaceuticallyactive ingredient having a primary or secondary amino group is provided.To be specific, since development of a decomposed product of thepharmaceutically active ingredient (nonpeptidic one having a primary orsecondary amino group) in the pharmaceutical composition is suppressed,a more stable pharmaceutical composition is provided. According to thepresent invention, moreover, since development of a decomposed productof the pharmaceutically active ingredient is suppressed regardless ofbeing in a closed bottle/open bottle, a pharmaceutical composition alsosuperior in the preservation stability can be provided. In addition,according to the second invention of the present invention, a solidpreparation improved in the stability of a pharmaceutically activeingredient to light irradiation is provided. To be specific, a solidpreparation stable to light irradiation can be provided by, when thepharmaceutically active ingredient contained in the solid preparation isexposed to light, shielding the light and suppressing an increase in adecomposed product.

This application is based on a patent application No. 2008-194219 filedin Japan, the contents of which are incorporated in full herein by thisreference.

1. A method of stabilizing a pharmaceutical composition comprising anonpeptidic pharmaceutically active ingredient having a primary orsecondary amino group and an excipient, comprising adding an acidiccompound to the pharmaceutical composition.
 2. A solid preparationimproved in the stability during light irradiation, comprising apharmaceutically active ingredient, titanium oxide, a plasticizer and achain organic acid.
 3. The solid preparation of claim 2, wherein theplasticizer is represented by the formula:HOCH₂(CH₂OCH₂)_(n)CH₂OH (n=an integer of 2-870).
 4. The solidpreparation of claim 2, wherein the plasticizer is polyethylene glycol(PEG).
 5. The solid preparation of claim 2, wherein the chain organicacid has pH 6.0 or below when dissolved or dispersed in water.
 6. Thesolid preparation of claim 2, wherein the chain organic acid has an aciddissociation constant (pKa) of a proton complex of 4.0 or below whendissolved or dispersed in water.
 7. The solid preparation of claim 2,wherein the chain organic acid is any one kind or more selected from thegroup consisting of adipic acid, oleic acid, succinic acid, acetic acid,tartaric acid, sorbic acid, fumaric acid, lactic acid, maleic acid,malonic acid, citric acid and malic acid.
 8. The solid preparation ofclaim 2, wherein the content (%) of the chain organic acid is 0.01-50 wt%.
 9. The solid preparation of claim 2, wherein the pharmaceuticallyactive ingredient is a compound represented by the formula:

wherein X and Y are the same or different and each is a bond or a spacerhaving 1 to 20 atoms in the main chain, R⁴ is an optionally substitutedhydrocarbon group or an optionally substituted heterocyclic group, R²,R³ and R⁴ are the same or different and each is a hydrogen atom, anoptionally substituted hydrocarbon group, an optionally substitutedthienyl group, an optionally substituted benzo[b]thienyl group, anoptionally substituted furyl group, an optionally substituted pyridylgroup, an optionally substituted pyrazolyl group, an optionallysubstituted pyrimidinyl group, an acyl group, a halogen atom, a cyanogroup or a nitro group, and R⁵ is a hydrogen atom or an optionallysubstituted hydrocarbon group, or a salt thereof.
 10. The solidpreparation of claim 2, wherein the pharmaceutically active ingredientis1-{5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamineor a salt thereof,1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamineor a salt thereof,1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof,N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamineor a salt thereof, or1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamineor a salt thereof.
 11. A method of stabilizing a solid preparationcomprising a pharmaceutically active ingredient, titanium oxide, and aplasticizer during light irradiation, comprising adding a chain organicacid to the solid preparation.